WO2009141386A1 - Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors - Google Patents

Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2009141386A1
WO2009141386A1 PCT/EP2009/056154 EP2009056154W WO2009141386A1 WO 2009141386 A1 WO2009141386 A1 WO 2009141386A1 EP 2009056154 W EP2009056154 W EP 2009056154W WO 2009141386 A1 WO2009141386 A1 WO 2009141386A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
carboxylic acid
quinoxaline
amide
dimethoxy
Prior art date
Application number
PCT/EP2009/056154
Other languages
French (fr)
Inventor
Pascal Furet
Diana Graus Porta
Vito Guagnano
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020107026049A priority Critical patent/KR101257158B1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to EA201001769A priority patent/EA021421B1/en
Priority to AU2009248774A priority patent/AU2009248774B2/en
Priority to JP2011509980A priority patent/JP5351254B2/en
Priority to MX2010012699A priority patent/MX2010012699A/en
Priority to NZ588511A priority patent/NZ588511A/en
Priority to CN2009801187578A priority patent/CN102036963B/en
Priority to EP09749876.0A priority patent/EP2282995B1/en
Priority to BRPI0913031 priority patent/BRPI0913031A2/en
Priority to UAA201013893A priority patent/UA103478C2/en
Priority to CA2725185A priority patent/CA2725185C/en
Priority to ES09749876.0T priority patent/ES2554513T3/en
Publication of WO2009141386A1 publication Critical patent/WO2009141386A1/en
Priority to ZA2010/07086A priority patent/ZA201007086B/en
Priority to TNP2010000480A priority patent/TN2010000480A1/en
Priority to IL209124A priority patent/IL209124A/en
Priority to CU2010000219A priority patent/CU24001B1/en
Priority to MA33351A priority patent/MA32306B1/en
Priority to SM201000124T priority patent/SMP201000124B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention relates to quinoline/quinoxaline-carboxamide derivatives of the formula (I) given below (including its salts, solvates, esters, N-oxides); processes for the preparation thereof; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; the application of a compound of formula (I) in a process for the treatment of the human or animal body, (in particular with regard to a proliferative disease); the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases.
  • PKs Protein kinases
  • PKs Protein kinases
  • These post-translational modifications of substrate proteins act as molecular switch regulating cell proliferation, activation and/or dif- ferentiation.
  • Aberrant or excessive PK activity has been observed in many disease states including benign and malignant proliferative disorders.
  • the kinases fall largely into two groups, those specific for phosphorylating serine and threonine, and those specific for phosphorylating tyrosine.
  • some kinases referred to as "dual specificity" kinases, are able to phosphorylate tyrosine as well as serine/threonine residues.
  • WO2006/000420 discloses details on PKs, their mode of action and relation to disorders or conditions to be treated. This document also discloses heteroaryl aryl ureas, useful for the treatment of protein kinase dependent diseases. Further,
  • WO03/023004 and WO02/102972 disclose disorders resulting from FGFR3 mutations.
  • WO05/118580 generically discloses quinoline derivatives useful as HIV inhibitors.
  • the invention relates to compounds of the formula (I),
  • R 1 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy;
  • R 2 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylamin
  • R A1 represents hydrogen or a substituent different from hydrogen
  • R A2 represents a direct bond or an alkanediyl
  • R B1 represents hydrogen or a substituent different from hydrogen
  • R represents a direct bond or aminocarbonyl
  • m represents an integer selected from 0 to 3
  • n represents an integer selected from 0 to 5; or a salt, solvate, ester, N-oxide thereof.
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. If at least one asymmetrical carbon atom is present in a compound of the formula (I), such a compound may exist in optically active form or in the form of a - A -
  • any given formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, and mixtures thereof.
  • certain structures may exist as geometric isomers (i.e. cis and trans isomers), as tautomers, or as atropisomers.
  • any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds, lsotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 I respectively.
  • isotopically labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 13 C, and 14 C are incorporated.
  • Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly preferred for PET or SPECT studies.
  • isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere.
  • the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula (where one or more up to all more general expressions in embodiments characterized as preferred above or below can be replaced with a more specific definition, thus leading to a more preferred embodiment of the invention, respectively).
  • substituents are only at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort which substitutions are possible and which are not.
  • amino or hydroxy groups with free hydrogen may be unstable if bound to carbon atoms with unsaturated (e.g. olefinic) bonds.
  • substituents as listed above may themselves be substituted by any substituent, subject to the aforementioned restriction to appropriate substitutions as recognised by the skilled man.
  • the acid addition salt of compounds of formula (I) are preferably pharmaceutically acceptable salts. Such salts are known in the field.
  • Halogen denotes fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine.
  • Halogen-substituted groups and moieties, such as alkyl substituted by halogen (halogenalkyl) can be mono-, poly- or per-halogenated.
  • Heteroatoms are atoms other than Carbon and Hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S).
  • C 1 -C 7 denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
  • Alkyl refers to a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain Ci-i 2 alkyl, particularly preferably represents a straight- chain or branched-chain Ci -7 alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl, iso-propyl and n-butyl and iso-butyl.
  • Alkyl may be unsubstituted or substituted.
  • substituents include, but are not limited to hydroxyl, alkoxy, halogen and amino.
  • An example of a substituted alkyl is trifluoromethyl.
  • Cycloalkyl may also be a substituent to alkyl. An example of such a case is the moiety (alkyl)-cyclopropyl or alkanediyl-cycloproyl, e.g. -CH 2 -cyclopropyl.
  • Ci-C 7 -alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or preferably methyl.
  • alkoxycarbonylalkyl shall have the same meaning as described in the above-mentioned definition of "alkyl”.
  • Alkanediyl refers to a straight-chain or branched-chain alkanediyl group. It preferably represents a straight-chain or branched-chain C M2 alkanediyl, particularly preferably represents a straight-chain or branched-chain Ci_6 alkanediyl; for example, methandiyl (- CH 2 -), 1 ,2-ethanediyl (-CH 2 -CH 2 -), 1 ,1-ethanediyl ((-CH(CH 3 )-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1 ,1- ethanediyl, 1 ,2-ethanediyl, 1 ,3-propanediyl, 1 ,4-butane
  • Cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to 12 ring atoms per carbocycle.
  • Illustrative examples of cycloalkyl groups include the following moieties: cyclopropyl, cyclobutyl, cyclpentyl and cylclohexyl. Cycloalkyl may be unsubstituted or substituted; exemplary substituents are provided in the definition for alkyl.
  • Aryl refers to an aromatic homocyclic ring system with 6 or more carbon atoms; aryl is preferably an aromatic moiety with 6 to 14 ring carbon atoms, more preferably with 6 to 10 ring carbon atoms, such as phenyl or naphthyl, preferably phenyl.
  • Aryl may be unsubstituted or substituted by one or more, preferably up to three, more preferably up to two substituents independently selected from the group consisting of unsubstituted or substituted heterocyclyl as described below, especially pyrrolidinyl, such as pyrrolidine oxopyrrolidinyl, such as oxopyrrolidino, d-C 7 -alkyl-pyrrolidinyl, 2,5-di-(Ci-C 7 alkyl)pyrrolidinyl, such as 2,5-di-(Ci-C 7 alkyl)-pyrrolidino, tetrahydrofuranyl, thiophenyl, d-C 7 - alkylpyrazolidinyl, pyridinyl, Ci-C 7 -alkylpiperidinyl, piperidino, piperidino substituted by amino or N-mono- or N,N-di-[lower alkyl, phen
  • halo halo-lower alkyl
  • substituents independently selected from halo, halo-lower alkyl, such as trifluoromethyl, hydroxy, lower alkoxy, azido, amino, N-mono- or N,N-di-(lower alkyl and/or Ci-C 7 -alkanoyl)-amino, nitro, carboxy, lower-alkoxycarbonyl, carbamoyl, cyano and/or sulf- amoyl.
  • Heteroaryl refers to a specific subgroup of heterocyclyl, namely such unsaturated heterocyclic groups that are also aromatic. Such heteroaryl may be substituted with substituents as identified above for heterocyclyl. Further, heteroaryl may be a charged moiety, such as in pyridine-N-oxide. Due to tautomerism, e.g. keto-enol-tautomerism, heteroaryl may also be drawn as a partly unsaturated heterocyclyl (e.g. 2-hydroxypyridine).
  • heteroaryl includes pyridyl, pyrimidinyl, pyridazinyl, 1 ,3,5-triazolyl, 1 ,2,3- triazolyl, 1 ,2,4-triazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, acridinyl, purinyl, pteridinyl, pyrrolyl, pyrazolyl, imidazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, indolyl, indazolyl, benzopyranyl, benzothiopyranyl, benzo[1 ,3]dioxole, benzo-imidazolyl, tetrazolyl, furanyl, benzofuranyl, oxazolyl, isoxazolyl, thienyl, thiazolyl, isothiazolyl, etc.
  • Arylalkyl refers to an aryl group bound to the molecule via an alkyl group, such as a methyl or ethyl group, preferably phenethyl or benzyl, in particular benzyl.
  • cycloalkylalkyl and heterocyclyl represents a cycloalkyl group bound to the molecule via an alkyl group or a heterocyclyl group bound to the molecule via an alkyl group.
  • aryl, heterocyclyl, cycloalkyl and alkyl may be substituted as defined above.
  • Treatment includes prophylactic (preventive) and therapeutic treatment as well as the delay of progression of a disease or disorter.
  • FGFR kinase mediated diseases are such diseases, disorders or conditions (collectively “diseases") that respond in a beneficial way, e.g. amelioration of one or more symptoms, delay of the onset of a disease, up to temporary or complete cure from a disease, to the inhibition of a protein tyrosine kinase, especially inhibition of a FGFR (such as FGFR3) kinase.
  • proliferative diseases such as cancer diseases, solid tumors like breast cancer, bladder cancer, endometrial cancer, hepatocellular cancer, glioblastoma, or multiple myeloma, EMS myeloid proliferative disorders, may be mentioned.
  • Salts (which, what is meant by “or salts thereof” or “or a salt thereof", can be present alone or in mixture with free compound of the formula (I) are preferably pharmaceutically acceptable salts.
  • Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom, especially the pharmaceutically acceptable salts.
  • Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
  • Suitable organic acids are, e.g., carboxylic acids or sulfonic acids, such as fumaric acid or methansulfonic acid.
  • any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient.
  • Combination refers to either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner (e.g. an other drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect.
  • a combination partner e.g. an other drug as explained below, also referred to as “therapeutic agent” or “co-agent”
  • co-agent e.g. an other drug as explained below, also referred to as “therapeutic agent” or “co-agent”
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • the invention relates to a compound of the formula (I), in free base form or in acid addition salt form, wherein the substituents are as defined herein.
  • the invention relates to a compound of formula IA
  • the invention relates to a compound of formula IB
  • the invention relates to a compound of formula IC
  • the invention relates to a compound of formula ID wherein the substituents are as defined for a compound of formula I.
  • the invention relates to a compound of formula IE
  • the invention relates to a compound of formula IF
  • the invention relates to a compound of formula IG
  • the invention relates to a compound of formula IH wherein the substituents are as defined for a compound of formula I.
  • R 1 preferably represents hydrogen, halogen, Ci-i 2 alkyl, substituted wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-i 2 alkyl, amino 1 2 alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-i 2 alkyl, amino i 2 alkyl,
  • R 1 particular preferably represents hydrogen, fluoro, chloro, Ci -4 alkyl, substituted Ci -4 alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci -4 alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci -4 alkyl, amino-Ci -4 alkyl, Ci -4 alkyl-amino-Ci -4 alkyl, di-Ci -4 alkyl-amino Ci -4 alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci -4 alkyl, amino-Ci -4 alkyl, Ci -4 alkyl-amino-Ci -4 alkyl, di-Ci -4 alkyl-alkyl-
  • R 1 very particular preferably represents hydrogen, (2-dimethylamino-ethyl)-methyl-amino, 4-ethyl-piperazin-1-ylmethyl, methyl; with particular preference given to hydrogen.
  • R 2 preferably represents hydrogen, halogen, Ci-i 2 alkyl, substituted wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-i 2 alkyl, amino i 2 alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-i 2 alkyl, amino 1 2 alkyl, Ci.i 2 alkoxy, halo-Ci-i 2 alkoxy.
  • R 2 particular preferably represents hydrogen, fluoro, chloro, Ci -4 alkyl, substituted Ci -4 alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci -4 alkyl), amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci -4 alkyl, amino-Ci -4 alkyl, Ci -4 alkyl-amino-Ci -4 alkyl, di-Ci -4 alkyl-amino Ci -4 alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci -4 alkyl, amino-Ci -4 alkyl, Ci -4 alkyl-amino-Ci -4 alkyl, di-Ci -4 alkyl-amino Ci -4 alkyl, Ci -4 alkoxy, fluoro
  • A preferably represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaromatic moiety with 5 - 13 ring; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -R A1 -R A2 as defined herein.
  • a particular preferably represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 6 ring atoms and whereby at least one of the heteroatoms is nitrogen, each aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -R A1 -R A2 as defined herein.
  • a very particular preferably represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selected from the group consisting of phenyl, pyridyl (such as pyrid-2-yl, pyrid-3-yl), pyrimidyl (such as pyramid-5-yl), pyrolyl (such as pyrol-3-yl), imidazolyl (such as imidazo-2-yl or imidazo-4-yl), pyrazolyl (such as pyradzo-3-yl), triazolyl (such as triazo-3-yl) and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -R A1 -R A2 as defined herein.
  • B preferably represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaromatic moiety with 5 - 13 ring atoms; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents - R B1 -R B2 as defined below.
  • B particular preferably represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 10 ring atoms and whereby at least one of the heteroatoms is nitrogen or sulfur, each aromatic or heteroaromatic
  • R1 R? moiety is unsubstituted or substituted by one or more substituents -R -R as defined herein.
  • B very particular preferably represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selcected from the group consisting of phenyl, naphthyl (such as alpha-naphtyl), pyridyl (such as pyrid-3-yl), pyridyl-N-oxide (such as pyrid-3-yl-N- oxide), chinolinyl, isochinolinyl (such as isochinolin-4-yl, isochinolin-5-yl), thiophenyl (such as thiophen-3-yl), thionaphthenyl (such as thionaphthen-3-yl) and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -R B1 -R B2 as defined herein.
  • aryl or heteroaryl is unsubstituted or substituted by one or more substituents
  • R A1 preferably represents hydrogen; or formyl, Ci -7 alkylcarbonyl, Ci -7 alkoxycarbonyl, aminocarbonyl, N-Ci -7 alkylaminocarbonyl, N ⁇ -di-Ci- T -alkylaminocarbonyl; benzyl; or hydroxy, Ci -7 alkoxy, amino-Ci -7 alkoxy, N-Ci -7 alkylamino- Ci -7 alkoxy, N,N-di- Ci -7 alkylamino-Ci- 7 alkoxy; heterocyclyl-Ci -7 alkoxy whereby said heterocyclyl has 3 to 10 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci -7 alkyl and/or hydroxy; or a group -NR A3 R M or a group -C(O)-N R A3 R M .
  • R A1 particular preferably represents hydrogen; or formyl, Ci -4 alkylcarbonyl, Ci- 4 alkoxycarbonyl, aminocarbonyl, N,N-di-Ci -4 alkylaminocarbonyl; benzyl;or hydroxy, Ci- 4 alkoxy, N,N-di-Ci -4 alkylamino-Ci -4 alkoxy; heterocyclyl-Ci -4 alkoxy whereby said heterocyclyl has 5 to 6 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci -4 alkyl; or a group -NR A3 R M .
  • R A1 very particular preferably represents hydrogen; or methoxycarbonyl, tert.butoxycarbonyl, aminocarbonyl; or a group -NR A3 R M ; or hydroxy, N,N-dimethylaminoethoxy, N,N-dimethylaminomethoxy; heterocyclyl-Ci. 4alkoxy whereby said heterocyclyl is bound via nitrogen and selected from the group consisiting of pyrrolidinyl, piperidinyl, N-methylpiperazinyl, N-ethyl-piperazinyl, N- isopropyl-piperazinyl or morpholinyl.
  • R A2 preferably represents a direct bond or a straight-chain or branched-chain Ci_i 2 alkanediyl.
  • R A2 particular preferably represents a direct bond or a straight-chain or branched-chain Ci- 6 alkanediyl.
  • R A2 very particular preferably represents a direct bond, methandiyl, 1 ,2-ethanediyl, 1 ,1- ethanediyl, 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to direct bond, methandiyl, 1 ,2-ethanediyl.
  • R A3 and R M preferably represent independent from each other hydrogen, Ci -7 alkyl, hydroxy-Ci -7 alkyl, halogen-Ci -7 alkyl, cyano-Ci -7 alkyl, amino-Ci -7 alkyl, N-Ci -7 alkylamino- Ci -7 -alkyl, N,N-di-Ci -7 alkylamin- Ci -7 -alkyl, aminocarbonyl-Ci -7 alkyl, N- d- T -alkylaminocarbonyl-Ci- T -alkyl, N ⁇ -di-Ci- T -alkylaminocarbonyl-d- T -alkyl, a saturated, partly saturated or unsaturated hetereocycle which has 3 to 10 ring atoms, and which is optionally substituted by 1 to 3 substituents selected from the group consisting of Ci -7 alkyl, hydroxyl, oxo, hydroxy-Ci -7
  • R A3 and R M particular preferably represent independent from each other methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, hydroxymethyl, 2-hydroxyethyl, amino-methyl or -ethyl, dimethylaminomethyl or -ethyl, aminocarbonyl-methyl or -ethyl, N, N- dimethylaminocarbonyl-methyl or -ethyl, N,N-diethylaminocarbonyl-methyl or -ethyl or
  • R A3 and R M particular preferably represent together with the nitrogen to which they are bound a saturated, partly saturated or unsaturated hetereocycle selected from the group consisting of azetidine, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and which is optionally substituted by 1 substituent selected from the group consisting of methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, cyano, halogen, hydroxy, oxo, hydroxyethyl, benzyl, methoxybenzyl, N,N-dimethylamino, N,N-diethylamino.
  • R B1 preferably represents halo, a straight-chain or branched-chain unsubstituted Ci -7 alkyl, a straight-chain or branched-chain unsubstituted Ci -7 alkoxy, straight-chain or branched-chain halo-Ci -7 alkyl.
  • R particular preferably represents methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, methyoxy, ethyoxy, n- or iso-propoxy, n-, iso-, sec- or tert-butoxy, n-pentoxy, n-hexoxy, n-heptoxy, fluormethyl, chlormethyl, trifluoromethyl, fluoro, chloro, bromo.
  • R very particular preferably represents methyl, methoxy, trifluormethyl, fluoro, chloro.
  • R? R preferably represents a direct bond.
  • n preferably represents 0, 1 , 2, 3 or 4. m particular preferably represents 0, 1 or 4.
  • n preferably represents 0, 1 or 2 n particular preferably represents 0 or 1.
  • R B2 -R B1 are preferably in the ortho-positions.
  • R -R are preferably in the ortho and meta-positions.
  • the invention further relates to pharmaceutically acceptable prodrugs of a compound of formula (I).
  • the invention further relates to pharmaceutically acceptable metabolites of a compound of formula (I).
  • the invention further relates to protected derivatives of a compound of formula (I).
  • the invention relates especially to the compounds of the formula (I) given in the Examples, as well as the methods of manufacture described therein.
  • the invention also provides, in a second aspect, pharmacological uses of compounds of formula (I).
  • the compounds of formula (I) have valuable pharmacological properties, as described hereinbefore and hereinafter. They inhibit various protein kinases, such as tyrosine kinases, for example VEGFR2 (KDR), PDGFR, cKIT, LCK, cAbl, RET and FGFR kinases, especially FGFR1 , FGFR2, FGFR3, FGFR4.
  • the efficacy of the compounds of formula (I) as inhibitors of protein kinase activity can be demonstrated according to known procedures; in particular according to the assays described in the experimental part below.
  • the activity of a protein kinase is assayed in the presence or absence of inhibitor by measuring the phosphorylation of a synthetic substrate by purified N-terminally His- or GST-tagged kinase domains, in the presence of selected concentrations of ATP and using the appropriate assay technology: Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) (LanthaScreenTM) or microfluidic Caliper system.
  • TR-FRET Time-Resolved Fluorescence Resonance Energy Transfer
  • LanthaScreenTM microfluidic Caliper system.
  • bladder carcinoma cell lines such as the human urinary bladder transitional cell carcinoma RT1 12 cell line (DSMZ ACC # 418).
  • Tumors are obtained after subcutaneous injection of the respective cells (minimum 1 x 10 6 cells in 100 ml phosphate buffered physiological saline) into the carrier mice or rat. The treatment is started, as soon as the tumor has reached an average size of 100 mm 3 . Tumor growth is determined three times weekly and 24 h after the last treatment by measurement of the perpendicular diameter. In case of tumors, tumor volumes are determined according to the Formula L x D x p/6 (see Evans, B. D., Smith, I.E., Shorthouse, AJ. and Millar, J. J., Brit. J. Cancer, 45: 466-468, 1982).
  • the antitumor activity is expressed as T/C% (average increase of the tumor volume of treated animals divided by the average increase of tumor volume in control animals multiplied by 100).
  • Tumor regression (%) represents the smallest mean tumor volume compared to the mean tumor volume at the beginning of the treatment. Each animal in which the tumor reaches a diameter of more than 1 ,5 to 2 cm 3 is sacrificed.
  • the pharmacological activity of a compound of formula (I) may, for example, be demonstrated in a clinical study or in a test procedure according to methods generally accepted in the field; e.g. as essentially described hereinafter.
  • Suitable clinical studies are, for example, open label non-randomized, dose escalation stu- dies in patients with one of the tumor diseases mentioned above.
  • the beneficial effects on proliferative diseases can be determined directly through the results of these studies or by changes in the study design which are known as such to a person skilled in the art.
  • the efficacy of the treatment can be determined in such studies, e.g., in case of tumors after 18 or 24 weeks by radiologic evaluation of the tumors every 6 weeks, in case of a leukemia e.g. by determination of the count of aberrant white blood cells, and by staining mononuclear cells and/or by means of determining minimum residual disease (MRD) e.g. by FACS-LPC MRD or PCR.
  • MRD minimum residual disease
  • An exemplary (though not limiting) schedule for administration of a compound of formula (I) is daily administration, with preferably 1 to 3 daily dosages for a longer time, possibly until the disease is cured or, if only palliative treatment is achieved, for as long as required; alternatively, treatment e.g. for 5 days, and/or administration at days 1 , 4 and 9, with eventual repetition after a certain time without treatment is possible.
  • treatment several times a day e.g. 2 to 5 times
  • treatment by continuous administration e.g. infusion
  • administration is orally or parenterally, preferably orally.
  • the test compounds are preferably diluted in water or in sterile 0.9% saline.
  • a compound of formula (I) according to the invention shows therapeutic efficacy especially against disorders dependent on protein tyrosine kinase ("protein tyrosine kinase dependent diseases") such as FGFR, VEGFR2 (KDR), PDGF-R, cKIT, LCK, cABL, RET, especially proliferative diseases mediated FGFR kinase activity.
  • protein tyrosine kinase dependent diseases such as FGFR, VEGFR2 (KDR), PDGF-R, cKIT, LCK, cABL, RET, especially proliferative diseases mediated FGFR kinase activity.
  • the compounds of formula (I), that inhibit the protein tyrosine kinase activities mentioned, especially tyrosine protein kinases mentioned above and below, can therefore be used in the treatment of protein kinase dependent diseases.
  • a compound of formula (I) is in particular useful in the treatment of diseases identified below.
  • FGFR dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • a first group of FGFR dependents diseases relates to a benign or malignant proliferative disease, e. g. a cancer, e. g. tumors and/or metastasis (wherever located).
  • the proliferative disease is a cancer.
  • the proliferative diseases include, without being limited to, cancers of the bladder, cervix, or oral squamous cell carcinomas (in particular with mutated FGFR3 and/or elevated FGFR3 expression), multiple myeloma (in particular with t(4,14) chromosomal translocation), breast cancers (in particular with gene amplification and /or protein overexpression of FGFR1 , FGFR2 or FGFR4), endometrial cancer (in particular with FGFR2 mutations), hepatocellular cancer (in particular with elevated expression of FGFR3 or FGFR4 or FGF ligands), any cancer type with an amplification of the 1 1q13 amplicon, which contains the FGF3, FGF4 and FGF19 loci, for example breast cancer, hepatocellular cancer, EMS myeloproliferative disorders (in particular with abnormal FGFR1 fusion proteins), lymphomas (in particular with abnormal FGFR3 fusion proteins), glioblastomas (in
  • FGFR4 FGFR4, or FGF ligands
  • pituitary tumors in particular with abnormal FGFR4
  • any cancer that requires angiogenesis any cancer that requires angiogenesis .
  • a second group of FGFR dependents diseases relates to non-cancer disorders.
  • non- cancer disorders include, without being limited to, benign skin tumors (in particular with FGFR3 activating mutations), skeletal disorders (in particular resulting from mutations in FGFRs) including achondroplasia, hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), thanatophoric dysplasia (TD), muenke coronal craniosynostosis, crouzon syndrome with acanthosis nigricans, both familial and sporadic forms of Pfeiffer syndrome; disorders related to alterations of phosphate homeostasis, for example autosomal dominant hypophosphatemic rickets (ADHR, in particular related to FGF23 missense mutations), x-linked hypophosphatemic rickets (XLH; an x-linked dominant disorder related to inactivating mutations in the PHEX gene), tumor-
  • a third group of FGFR dependent diseases relates to inflammatory or autoimmune diseases.
  • the inhibition of FGFR activity has been found to represent a means for treating T cell mediated inflammatory or autoimmune diseases, as for example in treatment of T- cell mediated inflammatory or autoimmune diseases including but not limited to rheumatoid arthritis (RA), collagen Il arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • SLE systemic lupus erythematosus
  • psoriasis juvenile onset diabetes
  • Sjogren's disease thyroid disease
  • sarcoidosis autoimmune uveit
  • a fourth group of FGFR dependent diseases relates tot the group consisting of obesity, diabetes and/or diseases related thereto.
  • Methods of antagonizing FGFRs, especially FGFR1 or FGFR4 have also been described to be useful in the treatment of obesity, diabetes and/or diseases related thereto, such as metabolic syndrome, cardiovascular diseases, hypertension, aberrant cholesterol and triglyceride levels, dermatological disorders e.g. infections, varicose veins, Acanthosis nigricans, eczema, exercise intolerance, diabetes type 2, insulin resistance, hypercholesterolemia, cholelithiasis, orthopedic injury, thromboembolic disease, coronary or vascular restriction (e.g.
  • Atherosclerosis daytime sleepiness, sleep apnoea, end stage renal disease, gallbladder disease, gout, heat disorders, impaired immune response, impaired respiratory function, infections following wounds, infertility, liver disease, lower back pain, obstetric and gynecological complications, pancreatitis, stroke, surgical complications, urinary stress incontinence and/or gastrointestinal disorders.
  • FGFRs especially FGFR1
  • COPD Chronic Obstructive Pulmonary Disease
  • FGF-1 acidic Fibroblast Growth Factor
  • FGFR1 have also been described to be involved in aberrant signaling in retinoblastoma, leading to proliferation upon binding of FGF-1.
  • Non-FGFR protein kinase dependent diseases include VEGFR2 (KDR), PDGF, cKIT, LCK, cABL and RET dependent diseases and are especially proliferative diseases, preferably benign or especially malignant tumours (for example carcinoma of the kidneys, liver, adrenal glands, bladder, breast, stomach, ovaries, colon, rectum, prostate, pancreas, lungs, vagina or thyroid, sarcoma, glioblastomas and numerous tumours of the neck and head, as well as leukemias). They are able to bring about the regression of tumours and to prevent the formation of tumour metastases and the growth of (also micro )-metastases. In addition they can be used in epidermal hyperproliferation (e.g.
  • the compounds of formula (I) in the treatment of diseases of the immune system insofar as several or, especially, individual tyrosine protein kinases are involved; furthermore, the compounds of formula (I) can be used also in the treatment of diseases of the central or peripheral nervous system where signal transmission by at least one tyrosine protein kinase, especially selected from those mentioned specifically, is involved.
  • VEGFR2 (KDR) dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • Vascular endothelial growth factor receptor-2 (VEGFR2; KDR) is expressed on the primary vascular endothelium and is essential for normal vascular development.
  • Angiogenesis or the sprouting of new blood vessels, is also a central process in the growth of solid tumors.
  • the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis.
  • Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF).
  • VEGF angiogenic factor vascular endothelial growth factor
  • the compounds of formula (I) as inhibitors of VEGF-receptor tyrosine kinase activity may primarily inhibit the growth of blood vessels and are thus, for example, effective against a number of diseases associated with deregulated angiogenesis, especially diseases caused by ocular neovascularisation, especially retinopathies, such as diabetic retinopathy or age-related macula degeneration, psoriasis, haemangioblastoma, such as haemangioma, mesangial cell proliferative disorders, such as chronic or acute renal diseases, e.g.
  • diabetic nephropathy malignant nephrosclerosis, thrombotic microangiopathy syndromes or transplant rejection, or especially inflammatory renal disease, such as glomerulonephritis, especially mesangioproliferative glomerulonephritis, haemolytic-uraemic syndrome, diabetic nephropathy, hypertensive nephrosclerosis, atheroma, arterial restenosis, autoimmune diseases, diabetes, endometriosis, chronic asthma, and especially neoplastic diseases, for example so-called solid tumors (especially cancers of the gastrointestinal tract, the pancreas, breast, stomach, cervix, bladder, kidney, prostate, ovaries, endometrium, lung, brain, melanoma, Kaposi's sarcoma, squamous cell carcinoma of heand and neck, malignant pleural mesotherioma, lymphoma or multiple myeloma) and liquid tumors (e.g.
  • leukemias especially those expressing KDR
  • a compound of formula (I) inhibits the growth of tumours and is especially suited to preventing the metastatic spread of tumors and the growth of micrometastases. These diseases are thus also Protein kinase dependent diseases.
  • PDGF dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • Compounds of the formula (I), in view of their activity as PDGF receptor inhibitors, are also especially appropriate in the treatment of proliferate diseases, especially glioblastoma, small lung cancer, atherosclerosis, thrombosis, psoriasis, scleroderma or fibrosis.
  • cKIT dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, head and neck cancers, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial, lung or pancreatic cancer.
  • KIT kinase expression has been documented in a wide variety of human malignancies such as mastocytosis/ mast cell leukemia, gastrointestinal stromal tumors (GIST), small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
  • GIST gastrointestinal stromal tumors
  • SCLC small cell lung carcinoma
  • sinonasal natural killer/T-cell lymphoma testicular cancer
  • thyroid carcinoma malignant melanoma
  • ovarian carcinoma adenoid cystic carcinoma
  • AML acute myelogenous leukemia
  • C-kit is a receptor tyrosine kinase expressed on the surface of mast cells, to which stem cell factor (SCF) is a ligand.
  • SCF stem cell factor
  • Aberrant c-kit signaling is a mediator of certain autoimmune diseases. Binding of SCF to the c-kit receptor mediates various functions of the mast cell. As an important mediator of mast cell function, c-kit plays a role in pathologies associated with mast cells (MC). C-kit functions through mast cell generation, which plays an important role in triggering autoimmune diseases.
  • LCK dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • LCK is a cytoplastic tyronsine kinase of the Src family expressed in T cells and natural killer cells. It is generally accepted that Lck activity is important for signaling mediated by the T cell receptor and leads to normal T cell development and activation.
  • compounds of formula (I) are a useful immunosuppressive for the treatment of autoimmune and inflammatory disorders and / or organ transplant rejection (in particular T cell mediated).
  • cABL dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • CML a reciprocally balanced chromosomal translocation in hematopoietic stem cells (HSCs) produces the BCR-ABL hybrid gene.
  • HSCs hematopoietic stem cells
  • the BCR-ABL fusion gene encodes as constitutively activated kinase, which transforms HSCs to produce a phenotype exhibiting deregulated clonal proliferation, reduced capacity to adhere to the bone marrow stroma and a reduces apoptotic response to mutagenic stimuli, which enable it to accumulate progressively more malignant transformations.
  • Compounds of the formula (I) in view of their activity as AbI protein tyrosune kinase inhibitors, are also especially appropriate in the treatment of leukemias, e.g. CML or acute lymphoblastic leukemia (ALL).
  • RET dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art.
  • activating RET mutations are found in the inherited cancer sysndrome multiple endocrine neoplasia 2 and in sporadic medullary and papillary thyroid carcinomas.
  • the specific type and location of RET mutations are strongly correlated with the desease phenotype and also have diagnostic and prognostic value.
  • RET - associated thyroid tumors encompass malignancies of the parafollicular C. cells and of follicular epithelial cells, of which the most common are papillary thyroid carcinomas.
  • RET mutations cause the early onset cancer syndrome multiple endocrine neoloasia type 2 associated with several endocrine tumors including MTX, PC and parathyroid hyperplasia.
  • the invention also provides, in a third aspect, a combination of a compound of formula (I) and one or more further therapeutic agents.
  • a compound of formula (I) can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents.
  • a compound of formula (I) can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
  • a compound of the formula (I) may be used to advantage in combination with other antiproliferative compounds.
  • antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase Il inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibit- tors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphospho- nates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhi- bitors of
  • tumor treatment approaches including surgery, ionizing radiation, photodynamic therapy, implants, e.g. with corticosteroids, hormones, or they may be used as radiosensitizers.
  • implants e.g. with corticosteroids, hormones, or they may be used as radiosensitizers.
  • anti-inflammatory and/or antiproliferative treatment combination with anti-inflammatory drugs is included. Combination is also possible with antihistamine drug substances, bronchodilatatory drugs, NSAID or antagonists of chemokine receptors.
  • aromatase inhibitor as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testoste- rone to estrone and estradiol, respectively.
  • the term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole.
  • Exemestane can be administered, e.g., in the form as it is marketed, e.g.
  • Form- estane can be administered, e.g., in the form as it is marketed, e.g. under the trademark LENTARON.
  • Fadrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark AFEMA.
  • Anastrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark ARIMIDEX.
  • Letrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark FEMARA or FEMAR.
  • Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the trademark ORIMETEN.
  • a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
  • antiestrogen as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
  • the term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
  • Tamoxifen can be administered, e.g., in the form as it is marketed, e.g. under the trademark NOLVADEX.
  • Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under the trademark EVISTA.
  • Fulvestrant can be formulated as disclosed in US 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g. under the trademark FASLODEX.
  • a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors.
  • anti-androgen as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g. as disclosed in US 4,636,505.
  • bicalutamide CASODEX
  • gonadorelin agonist as used herein includes, but is not limited to abarelix, go- serelin and goserelin acetate. Goserelin is disclosed in US 4,100,274 and can be administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEX.
  • Abarelix can be formulated, e.g. as disclosed in US 5,843,901.
  • topoisomerase I inhibitor includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/17804).
  • Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CAMPTOSAR.
  • Topotecan can be administered, e.g., in the form as it is marketed, e.g. under the trademark HYCAMTIN.
  • topoisomerase Il inhibitor includes, but is not limited to the an- thracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYX), dauno- rubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and lo- soxantrone, and the podophillotoxines etoposide and teniposide.
  • Etoposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOS.
  • Teniposide can be administered, e.g. in the form as it is marketed, e.g.
  • Doxorubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN.
  • Epirubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark FARMORUBICIN.
  • Idarubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOS.
  • Mitoxantrone can be administered, e.g. in the form as it is marketed, e.g. under the trademark NOVANTRON.
  • microtubule active compound relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolides, cochicine and epothilones and derivatives thereof, e.g. epothilone B or D or derivatives thereof.
  • Paclitaxel may be administered e.g. in the form as it is marketed, e.g. TAXOL.
  • Docetaxel can be administered, e.g., in the form as it is marketed, e.g. under the trademark TAXOTERE.
  • Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN R.
  • Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN.
  • Discodermolide can be obtained, e.g., as disclosed in US 5,010,099.
  • Epothilone derivatives which are disclosed in WO98/10121 , US 6,194,181 , WO98/25929, WO98/08849, WO99/43653, WO98/22461 and WO00/31247. Especially preferred are Epothilone A and/or B.
  • alkylating compound includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
  • Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLOSTIN.
  • Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark HOLOXAN.
  • histone deacetylase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO02/22577, especially N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H- indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1 H- indol-3-yl)-ethyl]-amino]methyl]phenyl]-2£-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).
  • SAHA Suberoylanilide hydroxamic acid
  • antimetabolite includes, but is not limited to, 5-Fluorouracil or 5- FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed.
  • Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA.
  • Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR.
  • platinum compound as used herein includes, but is not limited to, carboplatin, cis- platin, cisplatinum and oxaliplatin.
  • Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CARBOPLAT.
  • Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN.
  • compounds targeting/decreasing a protein or lipid kinase activity includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g., a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g.
  • PDGFR platelet-derived growth factor-receptors
  • a N-phenyl-2- pyrimidine-amine derivative e.g. imatinib, SU101 , SU6668 and GFB-1 1 1 ; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor- receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-1 R), such as compounds which target, decrease or inhibit the activity of IGF- 1 R, especially compounds which inhibit the kinase activity of IGF-1 receptor, such as those compounds disclosed in WO02/092599, or antibodies that target the extracellular domain of IGF-1 receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the AxI receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor t
  • imatinib compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases - (part of the PDGFR family), such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, e.g. imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g. BCR-AbI kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e.g.
  • N-phenyl-2-pyrimidine-amine derivative e.g. imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825) j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK1 , PKB/Akt, and Ras/MAPK family members, and/or members of the cyclin- dependent kinase family (CDK) and are especially those staurosporine derivatives disclosed in US 5,093,330, e.g.
  • PKC protein kinase C
  • Raf family of serine/threonine kinases members of the MEK, SRC, JAK, FAK, PDK1 , PKB/Akt
  • examples of further compounds include e.g. UCN-01 , safingol, BAY 43-9006, Bryostatin 1 , Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521 ; LY333531/LY379196; isochinoline compounds such as those disclosed in WO00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein- tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin.
  • GLEEVEC imatinib mesylate
  • tyrphostin include imatinib mesylate (GLEEVEC) or t
  • a tyrphostin is preferably a low molecular weight (Mr ⁇ 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S- arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810; AG 99;
  • compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers
  • compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g.
  • EGF receptor ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO98/10767, WO97/30034, WO97/49688, WO97/38983 and, especially, WO96/30347 (e.g. compound known as CP 358774), WO96/33980 (e.g.
  • compound ZD 1839 and WO95/03283 e.g. compound ZM105180
  • trastuzumab HerceptinTM
  • cetuximab ErbituxTM
  • Iressa Tarceva
  • OSI-774 CI-1033
  • EKB-569 E1.1 , E2.4, E2.5, E6.2, E6.4, E2.1 1 , E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO03/013541 ;
  • compounds targeting, decreasing or inhibiting the activity of the c-Met receptor such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF.
  • Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.
  • Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase includes, but is not limited to inhibitors of phosphatase 1 , phosphatase 2A, or CDC25, e.g. okadaic acid or a derivative thereof.
  • Compounds which induce cell differentiation processes includes, but is not limited to e.g. retinoic acid, ⁇ - ⁇ - or ⁇ -tocopherol or ⁇ - ⁇ - or ⁇ -tocotrienol.
  • cyclooxygenase inhibitor includes, but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
  • Cox-2 inhibitors such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
  • bisphosphonates as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
  • Etridonic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL.
  • Clodronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS.
  • titaniumudronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID.
  • “Pamidronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIATM.
  • “Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX.
  • “Ibandronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT.
  • “Risedronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTONEL.
  • "Zoledronic acid” can be administered, e.g. in the form as it is marketed, e.g.
  • mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (CerticanTM), CCI-779 and ABT578.
  • heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulfate degradation.
  • the term includes, but is not limited to, PI-88.
  • biological response modifier refers to a lymphokine or interferons, e.g. interferon ⁇ .
  • inhibitor of Ras oncogenic isoforms e.g. H-Ras, K-Ras, or N-Ras
  • telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase.
  • Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g. telomestatin.
  • methionine aminopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase.
  • Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g. bengamide or a derivative thereof.
  • proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
  • Compounds which target, decrease or inhibit the activity of the proteasome include e.g. Bortezomid (VelcadeTM) and MLN 341.
  • matrix metalloproteinase inhibitor or (“MMP” inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551 ) BMS- 279251 , BAY 12-9566, TAA21 1 , MMI270B or AAJ996.
  • MMP matrix metalloproteinase inhibitor
  • FMS-like tyrosine kinase inhibitors e.g. compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
  • FMS-like tyrosine kinase receptors are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, e.g. PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
  • HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway.
  • Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90 e.g., 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
  • antiproliferative antibodies includes, but is not limited to, trastuzumab (HerceptinTM), Trastuzumab-DM1 ,erbitux, bevacizumab (AvastinTM), rituximab (Rituxan ® ), PRO64553 (anti-CD40) and 2C4 Antibody.
  • antibodies is meant e.g. intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
  • compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
  • compounds of formula (I) can be administered in combination with, e.g., farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
  • antigenemic compounds includes, for example, Ara-C, a pyrimidine analog, which is the 2 ' -alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate.
  • HDAC histone deacetylase
  • SAHA suberoylanilide hydroxamic acid
  • HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065, in particular, ⁇ /-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]me- thyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and ⁇ /-hydro- xy-3-[4-[(2-hydroxyethyl) ⁇ 2-(1 /-/-indol-3-yl)ethyl]-amino]methyl]phenyl]-2£-2-propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt.
  • Somatostatin receptor antagonists refers to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230.
  • Tumor cell damaging approaches refer to approaches such as ionizing radiation.
  • ionizing radiation means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4 th Edition, Vol. 1 , pp. 248-275 (1993).
  • EDG binders refers a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720.
  • ribonucleotide reductase inhibitors includes, but is not limited to to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin.
  • Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1 /-/-isoindole-1 ,3-dione derivatives, such as PL-1 , PL-2, PL-3, PL-4, PL-5, PL-6, PL-7 or PL-8 mentioned in Nandy et al., Acta Oncologica, Vol. 33, No. 8, pp. 953-961 (1994).
  • S-adenosylmethionine decarboxylase inhibitors includes, but is not limited to the compounds disclosed in US 5,461 ,076.
  • VEGF vascular endothelial growth factor
  • WO98/35958 e.g. 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, e.g. the succinate, or in WO00/09495, WO00/27820, WO00/59509, WO98/1 1223, WO00/27819 and EP 0 769 947; those as described by Prewett et al, Cancer Res, Vol. 59, pp. 5209-5218 (1999); Yuan et al., Proc Natl Acad Sci U S A, Vol. 93, pp.
  • Photodynamic therapy refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers.
  • Examples of photodynamic therapy include treatment with compounds, such as e.g. VISUDYNE and porfimer sodium.
  • Angiostatic steroids refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 1 1- ⁇ -epihydrocotisol, cortexolone, 17 ⁇ -hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.
  • Plants containing corticosteroids includes, but is not limited to compounds, such as e.g. fluocinolone, dexamethasone.
  • “Other chemotherapeutic compounds” include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.
  • the compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of inflammatory diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
  • a compound of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • the invention includes a combination of a compound of the invention as hereinbefore described with an anti-inflammator or antihistamine drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition.
  • Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO02/88167, WO02/12266, WO02/100879, WO02/00679 (especially those of Examples 3, 11 , 14, 17, 19, 26, 34, 37, 39, 51 , 60, 67, 72, 73, 90, 99 and 101 ), WO03/035668, WO03/048181 , WO03/062259, WO03/064445, WO03/072592, non-steroidal glucocorticoid receptor agonists such as those described in WO00/00531 , WO02/10143, WO03/082280, WO03/082787, WO03/104195, WO04/005229;
  • steroids in particular glucocorticosteroids such
  • LTB4 antagonists such LY2931 1 1 , CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247 and those described in US 5451700; LTD4 antagonists such as montelu- kast and zafirlukast; PDE4 inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden),V-1 1294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Al mi rail Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-
  • Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in WO01/041 18, WO02/51841 , WO02/53564, WO03/00840, WO03/87094, WO04/05285, WO02/00652, WO03/53966, EP 424021 , US 5171744, US 3714357, WO03/33495 and WO04/018422.
  • Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine as well as those disclosed in WO03/099807, WO04/026841 and JP 2004107299.
  • Other useful combinations of compounds of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g.
  • Therapeutic agents for possible combination are especially one or more antiproliferative, cytostatic or cytotoxic compounds, for example one or several agents selected from the group which includes, but is not limited to, an inhibitor of polyamine biosynthesis, an inhibitor of a protein kinase, especially of a serine/threonine protein kinase, such as protein kinase C, or of a tyrosine protein kinase, such as the EGF receptor tyrosine kinase, e.g. Iressa®, the VEGF receptor tyrosine kinase, e.g. PTK787 or Avastin®, or the PDGF receptor tyrosine kinase, e.g.
  • an inhibitor of polyamine biosynthesis an inhibitor of a protein kinase, especially of a serine/threonine protein kinase, such as protein kinase C, or of a tyrosine protein kinase,
  • STI571 (Glivec®), a cytokine, a negative growth regulator, such as TGF- ⁇ or IFN- ⁇ , an aromatase inhibitor, e.g. letrozole (Femara®) or anastrozole, an inhibitor of the interaction of an SH2 domain with a phosphorylated protein, antiestrogens, topoisomerase I inhibitors, such as irinotecan, topoisomerase Il inhibitors, microtubule active agents, e.g.
  • paclitaxel or an epothilone alkylating agents, antiproliferative antimetabolites, such as gemcitabine or capecitabine, platin compounds, such as carboplatin or cis-platin, bisphosphonates, e.g. AREDIA® or ZOMETA®, and monoclonal antibodies, e.g. against HER2, such as trastuzumab.
  • alkylating agents such as gemcitabine or capecitabine
  • antiproliferative antimetabolites such as gemcitabine or capecitabine
  • platin compounds such as carboplatin or cis-platin
  • bisphosphonates e.g. AREDIA® or ZOMETA®
  • monoclonal antibodies e.g. against HER2, such as trastuzumab.
  • the above-mentioned compounds which can be used in combination with a compound of the formula (I), can be prepared and administered as described in the art, such as in the documents cited above.
  • the invention relates in a further aspect to a combination comprising a therapeutically effective amount of a compound of formula (I) in free form or in pharmaceutically acceptable salt form and a second drug substance, for simultaneous or sequential administration.
  • composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of such a compound, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier and / or diluents and optionally one or more further drug substances.
  • the compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
  • Topical administration is e.g. to the skin.
  • a further form of topical administration is to the eye.
  • Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
  • pharmaceutically acceptable carriers that are suitable for topical, enteral, for example oral or rectal, or parenteral administration and that may be inorganic or organic, solid or liquid.
  • diluents for example lactose, dextrose, mannitol, and/or glycerol, and/or lubricants and/or polyethylene glycol.
  • Tablets may also comprise binders, for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavorings and sweeteners. It is also possible to use the pharmacologically active compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions.
  • binders for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
  • disintegrators for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or
  • the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilisers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
  • excipients for example preservatives, stabilisers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
  • the present pharmaceutical compositions which may, if desired, comprise other pharmacologically active substances are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectionning, dissolving or lyophilising processes, and comprise approximately from 1% to 99%, especially from approx. 1 % to approx. 20%, active ingredient(s).
  • the dosage of the active ingredient to be applied to a warm-blooded animal depends upon a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals is preferably from approximately 3 mg to approximately 5 g, more preferably from approximately 10 mg to approximately 1.5 g per person per day, divided preferably into 1 to 3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, as a medicament / for use as a medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases.
  • the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, as active ingredient in a medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases.
  • the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, as medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases.
  • the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, for the manufacture of a medicament for the treatment of one or more Protein tyrosine kinase mediated diseases.
  • the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt of such a compound, for use in a method for the treatment of a subject in need thereof, especially for the treatment of a Protein tyrosine kinase mediated disease, most especially in a patient requiring such treatment.
  • the invention relates to a method for the treatment of a disease which responds to an inhibition of a FGFR (such as FGFR3) kinase, which comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above, especially in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
  • a FGFR such as FGFR3
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) as active ingredient in association with at least one pharmaceutical carrier or diluent.
  • Such compositions may be manufactured in conventional manner.
  • the invention relates to a method of treatment of one or more Protein tyrosine kinase mediated diseases, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of compound of formula I.
  • the invention relates to pharmaceutical compositions comprising: (a) an effective amount of compound of formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) one or more pharmaceutically acceptable excipients and / or diluents.
  • the invention also provides, in a further aspect, methods of manufacturing a compound of formula (I) and intermediates and their methods of manufacturing; such intermediates are useful for the manufacturing of a compound of formula (I).
  • a compound of the formula (I) may be prepared by processes that, though not applied hitherto for the new compounds of the present invention where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation.
  • a process for the manufacture of a compound of the formula (I) comprises either
  • a diluent such as a polar organic solvent
  • a reaction aid such as DMAP or TBTU
  • a base such as an amine
  • L 2 B represents represents a boronic acid residue or an ester thereof (such as (HO) 2 B-) or 4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl-), optionally in the presence of a diluent (such as an apolar organic solvent), optionally in the presence of a catalyst (such as a homogeneous Pd-catalyst), optionally in the presence of an reaction aid (such as an inorganic base) to obtain a compound of formula I;
  • a diluent such as an apolar organic solvent
  • a catalyst such as a homogeneous Pd-catalyst
  • an reaction aid such as an inorganic base
  • Method A) is particularly useful for manufacturing of compounds wherein X represents N (such as formula (I-A), (I-B), (I-C); while method B) is particular useful for manufacturing of compounds wherein X represents CH (such as formula (I-D)).
  • Protective gases such as argon
  • the starting materials may be used in equimolar amounts; alternatively, a compound may be used in excess, e.g. to function as a solvent or to shift equilibrium or to generally accelerate reation rates.
  • Reaction aids such as acids, bases or catalysts may be added in suitable amounts, as known in the field, required by a reation and in line with generally known procedures.
  • lntermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
  • Intermediates may be directly used in the further reaction step or may be subject to one or more work up and/or purification steps. Additionally, intermediates may be subject to further derivatization / functionalization, as the case may be. For example, substituion of an aryl/heteroaryl ring may take place to introduce additional substituents (such as chloro, fluoro).
  • Starting materials may be used as commercially available, and/or subject to one or more work up and/or purification steps and/or produced in situ.
  • reaction typically takes place in the presence of an activating agent (such as TBTU or others) which may be added in a slight excess and in the presence of a tert. amine and in the presence of one or more diluents
  • activating agent such as TBTU or others
  • reaction takes place at r.t, reaction times may vary, good convertion rates are typically obtained after 18 hours. Further details may be found in the examples.
  • This reaction is, inter alia, useful for manufacturing of compounds of formula (I) according to method B) as described above.
  • Reaction conditions, starting materials and catalysts for a Suzuki(-Miyaura) reaction are generally known in the field. This reaction typically takes place by palladium-catalyzed crosscoupling of organoboranes (e.g. of formula (V) or a reactive derivative thereof, whith a halogen derivative (e.g. of the formula (IV) or (X)).
  • the reaction may be typically performed in analogy to the procedure described by K. Jones, M. Keenan, and F. Hibbert [Synlett, 1996, (6), 509-510].
  • Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art.
  • Protecting groups are such groups that are typically no longer present in the final compounds once they are removed, while groups that remain as substituents are not protecting groups in the sense used here which are groups that are added at a starting material or intermediate stage and removed to obtain a final compound.
  • protecting groups may be introduced and removed, if useful or required.
  • the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etheri- fications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by acetolysis, protonolysis, solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
  • the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and below.
  • a compound of the formula (I) may be converted into a different compound of the formula (I).
  • the following description provides a non-limiting overview of particular relevant optional reactions and conversions:
  • Benzyl groups For example, in a compound of the formula (I) having a benzyl which is optionally substituted (e.g. methoxybenzyl), said benzyl moiety may be removed by hydrogenation, e.g. in the presence of a noble metal catalyst, such as palladium on coal, in an appropriate solvent, such as an alcohol, e.g. methanol, at appropriate temperatures, e.g. from 0 to 50 0 C, in the case of removal from the piperazine nitrogen in the additional presence of an acid, e.g. HCI, to yield the corresponding compound wherein instead of the benzyl moiety a hydrogen is present.
  • a noble metal catalyst such as palladium on coal
  • an appropriate solvent such as an alcohol, e.g. methanol
  • a compound of formula (I) can be converted to a corresponding N-oxide.
  • the reaction is typically carried out with a suitable oxidizing agent, preferably a peroxide, for example m-chloroperbenzoic acid, in a suitable solvent, e.g. halogenated hydrocarbon, typically chloroform or dichloromethane, or in a lower alkanecarboxylic acid, typically acetic acid, preferably at a temperature between O 0 C and the boiling temperature of the reaction mixture, especially at about room temperature.
  • a suitable oxidizing agent preferably a peroxide, for example m-chloroperbenzoic acid
  • a suitable solvent e.g. halogenated hydrocarbon, typically chloroform or dichloromethane
  • acetic acid typically at a temperature between O 0 C and the boiling temperature of the reaction mixture, especially at about room temperature.
  • Compounds of formula (I) in unoxidized form can typically be prepared from N-oxides of compounds of formula (I) by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80 0 C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
  • a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
  • Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se.
  • an acid addition salt of compounds of formula (I) with basic groups e.g. basic nitrogen
  • a salt of a compound of formula (I) having acid groups may be typically formed by treating the compound with a metal compound, such as an alkali metal salt of a suitable organic carboxylic acid, e.g.
  • the sodium salt of 2-ethylhexanoic acid with an organic alkali metal or alkaline earth metal compound, such as the corresponding hydroxide, carbonate or hydrogen carbonate, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with a corresponding calcium compound or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
  • an organic alkali metal or alkaline earth metal compound such as the corresponding hydroxide, carbonate or hydrogen carbonate, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with a corresponding calcium compound or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
  • Internal salts of compounds of formula (I) containing acid and basic salt-forming groups e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralization of salts
  • a salt of a compound of the formula (I) can be typically converted in customary manner into the free compound; a metal or ammonium salt can be converted, for example, by treatment with a suitable acid, and an acid addition salt, for example, by treatment with a suitable basic agent into a different salt. In both cases, suitable ion exchangers may be used.
  • Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
  • appropriate prodrugs can be typically prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1 ,1-acyloxyalkylcarbanochloridate, para- nitrophenyl carbonate, or the like).
  • Solvates Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
  • the amino can be converted into acylamino, e.g. Ci-C 7 - alkanoylamino or Ci-C 7 -alkanesulfonylamino, typically by reaction with a corresponding Ci-C 7 -alkanoylhalogenide or Ci-C 7 -alkanesulfonylhalogenide, e.g.
  • a corresponding chloride in the presence of a tertiary nitrogen base, such as triethylamine or pyridine, in the absence or presence of an appropriate solvent, such a methylene chloride, for example at temperatures in the range from -20 to 50 0 C, e.g. at about room temperature.
  • a tertiary nitrogen base such as triethylamine or pyridine
  • an appropriate solvent such as a methylene chloride
  • the cyano may be converted to an aminomethyl group, e.g. by hydrogenation in the presence of an appropriate metal catalyst, such as Raney Nickel or Raney Cobalt, in an appropriate solvent, e.g. a lower alkanol, such as methanol and/or ethanol, for example at temperatures in the range from -20 to 50 0 C, e.g. at about room temperature.
  • an appropriate metal catalyst such as Raney Nickel or Raney Cobalt
  • an appropriate solvent e.g. a lower alkanol, such as methanol and/or ethanol, for example at temperatures in the range from -20 to 50 0 C, e.g. at about room temperature.
  • a substituent carries a carboxyl group (- COOH)
  • the latter can be converted into an amide group, e.g. an N-Ci-C 7 -alkyl-carba- moyl group, typically by reaction with the corresponding amine, e.g.
  • a coupling agent that forms a preferred reactive derivative of the carboxyl group in situ
  • a coupling agent that forms a preferred reactive derivative of the carboxyl group in situ
  • DCC/ HOBT dicyclohexylcarbodiimide/i-hydroxybenzotriazole
  • BOPCI bis(2-oxo-3-oxaz- olidinyl)phosphinic chloride
  • TPTU O-(1 ,2-dihydro-2-oxo-1-pyridyl)- ⁇ /, ⁇ /, ⁇ /', ⁇ /-tetramethyl- uronium tetrafluoroborate
  • TBTU O-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
  • PyBOP (benzotriazol-1 -yloxy)-tripyrrolidinophosphonium-hexafluoro- phosphate
  • PyBOP O-(1
  • the reaction mixture is preferably stirred at a temperature of between approximately -20 and 50 0 C, especially between 0 0 C and 30 0 C, e.g. at room temperature.
  • Salts of a compound of formula (I) with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula (I) may thus be obtained by treatment with an acid or with a suitable anion exchange reagent.
  • a salt with two acid molecules for example a dihalogenide of a compound of formula I
  • Salts can usually be converted to free compounds, e.g. by treating with suitable basic compounds, for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically K 2 CO 3 or sodium NaOH.
  • Stereoisomeric mixtures e.g. mixtures of diastereomers
  • Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula (I) itself.
  • Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.
  • the starting materials of the formulae II, III, IV and V, as well as other starting materials mentioned herein, e.g. below, can be prepared according to or in analogy to methods that are known in the art, are known in the art and/or are commercially available. Novel starting materials, as well as processes for the preparation thereof, are likewise an embodiment of the present invention. In the preferred embodiments, such starting materials are used and the reaction chosen are selected so as to enable the preferred compounds to be obtained.
  • a process for the manufacture of a compound of the formula (II) comprises method A), step 1 : reacting first a compound of formula (IV)
  • L 2 B represents represents a boronic acid residue or an ester thereof (such as (HO) 2 B-) or
  • step 2 converting the thus obtained compound, optionally after purification or isolation, with
  • step 3 hydrolysing the thus obtained compound, optionally after purification or isolation, optionally in the presence of an polar organic solvent, to obtain a compound of formula (II);
  • a polar organic solvent such as NMP
  • halogenation step is particular suitable if a substituent -R -R (such as fluoro or chloro) is to be introduced in one or both of the ortho-position(s) of ring B.
  • a substituent -R -R such as fluoro or chloro
  • the invention relates also to a process of manufacturing a compound of formula (II) wherein a Suzuki- coupling reation as described above is followed by a substitution reaction, in particular a halogenation reaction of ring B.
  • a process for the manufacture of a compound of the formula (III) comprises the step of reducing a compound of formula (IX)
  • a process for the manufacture of a compound of the formula (IV) wherein X represents N comprises the step of reacting a compound of formula (Vl) Q P )— (
  • Hal represents halo, in particular bromo, optionally in the presence of a diluent
  • a process for the manufacture of a compound of the formula (V) comprises the step of reacting a compound of formula (XIII)
  • substituents are as defined for a compound of the formula (I) and hal represents halogen, in particular bromo, first with a lithiation agent (such as butyllitium), optionally in the presence of a diluent, followed by reaction with a boronic acid or derivative thereof (such as trimethylboranate or bis-pinacolate-diboron)
  • a lithiation agent such as butyllitium
  • a diluent optionally in the presence of a diluent
  • a boronic acid or derivative thereof such as trimethylboranate or bis-pinacolate-diboron
  • a process for the manufacture of a compound of the formula (X) comprises the step of reacting a compound of formula (Xl)
  • substituents are as defined for a compound of the formula (I), optionally in the presence of a diluent (such as a polor organic solvent), optionally in the presence of a reaction aid (such as DMAP or TBTU), optionally in the presence of a base (such as an amine) to obtain a compound of formula (X)
  • a diluent such as a polor organic solvent
  • a reaction aid such as DMAP or TBTU
  • base such as an amine
  • a process for the manufacture of a compound of the formula (Xl) comprises the step of oxidizing a compound of formula (XII)
  • substituents are as defined for a compound of the formula (I) (in particular wherein X represents CH) and hal represents halo (in particular bromo) with an oxidizing agent (such as KMnO 4 ) optionally in a diluent
  • System 1 Linear gradient 20-100% solvent A in 5 min + 1.5 min 100% solvent A; detection at 215 nm, flow rate 1 mL/min at 30 0 C.
  • Solvent A CH 3 CN + 0.1 % TFA;
  • Solvent B H 2 O + 0.1% TFA.
  • System 2 40% Solvent A for 5 min and then linear gradient 40-100% solvent A in 5 min + 5 min 100% solvent A, flow rate 0.8 mL/min.
  • Solvent A CH 3 CN;
  • Solvent B 20 mM NH 4 OAc in H 2 O.
  • scheme 1 relates to examples 1 - 81 scheme 2 relates to examples 82 - 84 scheme 3 relates to examples 85 - 87 scheme 4 relates to examples 88 - 96 scheme 5 relates to examples 174-178 schemes 6 and 7 relate to examples 179-187
  • Step 1.1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
  • Sulfuryl chloride (1.7 ml_, 21.3 mmol, 2 equiv) was added dropwise to a cold (5°C) suspension of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 1.2) (3.3 g, 10.6 mmol) in CH 3 CN (30 ml_).
  • Step 1.2 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
  • Step 1.3 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • a mixture of 5-bromo-8-(3,5-dimethoxy-phenyl)-quinoxaline (Step 1.4) (4.54 g, 13.2 mmol) and CuCN (1.54 g, 17.1 mmol, 1.3 equiv) in NMP (50 mL) was stirred for 2 h at 180 0 C, under an argon atmosphere.
  • the reaction mixture was allowed to cool to rt, diluted with EtOAc (10% aqueous solution of ethylenediamine) (150 ml_), and filtered to afford 1.19 g (batch 1 ) of the title compound as a yellow solid.
  • Step 1.7 4,7-Dibromo-benzo[1 ,2,51thiadiazole Bromine (18.6 ml_, 265 mmol, 1.2 equiv) was added to a refluxing solution of 1 ,2,5- benzothiazole (30 g, 220 mmol) in HBr (48% in H 2 O, 150 ml_). The reaction mixture was stirred for 4 h at reflux and allowed to cool to rt.
  • Step 1.8 3,5-dimethoxyphenylboronic acid f-BuLi (1.7 M in pentatne, 63 ml_, 106 mmol, 2.1 equiv) was added dropwise to a cold (-
  • Example 2 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl- piperazin-1 -vD-phenyli-amide
  • Step 2.1 3-(4-Ethylpiperazin-1-yl)-aniline
  • the title compound was prepared in analogy to the procedure described in Step 1.9 but using 1-ethyl-4-(3-nitro-phenyl)-piperazine (Step 2.2).
  • Title compound: ESI-MS: 206.2 [M+H] + ; t R 2.49 min (System 1 ).
  • Step 2.2 1-Ethyl-4-(3-nitro-phenyl)-piperazine
  • 2-fluoro-4-nitrobenzene 3.2 mL, 29.7 mmol
  • 1-ethylpiperazine 7.6 mL, 59.4 mmol, 2 equiv
  • the reaction mixture was diluted with H 2 O and DCM/MeOH, 9:1.
  • the aqueous layer was separated and extracted with DCM/MeOH, 9:1.
  • the organic phase was washed with brine, dried (Na 2 SO 4 ), filtered and concentrated.
  • Example 4 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- morpholin-4-yl-phenyl)-amide
  • Step 5.1 4-(2-Dimethylamino-ethoxy)-phenylamine i-Chloro-2-dimethylaminoethane hydrochloride (2 g, 21.9 mmol, 1.2 equiv) was added in one portion to a mixture of 4-aminophenol (2 g, 18.3 mmol) and finely powdered sodium hydroxide (1.8 g, 45.8 mmol, 2.5 equiv) in DMF (27 ml_), under an argon atmosphere. The reaction mixture was stirred for 17 h at rt. The resulting dark suspension was filtered. The filtrate was diluted with DCM (200 ml) and washed with brine (2 x 50 ml_).
  • Example 7 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-hvdroxy- phenvP-amide
  • Step 8.1 4-(4- ⁇ [8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonyl1-amino)- phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • Step 8.2 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • a suspension of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (Step 8.3) (1.26 g, 4.1 mmol) and palladium on carbon (200 mg) in MeOH (30 ml.) was stirred for 30 min at rt, under a hydrogen atmosphere.
  • Step 8.3 4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  • Example 9 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1-yl)-phenyl1-amide
  • Example 1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- isopropyl-piperazin-1-ylmethyl)-phenyl1-amide
  • Step 1 1.1 4-(4-lsopropyl-piperazin-1-ylmethyl)-phenylamine
  • a suspension of 1-isopropyl-4-(4-nitro-benzyl)-piperazine (Step 1 1.2) (5.7 g, 21.65 mmol) and Raney Nickel (2 g) in MeOH (100 ml.) was stirred for 6 h at rt, under a hydrogen atmosphere.
  • the reaction mixture was filtered through a pad of celite and concentrated to afford 4.9 g of the title compound as a white solid: ESI-MS: 234.2.
  • Step 1 1.2 1-lsopropyl-4-(4-nitro-benzyl)-piperazine
  • Example 12 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- ethyl-piperazin-1-ylmethyl)-phenyl1-amide
  • Step 12.1 4-(4-Ethyl-piperazin-1-ylmethyl)-phenylamine
  • Step 14.1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-yl1-amide
  • Step 14.2 1-(2-Trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-ylamine
  • 2-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1 H-imidazole (Step 14.3) (1.84 g, 7.57 mmol) and palladium on carbon (200 mg) in MeOH (30 ml.) was stirred for 40 min at rt, under a hydrogen atmosphere.
  • Example 15 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (2H- pyrazol-3-vD-amide
  • Example 17 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4H- ri ,2,41triazol-3-yl)-amide
  • Example 18 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- diethylaminomethyl-1 H-imidazol-2-yl)-amide
  • Example 19 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- pyrrolidin-1 -ylmethyl-1 H-imidazol-2-yl)-amide
  • Example 20 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
  • Step 20.1 1-Methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine
  • the title compound was prepared in analogy to the procedure described in Step 18.1 but using 1-methylpiperazine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
  • Example 21 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- ethyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
  • Step 21.1 1-Ethyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine
  • Example 23 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- morpholin-4-ylmethyl-1 H-imidazol-2-yl)-amide
  • Step 23.1 4-(2-Nitro-1 H-imidazol-4-ylmethyl)-morpholine
  • Example 24 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-oxo- 1 ,6-dihydro-pyridin-3-yl)-amide
  • Step 24.1 5-Amino-pyridin-2-ol
  • 2-hydroxy-5-nitropyridine 5 g, 35.7 mmol
  • palladium on carbon 500 mg
  • MeOH 100 mL
  • the reaction mixture was filtered through a pad of celite and concentrated to afford 3.8 g of the title compound: ESI-MS: 110.8 [M+H] + .
  • Example 25 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazine-1-carbonyl)-pyridin-2-yl1-amide
  • Step 25.1 (6-Amino-pyridin-3-ylH4-methyl-piperazin-1-yl)-methanone
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-amino-nicotinic acid and 1-methylpiperazine.
  • the reaction mixture was stirred overnight at 0 0 C.
  • DCM was used for dilution and extraction instead of EtOAc.
  • the dried organic phase was concentrated to afford an impure sample of the title compound which was used without further purification.
  • Example 26 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 26.1 5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride
  • a mixture of [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 26.2) (0.75 g, 2.8 mmol) and a 4 N solution of HCI in dioxane (20 ml.) was stirred for 72 h at rt and concentrated to afford 660 mg of the title compound as a white solid: ESI-MS: 221.1 [M+H] + ; t R 0.80 min (System 1 ).
  • Step 26.2 [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester
  • a mixture of methanesulfonic acid 6-tert-butoxycarbonylamino-pyridin-3-ylmethyl ester (Step 26.3) (0.8 g, 2.6 mmol), N-ethylpiperazine (0.37 ml_, 2.9 mmol, 1.1 equiv), cesium carbonate (1 g, 3.2 mmol, 1.2 equiv), and DMF (I O ml) was stirred for 2 h at rt, diluted with EtOAc and H 2 O, and extracted with EtOAc.
  • Step 26.4 (5-Hvdroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl Lithium aluminium hydride (1.6 g, 40.9 mmol, 1.1 equiv) was added portionwise to a cold (5°C) solution of ⁇ -tert-butoxycarbonylamino-nicotinic acid ethyl ester (Step 26.5) (9.9 g, 37.2 mmol) in THF (250 ml_), under an argon atmosphere. The reaction mixture was stired for 1 h at 5°C and quenched by sequential addition of H 2 O (4 ml_), 15% NaOH aqueous solution (4 ml.) and H 2 O (12 ml_).
  • Example 30 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- pyrrolidin-1-ylmethyl-pyridin-2-yl)-amide
  • Example 31 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 33.1 6-(4-lsopropyl-piperazin-1-yl)-pyridin-3-vlaniline
  • the reaction mixture was allowed to cool to rt, basified by addition of aqueous NH 3 , filtered through a pad of celite.
  • Example 34 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- ethyl-piperazin-1-yl)-pyridin-3-yl1-amide
  • Step 35.1 2-(4-lsopropyl-piperazin-1-yl)-pyrimidin-5-ylamine
  • Example 36 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [2-(4- ethyl-piperazin-1-yl)-pyrimidin-5-yl1-amide
  • Example 37 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 6- [methyl-(1-methyl-piperidin-4-yl)-amino1-pyridin-3-yl)-amide
  • Example 38 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 6-[(2- dimethylamino-ethyl)-methyl-amino1-pyridin-3-yl)-amide
  • Example 39 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • Step 39.1 6-(4-Methyl-piperazin-1-ylmethyl)-pyridin-3-ylamine
  • a suspension of 1-methyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine (Step 39.2) (0.529 g, 2.24 mmol) and Raney nickel (0.1 g) in MeOH (10 ml.) was stirred for 1 h at rt, under a hydrogen atmosphere.
  • the reaction mixture was filtered through a pad of celite and concentrated to afford 0.448 g of the title compound as an off-white solid: ESI-MS: 207.2 [M+H] + .
  • Step 39.4 ⁇ -Nitro-pyridine ⁇ -carboxylic acid ethyl ester
  • Step 39.5 ⁇ -Nitro-pyridine ⁇ -carboxylic acid
  • 2-bromo-5-nitro-pyridine 5.8 g, 28.6 mmol
  • CuCN 3.3 g, 37.1 mmol, 1.3 equiv
  • DMF 50 ml.
  • the reaction mixture was allowed to cool to rt, diluted with Et 2 O and H 2 O.
  • the aqueous layer was separated and extracted with Et 2 O.
  • the organic phase was washed with brine, dried (Na 2 SO 4 ), filtered and concentrated.
  • the residue was treated with 6N HCI (50 ml.) for 1.5 h at reflux.
  • Example 40 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- ethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • Example 41 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- PVrrolidin-1-ylmethyl-pyridin-3-yl)-amide
  • Example 43 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- morpholin-4-ylmethyl-pyridin-3-yl)-amide
  • Example 46 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-vD- phenyli-amide
  • Example 48 ⁇ -Naphthalen-i-yl-quinoxaline- ⁇ -carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
  • Example 50 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1-vD- pyridin-3-yli-amide
  • Example 51 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1- ylmethyl)-1 H-imidazol-2-yl1-amide
  • Example 52 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1-vD- phenyli-amide
  • Example 54 ⁇ -lsoquinolin ⁇ -yl-quinoxaline- ⁇ -carboxylic acid [4-(2-dimethylamino-ethoxy)- phenyli-amide
  • Example 56 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
  • Example 57 ⁇ -lsoquinolin ⁇ -yl-quinoxaline- ⁇ -carboxylic acid [6-(4-methyl-piperazin-1-yl)- pyridin-3-yli-amide
  • Example 58 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1- ylmethyl)-1 H-imidazol-2-yl1-amide
  • Example 63 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl- piperazin-1 -yl)-phenyll-amide
  • Example 64 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl- piperazin-1 -vD-phenyli-amide
  • Example 65 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2- dimethylamino-ethoxy)-phenyl1-amide
  • Example 70 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)- amide
  • Example 67 The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(4-methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (Example 67) in Step 14.1.
  • Example 71 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1- vD-phenyli-amide
  • Example 72 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1- vD-phenyli-amide
  • Example 73 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino- ethoxy)-phenyl1-amide
  • Example 75 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
  • Example 76 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1- yl)-pyridin-3-yl1-amide
  • Example 78 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3- ylamide
  • Example 81 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- ⁇ [(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
  • Example 82 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-3-ylamide
  • Step 82.2 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carbonitrile
  • N-Ethylpiperazine 0.308 mL, 2.43 mmol, 1.1 equiv
  • reaction mixture was stirred for 10 min at rt, quenched by addition of a saturated aqueous solution of NaHCO 3 (150 mL) and extracted with EtOAc (2 x 300 mL). The organic phase was washed with a saturated aqueous solution of NaHCO 3 (150 mL), dried (Na 2 SO 4 ), filtered and concentrated.
  • Step 82.3 3-Bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile and 2-bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • Step 82.4 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8- (2,6-dichloro-3,5-dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile
  • Sulfuryl chloride (2.14 ml_, 26.6 mmol, 1.8 equiv) was added dropwise to a cold (5°C) suspension of 8-(3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile (Step 82.5) (4.51 g, 14.8 mmol) in CH 3 CN (80 ml_).
  • reaction mixture was stirred at 5°C for 10 min, quenched by addition of a saturated aqueous solution of NaHCO 3 (250 ml.) and extracted with EtOAc (2 x 300 ml_). The organic phase was washed with a saturated aqueous solution of NaHCO 3 (150 ml_), dried (Na 2 SO 4 ), filtered and concentrated.
  • Step 82.5 8-(3,5-Dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile
  • Step 82.6 8-Bromo-5-(3,5-dimethoxy-phenyl)-2-methyl-quinoxaline and 5-bromo-8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline
  • the reaction mixture was stirred at 105 0 C for 4.5 h, allowed to cool to rt, quenched by addition of a saturated aqueous solution of NaHCOs and extracted with EtOAc. The organic phase was washed with a saturated aqueous solution of NaHCO 3 , dried (Na 2 SO 4 ), filtered and concentrated.
  • the crude product was purified by silica gel column chromatography (Hex/EtOAc, 1 :0 ⁇ 85:15) to afford 6.07 g of a mixture of 8-bromo-5-(3,5-dimethoxy- phenyl)-2-methyl-quinoxaline and 5-bromo-8-(3,5-dimethoxy-phenyl)-2-methyl-quinoxaline.
  • Example 83 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-3-ylamide
  • Step 83.1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1-ylmethyl)- quinoxaline-5-carboxylic acid
  • Example 84 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-2-ylamide
  • Example 85 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
  • Step 85.1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino1- quinoxaline-5-carboxylic acid
  • Step 85.2 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino1- quinoxaline-5-carbonitrile
  • Step 85.3 2-Chloro-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • Sulfuryl chloride (0.08 ml_, 0.98 mmol, 2 equiv) was added dropwise to a cold (5°C) suspension of 2-chloro-8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 85.4) (160 mg, 0.49 mmol) in CH 3 CN (3 ml_).
  • the reaction mixture was stirred at 5°C for 10 min, quenched by addition of H 2 O, and concentrated.
  • Step 85.4 2-Chloro-8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • Step 85.5 8-(3,5-Dimethoxy-phenyl)-2-hvdroxy-quinoxaline-5-carbonitrile
  • Step 85.6 5-Bromo-8-(3,5-dimethoxy-phenyl)-quinoxalin-2-ol and 8-bromo-5-(3,5- dimethoxy-phenyl)-quinoxalin-2-ol
  • Example 86 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid pyridin-2-ylamide
  • Example 87 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid pyridin-3-ylamide
  • Example 88 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl- piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 6-(4- ethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (prepared as described in Example 39 but using N-ethyl-piperazine in Step 39.2), and stirring the reaction mixture for 3 h at rt.
  • the crude product was purified by silica gel column chromatography (DCM/MeOH/NHs 301 , 94:5:1 ).
  • Step 88.1 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
  • KOH 2.4 g, 42.8 mmol, 10 equiv
  • H 2 O 10 ml.
  • 8-(2,6-difluoro- 3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 88.2) (1.4 g mg, 4.3 mmol) in ethylene glycol (20 ml_).
  • the reaction mixture was stirred at 150 0 C for 4 h, allowed to cool to rt, diluted with Et 2 O/ H 2 O, and extracted with Et 2 O.
  • Step 88.2 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • Step 88.3 5-Bromo-8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline
  • Example 90 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3- ylamide
  • Example 92 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 26.1 ), and stirring the reaction mixture for 48 h at rt and for 5 h at 50 0 C after addition of further 1.2 equiv of TBTU.
  • the crude product was purified by silica gel column chromatography (DCM/MeOH/NH 3 aq , 94:5:1 ).
  • Example 93 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- pyrrolidin-1 -ylmethyl-1 H-imidazol-2-yl)-amide
  • Example 94 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- ⁇ [(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 94.1 ), N-(6- amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2) and stirring the reaction mixture for 18 h at rt.
  • the crude product was purified by silica gel column chromatography (DCM/MeOH/NH 3 aq , 94:5:1 ).
  • Step 94.1 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
  • Step 94.2 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
  • Step 94.3 5-Bromo-8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline SelectFluor (20.5 g, 58 mmol, 2 equiv) was added portionwise to a solution of 5-bromo-8- (3,5-dimethoxy-phenyl)-quinoxaline (Step 1.4) (10 g, 29 mmol) in CH 3 CN (300 ml.) at rt. The reaction mixture was stirred at rt for 0.5 h, quenched by addition of H 2 O and concentrated to remove CH 3 CN. The resulting mixture was diluted with EtOAc/H 2 O and filtered to provide a white solid (batch 1 ).
  • Example 96 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin- 1 -ylmethyl-1 H-imidazol-2-yl)-amide
  • Example 97 8-(3-Methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(3-methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Step 97.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 24 h at rt.
  • the crude product was purified by silica gel column chromatography (DCM/MeOH/NH 3 aq , 94:5:1 ).
  • Step 97.1 8-(3-Methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid
  • Step 1.2 the reaction mixture was stirred at 150 0 C for 4 h.
  • Step 1.3 the reaction mixture was stirred at 160 0 C for 5 h; DCM was used instead of EtOAc; the crude product was purified by silica gel column chromatography (Hex/EtOAC, 1 :1 ). 3-Methoxy-2,5-dimethyl-phenyl boronic acid (Step 97.2) was used in Step 1.4.
  • Title compound: ESI-MS: 309.2 [M+H] + ; t R 4.71 min (System 1 ).
  • Step 97.2 3-Methoxy-2,5-dimethyl-phenyl boronic acid
  • Step 98.1 8-(2-Chloro-5-methoxy-3,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid
  • the title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,5-dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid (Step 99.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 24 h at rt.
  • the crude product was purified by silica gel column chromatography (DCM/MeOH/NH 3 aq , 91.5:7.5:1 ), followed by trituration in Et 2 O.
  • Step 99.1 8-(2,5-Dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid
  • Step 1.2 8-(2,5-dimethyl-1-oxy-pyridin-3-yl)- quinoxaline-5-carbonitrile (Step 99.2) was used; the reaction mixture was stirred at 150 0 C for 1 h; the aqueous phase was acidified to pH 1 by addition of 6 N HCI and extracted with DCM; the organic phase was concentrated to afford the title compound.
  • Step 1.2 8-(2,5-dimethyl-1-oxy-pyridin-3-yl)- quinoxaline-5-carbonitrile (Step 99.2) was used; the reaction mixture was stirred at 150 0 C for 1 h; the aqueous phase was acidified to pH 1 by addition of 6 N HCI and extracted with DCM; the organic phase was concentrated to afford the title compound.
  • Step 99.2 8-(2,5-Dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carbonitrile ( mCPBA (55% in H 2 O, 215 mg, 0.68 mmol, 1.2 equiv) was added to a cold (5°C) solution of 8-(2,5-dimethyl-pyridin-3-yl)-quinoxaline-5-carbonitrile (Step 99.3) (148 mg, 0.57 mmol) in DCM (3 ml_). The reaction mixture was stirred at 5°C for 20 min, diluted with DCM/saturated solution of NaHCO 3 and extracted with DCM.
  • Step 99.4 5-Bromo-8-(2,5-dimethyl-pyridin-3-yl)-quinoxaline n-BuLi (1.6 M in hexanes, 6.7 ml_, 10.8 mmol, 2.0 equiv) was added dropwise to a cold (- 78°C) solution of 3-bromo-2,5-dimethyl-pyridine (Bulletin de Ia Societe Chimique de France, 1972, (6), 2466-81 ) (1 g, 5.38 mmol) in Et 2 O (20 ml_), under an argon atmosphere. The reaction mixture was stirred for 1 h at -78°C.
  • Triisopropyl borate (3.7 ml_, 16.1 mmol, 3.0 equiv) was then added.
  • the reaction mixture was allowed to warm to rt, quenched by addition of a saturated solution of NH 4 CI (1 ml_), and concentrated.
  • the residue was diluted with EtOAc/H 2 O and the pH adjusted to 7.
  • the aqueous layer was separated and extracted with EtOAc.
  • the organic phase was dried (Na 2 SO 4 ), filtered and concentrated to afford 170 mg of the title compound as a beige solid (batch 1 ).
  • the aqueous layer was concentrated, the residue combined with batch 1 and dissolved in EtOH (5 ml_).
  • Example 100 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((R)-3- hvdroxy-pyrrolidin-1-ylrnethyl)-pyridin-2-vH-amide
  • Step 100.1 (R)-1-(6-Amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol
  • Step 100.2 210 mg, 0.72 mmol
  • MeOH (2 ml.) was stirred for 16 h at rt and concentrated.
  • Step 100.2 ⁇ -((RVS-Hydroxy-pyrrolidin-i-ylmethyD-pyridin ⁇ -yli-carbamic acid tert-butyl ester
  • Step 100.3 (5-Methyl-pyridin-2-yl)-carbamic acid tert-butyl ester
  • Example 101 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((S)-3- hvdroxy-pyrrolidin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 101.1 (S)-1-(6-Amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol
  • Example 102 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- acetyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 102.1 1-[4-(6-Amino-pyridin-3-ylmethyl)-piperazin-1-yl1-ethanone
  • Example 103 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3- oxo-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 103.1 4-(6-Amino-pyridin-3-ylmethyl)-piperazin-2-one
  • Example 104 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1- dioxothiomorpholin-4-ylmethyl)-pyridin-2-yl1-amide
  • Step 104.1 The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(1 ,1-dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine (Step 104.1 ) and stirring the reaction mixture for 72 h at rt.
  • the crude product was purified by silica gel column chromatography (DCM/NH 3 aq , 99:1 ⁇ DCM/MeOH/NH 3 aq , 95:4:1 ) followed by trituration in Et 2 O.
  • Step 104.1 5-(1 ,1-Dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine
  • Example 105 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
  • Step 100.2 but using 1-(4-methoxybenzyl)piperazine in Step 100.2: 313.3 [M+H] + .
  • Example 106 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5-[4-(2- hydroxy-ethyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
  • 2-lodoethanol (26 ⁇ l_, 0.33 mmol, 10 equiv) was added to a mixture of 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl-pyridin-2-yl)-amide (Example 105) (18 mg, 0.033 mmol) in CH 3 CN (1 ml_), under an argon atmosphere. The reaction mixture was stirred for 14 h at rt, quenched by addition of a saturated aqueous solution of NaHCC>3 (50 ml.) and extracted with EtOAc.
  • Example 107 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 107.1 5-(3,3,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine
  • Step 107.2 1 ,2,2-Trimethyl-piperazine
  • Example 108 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 108.1 5-[4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-1-ylmethyl1-pyridin-2-ylamine
  • the title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using 1-(4-methoxy-benzyl)-2,2-dimethyl-piperazine (Step 108.2) in Step 100.2:
  • TLC: R f 0.30 (DCM/MeOH, 9:1 ).
  • Step 108.2 1-(4-Methoxy-benzyl)-2,2-dimethyl-piperazine LiAIH 4 (1 M in THF, 27.8 mL, 27.8 mmol, 1.5 equiv) was added to a solution of 4-(4-methoxy- benzyl)-3,3-dimethyl-piperazin-2-one (Step 108.3) (4.6 g, 18.5 mmol) in THF (100 mL) at 50 0 C, under an argon atmosphere.
  • Step 108.3 4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-2-one
  • Example 109 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2- dimethyl-piperazin-1-ylmethyl)-Pvridin-2-yll-amide
  • Step 109.1 5-[4-(4-Methoxy-benzyl)-2,2-dimethyl-piperazin-1-ylmethyl1-pyridin-2-ylamine
  • Step 109.2 A mixture of ⁇ 5-[4-(4-methoxy-benzyl)-2,2-dimethyl-piperazin-1-ylmethyl]-pyridin-2-yl ⁇ - carbamic acid tert-butyl ester (Step 109.2) (1.88 g, 4.3 mmol), a 4 N solution of HCI in dioxane (25 ml.) and MeOH (25 ml.) was stirred for 22 h at rt. The reaction mixture was allowed to cool, quenched by addition of a saturated aqueous solution of NaHCO 3 and extracted with DCM. The organic layer was washed with a saturated aqueous solution of
  • Step 109.2 ⁇ 5-[4-(4-Methoxy-benzyl)-2,2-dimethyl-piperazin-1 -ylmethyli-pyridin-2-yl)- carbamic acid tert-butyl ester
  • a mixture of [5-(2,2-dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.3) (3.85 g, 12 mmol), 4-methoxybenzyl bromide (2.6 ml_, 18 mmol, 1.5 equiv) and triethylamine (1.83 ml_, 13.2 mmol, 1.1 equiv) in DCM (25 ml.) was stirred for 16 h at rt and concentrated.
  • Step 109.3 [5-(2,2-Dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester LiAIH 4 (1 M in THF, 78 ml_, 78 mmol, 2 equiv) was added to a solution of [5-(2,2-dimethyl-3- oxo-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.4) (13 g, 39 mmol) in THF (150 ml.) at 50 0 C, under an argon atmosphere.
  • Step 109.4 [5-(2,2-Dimethyl-3-oxo-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert- butyl ester
  • Intermediate 100.2 (Step 100.2) (18.4 g, 64 mmol)
  • 3,3-dimethyl-piperazin-2- one (Step 108.4) (9 g, 70 mmol, 1.1 equiv) and Cs 2 CO 3 (27.1 g, 83.2 mmol, 1.3 equiv) in DMF (75 ml) was stirred for 12 h at rt, quenched by addition of H 2 O (500 ml.) and filtered to afford 14.5 g of the title compound as an off-white solid.
  • Title compound: ESI-MS: 335.2 [M+H] + ; t R 2.22 min (System 1 ).
  • Example 1 10 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 1 10.1 5-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine
  • Step 1 10.2: [5-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester Methyl iodide (954 ⁇ L, 15.3 mmol, 1.3 equiv) was added dropwise to a suspension of [5- (2,2-dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.3) (3.8 g, 11.8 mmol) and potassium carbonate (2.13 g, 15.4 mmol, 1.3 equiv) in DME (25 mL).
  • Step 1 1 1.1 : 6-[4-(4-Methoxy-benzyl)-piperazin-1-ylmethyl1-pyridin-3-ylamine
  • Step 1 1 1.2 1-(4-Methoxy-benzyl)-4-(5-nitro-pyridin-2-ylmethyl)-piperazine The title compound was prepared in analogy to the procedures described in Steps 39.1-
  • Step 1 12.1 6-[4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-1-ylmethyl1-pyridin-3-ylamine
  • a suspension of 1-(4-methoxy-benzyl)-2,2-dimethyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine (Step 1 12.2) (0.64O g, 1.72 mmol) and Raney Nickel (0.150 g) in MeOH/THF (1 :1 , v/v; 50 mL) was stirred for 20 h at rt, under a hydrogen atmosphere. The mixture was filtered through a pad of celite and the filtrate was concentrated.
  • a mixture of methanesulfonic acid 5-nitro-pyridin-2-ylmethyl ester (Step 112.3) 0.5 g, 2.16 mmol
  • 1-(4-methoxy-benzyl)-2,2-dimethyl-piperazine (Step 108.2) (0.655 g, 2.8 mmol, 1.3 equiv)
  • cesium carbonate 0.845 g, 2.6 mmol, 1.2 equiv
  • DMF 4 ml
  • Methanesulfonic anhydride (1.79 g, 10.3 mmol, 1.1 equiv) was added portionwise to a cold (5°C) mixture of (5-nitro-pyridin-2-yl)-methanol (Step 1 12.4) (1.44 g, 9.4 mmol) and triethylamine (1.57 mL, 1 1.3 mmol, 1.2 equiv) in DCM (20 mL), under an argon atmosphere. The reaction mixture was allowed to stir for 0.5 h at 5°C, quenched with H 2 O and extracted with DCM.
  • Step 1 12.4: (5-Nitro-pyridin-2-yl)-methanol Diisobutylaluminium hydride (1 M in DCM, 41.6 ml_, 41.6 mmol, 1.3 equiv) was added dropwise to a cold (-78 0 C) solution of ⁇ -nitro-pyridine ⁇ -carboxylic acid ethyl ester (Step 39.4) (6.4 g, 32 mmol) in DCM (120 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to rt, quenched by addition of an aqueous solution of potassium sodium tartrate, diluted with DCM and H 2 O, and filtered through a pad of celite.
  • Example 1 13 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • Methyl iodide (15 ⁇ l_, 0.24 mmol, 1.2 equiv) was added to a mixture of 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3-dimethyl-piperazin-1 -ylmethyl)- pyridin-3-yl]-amide (Example 112) (115 mg, 0.2 mmol) and potassium carbonate (33 mg, 0.24 mmol, 1.2 equiv) in CH 3 CN (4 ml_). The reaction mixture was stirred for 72 h at rt, quenched by addition of a saturated aqueous solution of NaHCO 3 and extracted with EtOAc.
  • Example 1 14 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • Step 1 14.1 6-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine
  • the title compound was prepared in analogy to the procedures described in Steps 1 12.1 - 1 12.2 but using 1 ,3,3-trimethyl-piperazine (Step 114.2) in Step 1 12.2:
  • TLC: R f 0.13 (DCM/MeOH, 9:1 ).
  • Step 1 14.2: 1 ,3,3-Trimethyl-piperazine
  • Step 1 14.3: 3,3-Dimethyl-2-oxo-piperazine-1-carboxylic acid tert-butyl ester
  • Trimethyl aluminum (2 M in toluene, 0.37 ml_, 0.74 mmol, 2.5 equiv) was added to a mixture of
  • Step 1 15.1 : 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester
  • Example 1 16 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5-[4-(4-methoxy- benzyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
  • Example 1 17 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5-[4-(4-methoxy- benzyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
  • Example 1 18 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5- r(carbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
  • Step 1 18.1 : 2-[(6-Amino-pyridin-3-ylmethyl)-methyl-amino1-acetamide
  • Example 1 19 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
  • Step 1 19.1 : 2-[(6-Amino-pyridin-3-ylmethyl)-methyl-amino1-N,N-dimethyl-acetamide
  • Example 120 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- imidazol-1-ylmethyl-pyridin-2-yl)-amide
  • Step 120.1 5-lmidazol-1-ylmethyl-pyridin-2-ylamine
  • Example 121 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- dimethylamino-ethyl)-1 H-pyrrol-3-yl1-amide
  • Step 121.1 1-(2-Dimethylamino-ethyl)-1 H-pyrrol-3-ylamine
  • Step 121.2 Dimethyl-[2-(3-nitro-pyrrol-1-yl)-ethyll-amine
  • Example 122 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1 -ylmethyl)-pyridin-2-yl1-amide
  • Step 122.1 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid
  • Example 123 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl-pyridin-2-yl)-amide
  • Example 124 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Step 124.1 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester 2,6-dichloro-1-fluoropyridinium tetrafluoroborate (13.9 g, 54.6 mmol, 1.8 equiv) was added to a cold (-5 0 C) solution of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 1 15.1 ) (10.1 g, 29.9 mmol) in CH 3 CN (100 ml_).
  • Example 125 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
  • Example 126 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-vH-amide
  • Example 127 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
  • Example 128 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Example 129 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2- dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • Example 131 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
  • Example 132 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- piperazin-1-ylmethyl-pyridin-3-yl)-amide
  • Example 133 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3-oxo- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
  • the title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 4-(6-amino-pyridin-3-ylmethyl)-piperazin-2-one (Step 103.1 ), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 7 h at 80 0 C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM.
  • Example 134 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- ⁇ [(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
  • Step 124.1 N-(6-amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2 and purified by column chromatography), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 5 h at 80 0 C and pouring it onto a saturated aqueous solution of NaHCO 3 and DCM.
  • Example 135 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- morpholin-4-ylmethyl-1 H-imidazol-2-yl)-amide
  • Example 137 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ⁇ 5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
  • the title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-N,N-dimethyl-acetamide (Step 1 19.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 80 0 C and pouring it onto a saturated aqueous solution of NaHCO 3 and DCM.
  • Example 138 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- imidazol-1-ylmethyl-pyridin-2-yl)-amide
  • Example 139 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- dimethylamino-ethyl)-1 H-pyrrol-3-yl1-amide
  • Example 140 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1- dioxo-thiomorpholin-4-ylmethyl)-pyridin-2-yl1-amide
  • the title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-(1 ,1-dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine (Step 104.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 80 0 C and pouring it onto a saturated aqueous solution of NaHCO 3 and DCM.
  • Example 141 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
  • Example 142 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo- piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
  • Step 14.2 and 4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazin-2-one (Step 142.1 ) instead of 2- nitroimidazole in Step 14.3.
  • Title compound: ESI-MS: 524.1 [M+H] + ; t R 3.10 min (System

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

The invention relates to compounds of Formula (I), wherein the substituens are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

Description

DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS
The invention relates to quinoline/quinoxaline-carboxamide derivatives of the formula (I) given below (including its salts, solvates, esters, N-oxides); processes for the preparation thereof; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; the application of a compound of formula (I) in a process for the treatment of the human or animal body, (in particular with regard to a proliferative disease); the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases.
Protein kinases (PKs) are enzymes which catalyze the phosphorylation of specific serine, threonine or tyrosine residues in cellular proteins. These post-translational modifications of substrate proteins act as molecular switch regulating cell proliferation, activation and/or dif- ferentiation. Aberrant or excessive PK activity has been observed in many disease states including benign and malignant proliferative disorders. In many cases, it has been possible to treat diseases in vitro and in many cases in vivo, such as proliferative disorders, by making use of PK inhibitors. The kinases fall largely into two groups, those specific for phosphorylating serine and threonine, and those specific for phosphorylating tyrosine. In addition, some kinases, referred to as "dual specificity" kinases, are able to phosphorylate tyrosine as well as serine/threonine residues.
WO2006/000420 (in particular p.1-8) discloses details on PKs, their mode of action and relation to disorders or conditions to be treated. This document also discloses heteroaryl aryl ureas, useful for the treatment of protein kinase dependent diseases. Further,
WO03/023004 and WO02/102972 disclose disorders resulting from FGFR3 mutations.
Further, WO05/118580 generically discloses quinoline derivatives useful as HIV inhibitors.
In these documents and the references cited therein, where protein kinases are involved, the modulation of an aberrant activity (especially the inhibition of an activity of such a kinase) can be expected reasonably to be useful in the diseases mentioned in this document. Although considered active, the molecules disclosed in the above-referenced documents; they show certain disadvantages. There is thus an unmet need for improved (e.g. highly affine and/or selective) molecules capable of blocking aberrant constitutive receptor protein tyrosine kinase activity, in particular FGFR activity, thereby addressing the clinical manifestations associated with the above-mentioned mutations, and modulating various biological functions. In view of the large number of protein kinase inhibitors and the multitude of proliferative and other PK-related diseases, there is an ever-existing need to provide novel classes of compounds that are useful as PK inhibitors and thus in the treatment of these Protein Tyrosine Kinase (PTK) related diseases. Particularly required are new classes of pharmaceutically advantageous PK inhibiting compounds.
Thus, in a first aspect, the invention relates to compounds of the formula (I),
Figure imgf000003_0001
wherein X represents N or CH; R1 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy; R2 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy; A represents aryl or heteroaryl; B represents aryl or heteroaryl;
RA1 represents hydrogen or a substituent different from hydrogen; RA2 represents a direct bond or an alkanediyl; RB1 represents hydrogen or a substituent different from hydrogen; R represents a direct bond or aminocarbonyl; m represents an integer selected from 0 to 3; n represents an integer selected from 0 to 5; or a salt, solvate, ester, N-oxide thereof.
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense.
Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. If at least one asymmetrical carbon atom is present in a compound of the formula (I), such a compound may exist in optically active form or in the form of a - A -
mixture of optical isomers, e.g. in the form of a racemic mixture. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention. Thus, any given formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e. cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds, lsotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36CI, 125I respectively. Various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H, 13C, and 14C are incorporated. Such isotopically labelled compounds are useful in metabolic studies (preferably with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the moiety for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula (where one or more up to all more general expressions in embodiments characterized as preferred above or below can be replaced with a more specific definition, thus leading to a more preferred embodiment of the invention, respectively).
It goes without saying that substituents are only at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort which substitutions are possible and which are not. For example, amino or hydroxy groups with free hydrogen may be unstable if bound to carbon atoms with unsaturated (e.g. olefinic) bonds. Additionally, it will of course be understood that the substituents as listed above may themselves be substituted by any substituent, subject to the aforementioned restriction to appropriate substitutions as recognised by the skilled man.
Where the plural form (e.g. compounds, salts) is used, this includes the singular (e.g. a single compound, a single salt). "A compound" does not exclude that (e.g. in a pharmaceutical formulation) more than one compound of the formula (I) (or a salt thereof) is present.
The acid addition salt of compounds of formula (I) are preferably pharmaceutically acceptable salts. Such salts are known in the field.
The following general definitions shall apply in this specification, unless otherwise specified:
Halogen (or halo) denotes fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine. Halogen-substituted groups and moieties, such as alkyl substituted by halogen (halogenalkyl) can be mono-, poly- or per-halogenated.
Heteroatoms are atoms other than Carbon and Hydrogen, preferably nitrogen (N), oxygen (O) or sulfur (S).
The prefix "lower" or "C1-C7" denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching. "Alkyl" refers to a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain Ci-i2alkyl, particularly preferably represents a straight- chain or branched-chain Ci-7alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl, iso-propyl and n-butyl and iso-butyl. Alkyl may be unsubstituted or substituted. Exemplary substituents include, but are not limited to hydroxyl, alkoxy, halogen and amino. An example of a substituted alkyl is trifluoromethyl. Cycloalkyl may also be a substituent to alkyl. An example of such a case is the moiety (alkyl)-cyclopropyl or alkanediyl-cycloproyl, e.g. -CH2-cyclopropyl. Ci-C7-alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or preferably methyl.
Each alkyl part of other groups like "alkoxy", "alkoxyalkyl", "alkoxycarbonyl",
"alkoxycarbonylalkyl", "alkylsulfonyl", "alkylsulfinyl", "alkylamino", "halogenalkyl" shall have the same meaning as described in the above-mentioned definition of "alkyl".
"Alkanediyl" refers to a straight-chain or branched-chain alkanediyl group. It preferably represents a straight-chain or branched-chain CM2 alkanediyl, particularly preferably represents a straight-chain or branched-chain Ci_6 alkanediyl; for example, methandiyl (- CH2-), 1 ,2-ethanediyl (-CH2-CH2-), 1 ,1-ethanediyl ((-CH(CH3)-), 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1 ,1- ethanediyl, 1 ,2-ethanediyl, 1 ,3-propanediyl, 1 ,4-butanediyl. Alkanediyl may be substituted or unsubstituted as defined for alkyl, preferably unsubstituted.
"Cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic, carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following moieties: cyclopropyl, cyclobutyl, cyclpentyl and cylclohexyl. Cycloalkyl may be unsubstituted or substituted; exemplary substituents are provided in the definition for alkyl. "Aryl" refers to an aromatic homocyclic ring system with 6 or more carbon atoms; aryl is preferably an aromatic moiety with 6 to 14 ring carbon atoms, more preferably with 6 to 10 ring carbon atoms, such as phenyl or naphthyl, preferably phenyl. Aryl may be unsubstituted or substituted by one or more, preferably up to three, more preferably up to two substituents independently selected from the group consisting of unsubstituted or substituted heterocyclyl as described below, especially pyrrolidinyl, such as pyrrolidine oxopyrrolidinyl, such as oxopyrrolidino, d-C7-alkyl-pyrrolidinyl, 2,5-di-(Ci-C7alkyl)pyrrolidinyl, such as 2,5-di-(Ci-C7alkyl)-pyrrolidino, tetrahydrofuranyl, thiophenyl, d-C7- alkylpyrazolidinyl, pyridinyl, Ci-C7-alkylpiperidinyl, piperidino, piperidino substituted by amino or N-mono- or N,N-di-[lower alkyl, phenyl, Ci-C7-alkanoyl and/or phenyl-lower alkyl)-amino, unsubstituted or N-lower alkyl substituted piperidinyl bound via a ring carbon atom, pi- perazino, lower alkylpiperazino, morpholino, thiomorpholino, S-oxo-thiomorpholino or S, S- dioxothiomorpholino; Ci-C7-alkyl, amino-Ci-C7-alkyl, N-Ci-C7-alkanoylamino-Ci-C7-alkyl, N- Ci-C7-alkanesulfonyl-amino-Ci-C7-alkyl, carbamoyl-Ci-C7-alkyl, [N-mono- or N,N-di-(Ci-C7- alkyO-carbamoylJ-Ci-CT-alkyl, Ci-C7-alkanesulfinyl-Ci-C7-alkyl, Ci-C7-alkanesulfonyl-Ci-C7- alkyl, phenyl, naphthyl, mono- to tri-[Ci-C7-alkyl, halo and/or cyano]-phenyl or mono- to tri- [Ci-C7-alkyl, halo and/or cyano]-naphthyl; C3-C8-cycloalkyl, mono- to tri-[Ci-C7-alkyl and/or hydroxy]-C3-C8-cycloalkyl; halo, hydroxy, lower alkoxy, lower-alkoxy-lower alkoxy, (lower- alkoxy)-lower alkoxy-lower alkoxy, halo-Ci-C7-alkoxy, phenoxy, naphthyloxy, phenyl- or naphthyl-lower alkoxy; amino-C-ι-C7-alkoxy, lower-alkanoyloxy, benzoyloxy, naphthoyloxy, formyl (CHO), amino, N-mono- or N,N-di-(Ci-C7-alkyl)-amino, Ci-C7-alkanoylamino, CrC7- alkanesulfonylamino, carboxy, lower alkoxy carbonyl, e.g.; phenyl- or naphthyl-lower alkoxy- carbonyl, such as benzyloxycarbonyl; Ci-C7-alkanoyl, such as acetyl, benzoyl, naphthoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, such as N-mono- or N,N-di-substituted carbamoyl wherein the substitutents are selected from lower alkyl, (lower-alkoxy)-lower alkyl and hydroxy-lower alkyl; amidino, guanidino, ureido, mercapto, lower alkylthio, phenyl- or naphthylthio, phenyl- or naphthyl-lower alkylthio, lower alkyl-phenylthio, lower alkyl-naph- thylthio, halogen-lower alkylmercapto, sulfo (-SO3H), lower alkanesulfonyl, phenyl- or naphthyl-sulfonyl, phenyl- or naphthyl-lower alkylsulfonyl, alkylphenylsulfonyl, halogen-lower alkylsulfonyl, such as trifluoromethanesulfonyl; sulfonamido, benzosulfonamido, azido, azido-Ci-C7-alkyl, especially azidomethyl, Ci-C7-alkanesulfonyl, sulfamoyl, N-mono- or N, N- di-(Ci-C7-alkyl)-sulfamoyl, morpholinosulfonyl, thiomorpholinosulfonyl, cyano and nitro; where each phenyl or naphthyl (also in phenoxy or naphthoxy) mentioned above as sub- stituent or part of a substituent of substituted alkyl (or also of substituted aryl, heterocyclyl etc. mentioned herein) is itself unsubstituted or substituted by one or more, e.g. up to three, preferably 1 or 2, substituents independently selected from halo, halo-lower alkyl, such as trifluoromethyl, hydroxy, lower alkoxy, azido, amino, N-mono- or N,N-di-(lower alkyl and/or Ci-C7-alkanoyl)-amino, nitro, carboxy, lower-alkoxycarbonyl, carbamoyl, cyano and/or sulf- amoyl.
"Heterocyclyl" refers to a heterocyclic radical that is unsaturated (= carrying the highest possible number of conjugated double bonds in the ring(s)), saturated or partially saturated and is preferably a monocyclic or in a broader aspect of the invention bicyclic, tricyclic or spirocyclic ring; and has 3 to 24, more preferably 4 to 16, most preferably 5 to 10 and most preferably 5 or 6 ring atoms; the bonding ring preferably having 4 to 12, especially 5 to 7 ring atoms. The heterocyclic radical (heterocyclyl) may be unsubstituted or substituted by one or more, especially 1 to 3, substituents independently selected from the group consisting of the substituents defined above for substituted alkyl and / or from one or more of the following substituents: oxo (=0), thio (=S), imino(=NH), imino-lower alkyl. Further, heterocyclyl is especially a heterocyclyl radical selected from the group consisting of oxiranyl, azetidine, azirinyl, aziridinyl, 1 ,2-oxathiolanyl, thienyl (= thiophenyl), furanyl, tetrahydrofuryl, pyranyl, thiopyranyl, thianthrenyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolidinyl, benzimidazolyl, pyrazolyl, pyrazinyl, pyrazolidinyl, thiazolyl, isothiazolyl, dithiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, piperidinyl, piperazinyl, pyridazinyl, morpholinyl, thiomorpholinyl, (S-oxo or S,S-dioxo)-thiomorpholinyl, indolizinyl, azepanyl, diazepanyl, especially 1 ,4-diazepanyl, isoindolyl, 3H-indolyl, indolyl, benzimidazolyl, cumaryl, indazolyl, triazolyl, tetrazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, benzofuranyl, dibenzofuranyl, benzothiophenyl, dibenzothiophenyl, phthalazinyl, naphthyridinyl, quin- oxalyl, quinazolinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, beta-carbolinyl, phenan- thridinyl, acridinyl, perimidinyl, phenanthrolinyl, furazanyl, phenazinyl, phenothiazinyl, phenoxazinyl, chromenyl, isochromanyl, chromanyl, benzo[1 ,3]dioxol-5-yl and 2,3-dihydro- benzo[1 ,4]dioxin-6-yl, each of these radicals being unsubstituted or substituted by one or more, preferably up to three, substituents selected from those mentioned above for substituted aryl and/or from one or more of the following substituents: oxo (=0), thio (=S), imino(=NH), imino-lower alkyl. "Heteroaryl" refers to a specific subgroup of heterocyclyl, namely such unsaturated heterocyclic groups that are also aromatic. Such heteroaryl may be substituted with substituents as identified above for heterocyclyl. Further, heteroaryl may be a charged moiety, such as in pyridine-N-oxide. Due to tautomerism, e.g. keto-enol-tautomerism, heteroaryl may also be drawn as a partly unsaturated heterocyclyl (e.g. 2-hydroxypyridine). For example, heteroaryl includes pyridyl, pyrimidinyl, pyridazinyl, 1 ,3,5-triazolyl, 1 ,2,3- triazolyl, 1 ,2,4-triazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, acridinyl, purinyl, pteridinyl, pyrrolyl, pyrazolyl, imidazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, indolyl, indazolyl, benzopyranyl, benzothiopyranyl, benzo[1 ,3]dioxole, benzo-imidazolyl, tetrazolyl, furanyl, benzofuranyl, oxazolyl, isoxazolyl, thienyl, thiazolyl, isothiazolyl, etc.
"Arylalkyl" refers to an aryl group bound to the molecule via an alkyl group, such as a methyl or ethyl group, preferably phenethyl or benzyl, in particular benzyl. Similarly, cycloalkylalkyl and heterocyclyl represents a cycloalkyl group bound to the molecule via an alkyl group or a heterocyclyl group bound to the molecule via an alkyl group. In each instance, aryl, heterocyclyl, cycloalkyl and alkyl may be substituted as defined above.
"Treatment" includes prophylactic (preventive) and therapeutic treatment as well as the delay of progression of a disease or disorter.
"FGFR kinase mediated diseases" (especially FGFR3 kinase mediated diseases) are such diseases, disorders or conditions (collectively "diseases") that respond in a beneficial way, e.g. amelioration of one or more symptoms, delay of the onset of a disease, up to temporary or complete cure from a disease, to the inhibition of a protein tyrosine kinase, especially inhibition of a FGFR (such as FGFR3) kinase. Among the diseases to be treated by FGFR inhibition, especially proliferative diseases such as cancer diseases, solid tumors like breast cancer, bladder cancer, endometrial cancer, hepatocellular cancer, glioblastoma, or multiple myeloma, EMS myeloid proliferative disorders, may be mentioned.
"Salts" (which, what is meant by "or salts thereof" or "or a salt thereof", can be present alone or in mixture with free compound of the formula (I) are preferably pharmaceutically acceptable salts. Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, e.g., carboxylic acids or sulfonic acids, such as fumaric acid or methansulfonic acid. For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred. In view of the close relationship between the novel compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the novel compounds, any reference to the free compounds hereinbefore and hereinafter is to be understood as referring also to the corresponding salts, as appropriate and expedient.
Combination refers to either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner (e.g. an other drug as explained below, also referred to as "therapeutic agent" or "co-agent") may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect. The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non- fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
In preferred embodiments, which are preferred independently, collectively or in any combination or sub-combination, the invention relates to a compound of the formula (I), in free base form or in acid addition salt form, wherein the substituents are as defined herein.
In another embodiment, the invention relates to a compound of formula IA
Figure imgf000012_0001
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IB
Figure imgf000012_0002
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IC
Figure imgf000012_0003
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula ID
Figure imgf000013_0001
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IE
Figure imgf000013_0002
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IF
Figure imgf000013_0003
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IG
Figure imgf000013_0004
wherein the substituents are as defined for a compound of formula I.
In a further embodiment, the invention relates to a compound of formula IH
Figure imgf000014_0001
wherein the substituents are as defined for a compound of formula I.
The below mentioned preferences for the substituents may apply in any combination or sub-combination to the compounds of formulae IA to IH.
R1 preferably represents hydrogen, halogen, Ci-i2alkyl, substituted
Figure imgf000014_0002
wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by
Figure imgf000014_0003
amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-i2alkyl, amino
Figure imgf000014_0004
12alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-i2alkyl, amino
Figure imgf000014_0005
i2alkyl,
Ci.i2alkoxy, halo-Ci-i2alkoxy. R1 particular preferably represents hydrogen, fluoro, chloro, Ci-4alkyl, substituted Ci-4alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci-4alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl-amino Ci-4alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl-amino Ci-4alkyl, Ci-4alkoxy, fluoro-Ci_4alkoxy, chloro-Ci-4alkoxy.
R1 very particular preferably represents hydrogen, (2-dimethylamino-ethyl)-methyl-amino, 4-ethyl-piperazin-1-ylmethyl, methyl; with particular preference given to hydrogen.
R2 preferably represents hydrogen, halogen, Ci-i2alkyl, substituted
Figure imgf000015_0001
wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by
Figure imgf000015_0002
amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-i2alkyl, amino
Figure imgf000015_0003
i2alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-i2alkyl, amino
Figure imgf000015_0004
12alkyl, Ci.i2alkoxy, halo-Ci-i2alkoxy.
R2 particular preferably represents hydrogen, fluoro, chloro, Ci-4alkyl, substituted Ci-4alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci-4alkyl), amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl-amino Ci-4alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl-amino Ci-4alkyl, Ci-4alkoxy, fluoro-Ci_4alkoxy, chloro-Ci-4alkoxy. R2 very particular preferably represents hydrogen, (2-dimethylamino-ethyl)-methyl-amino,
4-ethyl-piperazin-1-yl-methyl, methyl; with particular preference given to hydrogen.
A preferably represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaromatic moiety with 5 - 13 ring; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RA1-RA2 as defined herein. A particular preferably represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 6 ring atoms and whereby at least one of the heteroatoms is nitrogen, each aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RA1-RA2 as defined herein. A very particular preferably represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selected from the group consisting of phenyl, pyridyl (such as pyrid-2-yl, pyrid-3-yl), pyrimidyl (such as pyramid-5-yl), pyrolyl (such as pyrol-3-yl), imidazolyl (such as imidazo-2-yl or imidazo-4-yl), pyrazolyl (such as pyradzo-3-yl), triazolyl (such as triazo-3-yl) and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -RA1-RA2 as defined herein.
B preferably represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaromatic moiety with 5 - 13 ring atoms; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents - RB1-RB2 as defined below. B particular preferably represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 10 ring atoms and whereby at least one of the heteroatoms is nitrogen or sulfur, each aromatic or heteroaromatic
R1 R? moiety is unsubstituted or substituted by one or more substituents -R -R as defined herein.
B very particular preferably represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selcected from the group consisting of phenyl, naphthyl (such as alpha-naphtyl), pyridyl (such as pyrid-3-yl), pyridyl-N-oxide (such as pyrid-3-yl-N- oxide), chinolinyl, isochinolinyl (such as isochinolin-4-yl, isochinolin-5-yl), thiophenyl (such as thiophen-3-yl), thionaphthenyl (such as thionaphthen-3-yl) and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -RB1-RB2 as defined herein.
RA1 preferably represents hydrogen; or formyl, Ci-7alkylcarbonyl, Ci-7alkoxycarbonyl, aminocarbonyl, N-Ci-7alkylaminocarbonyl, N^-di-Ci-T-alkylaminocarbonyl; benzyl; or hydroxy, Ci-7alkoxy, amino-Ci-7alkoxy, N-Ci-7alkylamino- Ci-7alkoxy, N,N-di- Ci-7alkylamino-Ci-7alkoxy; heterocyclyl-Ci-7alkoxy whereby said heterocyclyl has 3 to 10 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci-7alkyl and/or hydroxy; or a group -NRA3RM or a group -C(O)-N RA3RM.
RA1 particular preferably represents hydrogen; or formyl, Ci-4alkylcarbonyl, Ci- 4alkoxycarbonyl, aminocarbonyl, N,N-di-Ci-4alkylaminocarbonyl; benzyl;or hydroxy, Ci- 4alkoxy, N,N-di-Ci-4alkylamino-Ci-4alkoxy; heterocyclyl-Ci-4alkoxy whereby said heterocyclyl has 5 to 6 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci-4alkyl; or a group -NRA3RM.
RA1 very particular preferably represents hydrogen; or methoxycarbonyl, tert.butoxycarbonyl, aminocarbonyl; or a group -NRA3RM; or hydroxy, N,N-dimethylaminoethoxy, N,N-dimethylaminomethoxy; heterocyclyl-Ci. 4alkoxy whereby said heterocyclyl is bound via nitrogen and selected from the group consisiting of pyrrolidinyl, piperidinyl, N-methylpiperazinyl, N-ethyl-piperazinyl, N- isopropyl-piperazinyl or morpholinyl.
RA2 preferably represents a direct bond or a straight-chain or branched-chain Ci_i2 alkanediyl. RA2 particular preferably represents a direct bond or a straight-chain or branched-chain Ci- 6 alkanediyl. RA2 very particular preferably represents a direct bond, methandiyl, 1 ,2-ethanediyl, 1 ,1- ethanediyl, 1 ,1-, 1 ,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to direct bond, methandiyl, 1 ,2-ethanediyl.
RA3 and RM preferably represent independent from each other hydrogen, Ci-7alkyl, hydroxy-Ci-7alkyl, halogen-Ci-7alkyl, cyano-Ci-7alkyl, amino-Ci-7alkyl, N-Ci-7alkylamino- Ci-7-alkyl, N,N-di-Ci-7alkylamin- Ci-7-alkyl, aminocarbonyl-Ci-7alkyl, N- d-T-alkylaminocarbonyl-Ci-T-alkyl, N^-di-Ci-T-alkylaminocarbonyl-d-T-alkyl, a saturated, partly saturated or unsaturated hetereocycle which has 3 to 10 ring atoms, and which is optionally substituted by 1 to 3 substituents selected from the group consisting of Ci-7alkyl, hydroxyl, oxo, hydroxy-Ci-7alkyl, benzyl, methoxybenzyl, amino, Ci-7alkylamino, N,N-di-Ci-7alkylamino or RA3 and RM preferably represent together with the nitrogen to which they are bound a saturated, partly saturated or unsaturated hetereocycle which has 3 to 10 ring atoms, and which is optionally substituted by 1 to 3 substituents selected from the group consisting of Ci-7alkyl, cyano, halogen, hydroxyl, oxo, hydroxy-Ci-7alkyl, Ci-7alkylcarbonyl, benzyl, methoxybenzyl, amino, Ci-7alkylamino, N,N-di-Ci_ 7alkylamino.
RA3 and RM particular preferably represent independent from each other methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, hydroxymethyl, 2-hydroxyethyl, amino-methyl or -ethyl, dimethylaminomethyl or -ethyl, aminocarbonyl-methyl or -ethyl, N, N- dimethylaminocarbonyl-methyl or -ethyl, N,N-diethylaminocarbonyl-methyl or -ethyl or
RA3 and RM particular preferably represent together with the nitrogen to which they are bound a saturated, partly saturated or unsaturated hetereocycle selected from the group consisting of azetidine, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and which is optionally substituted by 1 substituent selected from the group consisting of methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, cyano, halogen, hydroxy, oxo, hydroxyethyl, benzyl, methoxybenzyl, N,N-dimethylamino, N,N-diethylamino. RB1 preferably represents halo, a straight-chain or branched-chain unsubstituted Ci-7alkyl, a straight-chain or branched-chain unsubstituted Ci-7alkoxy, straight-chain or branched-chain halo-Ci-7alkyl.
R particular preferably represents methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, methyoxy, ethyoxy, n- or iso-propoxy, n-, iso-, sec- or tert-butoxy, n-pentoxy, n-hexoxy, n-heptoxy, fluormethyl, chlormethyl, trifluoromethyl, fluoro, chloro, bromo.
R1
R very particular preferably represents methyl, methoxy, trifluormethyl, fluoro, chloro.
R? R preferably represents a direct bond.
m preferably represents 0, 1 , 2, 3 or 4. m particular preferably represents 0, 1 or 4.
n preferably represents 0, 1 or 2 n particular preferably represents 0 or 1.
In a further embodiment when ring B represents phenyl and n represents 2, the substituents
RB2-RB1 are preferably in the ortho-positions.
In a further embodiment when ring B represents phenyl and n represents 4, the substituents
R? R1
R -R are preferably in the ortho and meta-positions.
The invention further relates to pharmaceutically acceptable prodrugs of a compound of formula (I).
The invention further relates to pharmaceutically acceptable metabolites of a compound of formula (I).
The invention further relates to protected derivatives of a compound of formula (I).
The invention relates especially to the compounds of the formula (I) given in the Examples, as well as the methods of manufacture described therein. The invention also provides, in a second aspect, pharmacological uses of compounds of formula (I). The compounds of formula (I) have valuable pharmacological properties, as described hereinbefore and hereinafter. They inhibit various protein kinases, such as tyrosine kinases, for example VEGFR2 (KDR), PDGFR, cKIT, LCK, cAbl, RET and FGFR kinases, especially FGFR1 , FGFR2, FGFR3, FGFR4.
In vitro experiments
The efficacy of the compounds of formula (I) as inhibitors of protein kinase activity can be demonstrated according to known procedures; in particular according to the assays described in the experimental part below. Generally, the activity of a protein kinase is assayed in the presence or absence of inhibitor by measuring the phosphorylation of a synthetic substrate by purified N-terminally His- or GST-tagged kinase domains, in the presence of selected concentrations of ATP and using the appropriate assay technology: Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) (LanthaScreen™) or microfluidic Caliper system.
In vivo experiments
There are also experiments to demonstrate the antitumor activity of compounds of the formula (I) in vivo according to methods known in the field (e.g. as described herein).
The in vivo antitumor activity is tested, for example, using bladder carcinoma cell lines, such as the human urinary bladder transitional cell carcinoma RT1 12 cell line (DSMZ ACC # 418).
Tumors are obtained after subcutaneous injection of the respective cells (minimum 1 x 106 cells in 100 ml phosphate buffered physiological saline) into the carrier mice or rat. The treatment is started, as soon as the tumor has reached an average size of 100 mm3. Tumor growth is determined three times weekly and 24 h after the last treatment by measurement of the perpendicular diameter. In case of tumors, tumor volumes are determined according to the Formula L x D x p/6 (see Evans, B. D., Smith, I.E., Shorthouse, AJ. and Millar, J. J., Brit. J. Cancer, 45: 466-468, 1982). The antitumor activity is expressed as T/C% (average increase of the tumor volume of treated animals divided by the average increase of tumor volume in control animals multiplied by 100). Tumor regression (%) represents the smallest mean tumor volume compared to the mean tumor volume at the beginning of the treatment. Each animal in which the tumor reaches a diameter of more than 1 ,5 to 2 cm3 is sacrificed.
Clinical Studies The pharmacological activity of a compound of formula (I) may, for example, be demonstrated in a clinical study or in a test procedure according to methods generally accepted in the field; e.g. as essentially described hereinafter.
Suitable clinical studies are, for example, open label non-randomized, dose escalation stu- dies in patients with one of the tumor diseases mentioned above. The beneficial effects on proliferative diseases can be determined directly through the results of these studies or by changes in the study design which are known as such to a person skilled in the art. The efficacy of the treatment can be determined in such studies, e.g., in case of tumors after 18 or 24 weeks by radiologic evaluation of the tumors every 6 weeks, in case of a leukemia e.g. by determination of the count of aberrant white blood cells, and by staining mononuclear cells and/or by means of determining minimum residual disease (MRD) e.g. by FACS-LPC MRD or PCR.
Alternatively, a placebo-controlled, double blind study can be used in order to prove the benefits of the compounds of the formula (I) mentioned herein.
An exemplary (though not limiting) schedule for administration of a compound of formula (I) is daily administration, with preferably 1 to 3 daily dosages for a longer time, possibly until the disease is cured or, if only palliative treatment is achieved, for as long as required; alternatively, treatment e.g. for 5 days, and/or administration at days 1 , 4 and 9, with eventual repetition after a certain time without treatment is possible. Alternatively, treatment several times a day (e.g. 2 to 5 times) or treatment by continuous administration (e.g. infusion), e.g. at the time points indicated in the last sentence, are possible. Generally, administration is orally or parenterally, preferably orally. The test compounds are preferably diluted in water or in sterile 0.9% saline.
Diseases:
On the basis of these tests and studies, a compound of formula (I) according to the invention shows therapeutic efficacy especially against disorders dependent on protein tyrosine kinase ("protein tyrosine kinase dependent diseases") such as FGFR, VEGFR2 (KDR), PDGF-R, cKIT, LCK, cABL, RET, especially proliferative diseases mediated FGFR kinase activity. The compounds of formula (I), that inhibit the protein tyrosine kinase activities mentioned, especially tyrosine protein kinases mentioned above and below, can therefore be used in the treatment of protein kinase dependent diseases. Thus, a compound of formula (I) is in particular useful in the treatment of diseases identified below.
FGFR dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. A first group of FGFR dependents diseases relates to a benign or malignant proliferative disease, e. g. a cancer, e. g. tumors and/or metastasis (wherever located). In a preferred embodiment, the proliferative disease is a cancer. The proliferative diseases include, without being limited to, cancers of the bladder, cervix, or oral squamous cell carcinomas (in particular with mutated FGFR3 and/or elevated FGFR3 expression), multiple myeloma (in particular with t(4,14) chromosomal translocation), breast cancers (in particular with gene amplification and /or protein overexpression of FGFR1 , FGFR2 or FGFR4), endometrial cancer (in particular with FGFR2 mutations), hepatocellular cancer (in particular with elevated expression of FGFR3 or FGFR4 or FGF ligands), any cancer type with an amplification of the 1 1q13 amplicon, which contains the FGF3, FGF4 and FGF19 loci, for example breast cancer, hepatocellular cancer, EMS myeloproliferative disorders (in particular with abnormal FGFR1 fusion proteins), lymphomas (in particular with abnormal FGFR3 fusion proteins), glioblastomas (in particular with FGFR1 abnormal expression or mutations), gastric carcinomas (in particular with FGFR2 mutations or overexpression or FGFR3 mutations), pancreatic carcinomas (in particular with abnormal FGFR1 or FGFR4 expression), prostate carcinomas (in particular with abnormal expression of FGFR1 ,
FGFR4, or FGF ligands); pituitary tumors (in particular with abnormal FGFR4), any cancer that requires angiogenesis .
A second group of FGFR dependents diseases relates to non-cancer disorders. Such non- cancer disorders include, without being limited to, benign skin tumors (in particular with FGFR3 activating mutations), skeletal disorders (in particular resulting from mutations in FGFRs) including achondroplasia, hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), thanatophoric dysplasia (TD), muenke coronal craniosynostosis, crouzon syndrome with acanthosis nigricans, both familial and sporadic forms of Pfeiffer syndrome; disorders related to alterations of phosphate homeostasis, for example autosomal dominant hypophosphatemic rickets (ADHR, in particular related to FGF23 missense mutations), x-linked hypophosphatemic rickets (XLH; an x-linked dominant disorder related to inactivating mutations in the PHEX gene), tumor-induced osteomalacia (TIO, an acquired disorder of isolated phosphate), or fibrous dysplasia of the bone (FD) .
A third group of FGFR dependent diseases relates to inflammatory or autoimmune diseases. The inhibition of FGFR activity has been found to represent a means for treating T cell mediated inflammatory or autoimmune diseases, as for example in treatment of T- cell mediated inflammatory or autoimmune diseases including but not limited to rheumatoid arthritis (RA), collagen Il arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), psoriasis, juvenile onset diabetes, Sjogren's disease, thyroid disease, sarcoidosis, autoimmune uveitis, inflammatory bowel disease (Crohn's and ulcerative colitis), celiac disease and myasthenia gravis.
A fourth group of FGFR dependent diseases relates tot the group consisting of obesity, diabetes and/or diseases related thereto. Methods of antagonizing FGFRs, especially FGFR1 or FGFR4, have also been described to be useful in the treatment of obesity, diabetes and/or diseases related thereto, such as metabolic syndrome, cardiovascular diseases, hypertension, aberrant cholesterol and triglyceride levels, dermatological disorders e.g. infections, varicose veins, Acanthosis nigricans, eczema, exercise intolerance, diabetes type 2, insulin resistance, hypercholesterolemia, cholelithiasis, orthopedic injury, thromboembolic disease, coronary or vascular restriction (e.g. atherosclerosis), daytime sleepiness, sleep apnoea, end stage renal disease, gallbladder disease, gout, heat disorders, impaired immune response, impaired respiratory function, infections following wounds, infertility, liver disease, lower back pain, obstetric and gynecological complications, pancreatitis, stroke, surgical complications, urinary stress incontinence and/or gastrointestinal disorders.
Further, enhanced (especially bronchial) expression of FGFRs, especially FGFR1 , has been reported to be associated with Chronic Obstructive Pulmonary Disease (COPD). Further, acidic Fibroblast Growth Factor (especially FGF-1 ) and FGFR1 have also been described to be involved in aberrant signaling in retinoblastoma, leading to proliferation upon binding of FGF-1.
Non-FGFR protein kinase dependent diseases include VEGFR2 (KDR), PDGF, cKIT, LCK, cABL and RET dependent diseases and are especially proliferative diseases, preferably benign or especially malignant tumours (for example carcinoma of the kidneys, liver, adrenal glands, bladder, breast, stomach, ovaries, colon, rectum, prostate, pancreas, lungs, vagina or thyroid, sarcoma, glioblastomas and numerous tumours of the neck and head, as well as leukemias). They are able to bring about the regression of tumours and to prevent the formation of tumour metastases and the growth of (also micro )-metastases. In addition they can be used in epidermal hyperproliferation (e.g. psoriasis), in prostate hyperplasia, and in the treatment of neoplasias, especially of epithelial character, for example mammary carcinoma. It is also possible to use the compounds of formula (I) in the treatment of diseases of the immune system insofar as several or, especially, individual tyrosine protein kinases are involved; furthermore, the compounds of formula (I) can be used also in the treatment of diseases of the central or peripheral nervous system where signal transmission by at least one tyrosine protein kinase, especially selected from those mentioned specifically, is involved.
VEGFR2 (KDR) dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. Vascular endothelial growth factor receptor-2 (VEGFR2; KDR) is expressed on the primary vascular endothelium and is essential for normal vascular development. Angiogenesis, or the sprouting of new blood vessels, is also a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). The compounds of formula (I) as inhibitors of VEGF-receptor tyrosine kinase activity, may primarily inhibit the growth of blood vessels and are thus, for example, effective against a number of diseases associated with deregulated angiogenesis, especially diseases caused by ocular neovascularisation, especially retinopathies, such as diabetic retinopathy or age-related macula degeneration, psoriasis, haemangioblastoma, such as haemangioma, mesangial cell proliferative disorders, such as chronic or acute renal diseases, e.g. diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes or transplant rejection, or especially inflammatory renal disease, such as glomerulonephritis, especially mesangioproliferative glomerulonephritis, haemolytic-uraemic syndrome, diabetic nephropathy, hypertensive nephrosclerosis, atheroma, arterial restenosis, autoimmune diseases, diabetes, endometriosis, chronic asthma, and especially neoplastic diseases, for example so-called solid tumors (especially cancers of the gastrointestinal tract, the pancreas, breast, stomach, cervix, bladder, kidney, prostate, ovaries, endometrium, lung, brain, melanoma, Kaposi's sarcoma, squamous cell carcinoma of heand and neck, malignant pleural mesotherioma, lymphoma or multiple myeloma) and liquid tumors (e.g. leukemias), especially those expressing KDR, are especially important. A compound of formula (I) inhibits the growth of tumours and is especially suited to preventing the metastatic spread of tumors and the growth of micrometastases. These diseases are thus also Protein kinase dependent diseases.
PDGF dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. Compounds of the formula (I), in view of their activity as PDGF receptor inhibitors, are also especially appropriate in the treatment of proliferate diseases, especially glioblastoma, small lung cancer, atherosclerosis, thrombosis, psoriasis, scleroderma or fibrosis.
cKIT dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, head and neck cancers, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial, lung or pancreatic cancer. KIT kinase expression has been documented in a wide variety of human malignancies such as mastocytosis/ mast cell leukemia, gastrointestinal stromal tumors (GIST), small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma. The kinase activity of KIT has been implicated in the pathophysiology of several of these - and additional tumors - including breast carcinoma, SCLC, GIST, germ cell tumors, mast cell leukemia, neuroblastoma, AML, melanoma and ovarian carcinoma. Further, C-kit is a receptor tyrosine kinase expressed on the surface of mast cells, to which stem cell factor (SCF) is a ligand. Aberrant c-kit signaling is a mediator of certain autoimmune diseases. Binding of SCF to the c-kit receptor mediates various functions of the mast cell. As an important mediator of mast cell function, c-kit plays a role in pathologies associated with mast cells (MC). C-kit functions through mast cell generation, which plays an important role in triggering autoimmune diseases.
LCK dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. LCK is a cytoplastic tyronsine kinase of the Src family expressed in T cells and natural killer cells. It is generally accepted that Lck activity is important for signaling mediated by the T cell receptor and leads to normal T cell development and activation. Thus, compounds of formula (I) are a useful immunosuppressive for the treatment of autoimmune and inflammatory disorders and / or organ transplant rejection (in particular T cell mediated).
cABL dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. In CML, a reciprocally balanced chromosomal translocation in hematopoietic stem cells (HSCs) produces the BCR-ABL hybrid gene. The latter encodes the oncogenic Bcr-Abl fusion protein. Whereas ABL encodes a tightly regulated protein tyrosine kinase, which plays a fundamental role in regulating cell proliferation, adherence and apoptosis, the BCR-ABL fusion gene encodes as constitutively activated kinase, which transforms HSCs to produce a phenotype exhibiting deregulated clonal proliferation, reduced capacity to adhere to the bone marrow stroma and a reduces apoptotic response to mutagenic stimuli, which enable it to accumulate progressively more malignant transformations. Compounds of the formula (I), in view of their activity as AbI protein tyrosune kinase inhibitors, are also especially appropriate in the treatment of leukemias, e.g. CML or acute lymphoblastic leukemia (ALL).
RET dependent diseases include a wide variety of disorders or conditions known to the person skilled in the art. In humans, activating RET mutations are found in the inherited cancer sysndrome multiple endocrine neoplasia 2 and in sporadic medullary and papillary thyroid carcinomas. The specific type and location of RET mutations are strongly correlated with the desease phenotype and also have diagnostic and prognostic value. Further, RET - associated thyroid tumors encompass malignancies of the parafollicular C. cells and of follicular epithelial cells, of which the most common are papillary thyroid carcinomas. In addition, RET mutations cause the early onset cancer syndrome multiple endocrine neoloasia type 2 associated with several endocrine tumors including MTX, PC and parathyroid hyperplasia.
The invention also provides, in a third aspect, a combination of a compound of formula (I) and one or more further therapeutic agents. A compound of formula (I) can be administered alone or in combination with one or more other therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents. A compound of formula (I) can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.
Thus, a compound of the formula (I) may be used to advantage in combination with other antiproliferative compounds. Such antiproliferative compounds include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase Il inhibitors; microtubule active compounds; alkylating compounds; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibit- tors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphospho- nates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhi- bitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; compounds used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors such as 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010 from Conforma Therapeutics; temo- zolomide (TEMODAL®); kinesin spindle protein inhibitors, such as SB715992 or SB743921 from GlaxoSmithKline, or pentamidine/chlorpromazine from CombinatoRx; MEK inhibitors such as ARRY142886 from Array PioPharma, AZD6244 from AstraZeneca, PD181461 from Pfizer, leucovorin, EDG binders, antileukemia compounds, ribonucleotide reductase inhibit- tors, S-adenosylmethionine decarboxylase inhibitors, antiproliferative antibodies or other chemotherapeutic compounds. Further, alternatively or in addition they may be used in combination with other tumor treatment approaches, including surgery, ionizing radiation, photodynamic therapy, implants, e.g. with corticosteroids, hormones, or they may be used as radiosensitizers. Also, in anti-inflammatory and/or antiproliferative treatment, combination with anti-inflammatory drugs is included. Combination is also possible with antihistamine drug substances, bronchodilatatory drugs, NSAID or antagonists of chemokine receptors.
The term "aromatase inhibitor" as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testoste- rone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane can be administered, e.g., in the form as it is marketed, e.g. under the trademark AROMASIN. Form- estane can be administered, e.g., in the form as it is marketed, e.g. under the trademark LENTARON. Fadrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark AFEMA. Anastrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark ARIMIDEX. Letrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark FEMARA or FEMAR. Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the trademark ORIMETEN. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can be administered, e.g., in the form as it is marketed, e.g. under the trademark NOLVADEX. Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under the trademark EVISTA. Fulvestrant can be formulated as disclosed in US 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g. under the trademark FASLODEX. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors.
The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g. as disclosed in US 4,636,505. The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, go- serelin and goserelin acetate. Goserelin is disclosed in US 4,100,274 and can be administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEX. Abarelix can be formulated, e.g. as disclosed in US 5,843,901.
The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/17804). Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CAMPTOSAR. Topotecan can be administered, e.g., in the form as it is marketed, e.g. under the trademark HYCAMTIN.
The term "topoisomerase Il inhibitor" as used herein includes, but is not limited to the an- thracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYX), dauno- rubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and lo- soxantrone, and the podophillotoxines etoposide and teniposide. Etoposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOS. Teniposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark VM 26-BRISTOL. Doxorubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN. Epirubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark FARMORUBICIN. Idarubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOS. Mitoxantrone can be administered, e.g. in the form as it is marketed, e.g. under the trademark NOVANTRON. The term "microtubule active compound" relates to microtubule stabilizing, microtubule destabilizing compounds and microtublin polymerization inhibitors including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermolides, cochicine and epothilones and derivatives thereof, e.g. epothilone B or D or derivatives thereof. Paclitaxel may be administered e.g. in the form as it is marketed, e.g. TAXOL. Docetaxel can be administered, e.g., in the form as it is marketed, e.g. under the trademark TAXOTERE. Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN R. P. Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN. Discodermolide can be obtained, e.g., as disclosed in US 5,010,099. Also included are Epothilone derivatives which are disclosed in WO98/10121 , US 6,194,181 , WO98/25929, WO98/08849, WO99/43653, WO98/22461 and WO00/31247. Especially preferred are Epothilone A and/or B.
The term "alkylating compound" as used herein includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLOSTIN. Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark HOLOXAN.
The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO02/22577, especially N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1 H- indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1 H- indol-3-yl)-ethyl]-amino]methyl]phenyl]-2£-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).
The term "antineoplastic antimetabolite" includes, but is not limited to, 5-Fluorouracil or 5- FU, capecitabine, gemcitabine, DNA demethylating compounds, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA. Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR. The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis- platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CARBOPLAT. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN.
The term "compounds targeting/decreasing a protein or lipid kinase activity"; or a "protein or lipid phosphatase activity"; or "further anti-angiogenic compounds" as used herein includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g., a) compounds targeting, decreasing or inhibiting the activity of the platelet-derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g. a N-phenyl-2- pyrimidine-amine derivative, e.g. imatinib, SU101 , SU6668 and GFB-1 1 1 ; b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor- receptors (FGFR); c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-1 R), such as compounds which target, decrease or inhibit the activity of IGF- 1 R, especially compounds which inhibit the kinase activity of IGF-1 receptor, such as those compounds disclosed in WO02/092599, or antibodies that target the extracellular domain of IGF-1 receptor or its growth factors; d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family, or ephrin B4 inhibitors; e) compounds targeting, decreasing or inhibiting the activity of the AxI receptor tyrosine kinase family; f) compounds targeting, decreasing or inhibiting the activity of the Ret receptor tyrosine kinase; g) compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase, e.g. imatinib; h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases - (part of the PDGFR family), such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c-Kit receptor, e.g. imatinib; i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family, their gene-fusion products (e.g. BCR-AbI kinase) and mutants, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e.g. a N-phenyl-2-pyrimidine-amine derivative, e.g. imatinib or nilotinib (AMN107); PD180970; AG957; NSC 680410; PD173955 from ParkeDavis; or dasatinib (BMS-354825) j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK1 , PKB/Akt, and Ras/MAPK family members, and/or members of the cyclin- dependent kinase family (CDK) and are especially those staurosporine derivatives disclosed in US 5,093,330, e.g. midostaurin; examples of further compounds include e.g. UCN-01 , safingol, BAY 43-9006, Bryostatin 1 , Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; lsis 3521 ; LY333531/LY379196; isochinoline compounds such as those disclosed in WO00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor) or AT7519 (CDK inhibitor); k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein- tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin. A tyrphostin is preferably a low molecular weight (Mr < 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S- arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810; AG 99;
Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); I) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers) and their mutants, such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO98/10767, WO97/30034, WO97/49688, WO97/38983 and, especially, WO96/30347 (e.g. compound known as CP 358774), WO96/33980 (e.g. compound ZD 1839) and WO95/03283 (e.g. compound ZM105180); e.g. trastuzumab (Herceptin™), cetuximab (Erbitux™), Iressa, Tarceva, OSI-774, CI-1033, EKB-569, GW-2016, E1.1 , E2.4, E2.5, E6.2, E6.4, E2.1 1 , E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO03/013541 ; and m) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor, such as compounds which target, decrease or inhibit the activity of c-Met, especially compounds which inhibit the kinase activity of c-Met receptor, or antibodies that target the extracellular domain of c-Met or bind to HGF. Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (THALOMID) and TNP-470.
The term "Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase" includes, but is not limited to inhibitors of phosphatase 1 , phosphatase 2A, or CDC25, e.g. okadaic acid or a derivative thereof.
The term "Compounds which induce cell differentiation processes" includes, but is not limited to e.g. retinoic acid, α- γ- or δ-tocopherol or α- γ- or δ-tocotrienol.
The term "cyclooxygenase inhibitor" as used herein includes, but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. "Etridonic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL. "Clodronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS. "Tiludronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID. "Pamidronic acid" can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIA™. "Alendronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX. "Ibandronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT. "Risedronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTONEL. "Zoledronic acid" can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETA. The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (Certican™), CCI-779 and ABT578.
The term "heparanase inhibitor" as used herein refers to compounds which target, decrease or inhibit heparin sulfate degradation. The term includes, but is not limited to, PI-88. The term " biological response modifier" as used herein refers to a lymphokine or interferons, e.g. interferon γ.
The term "inhibitor of Ras oncogenic isoforms", e.g. H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras e.g. a "farnesyl transferase inhibitor" e.g. L-744832, DK8G557 or R1 15777 (Zarnestra). The term "telomerase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g. telomestatin.
The term "methionine aminopeptidase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g. bengamide or a derivative thereof.
The term "proteasome inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include e.g. Bortezomid (Velcade™) and MLN 341.
The term "matrix metalloproteinase inhibitor" or ("MMP" inhibitor) as used herein includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551 ) BMS- 279251 , BAY 12-9566, TAA21 1 , MMI270B or AAJ996.
The term "compounds used in the treatment of hematologic malignancies" as used herein includes, but is not limited to, FMS-like tyrosine kinase inhibitors e.g. compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1-b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase. Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, e.g. PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteosome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90 e.g., 17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
The term "antiproliferative antibodies" as used herein includes, but is not limited to, trastuzumab (Herceptin™), Trastuzumab-DM1 ,erbitux, bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody. By antibodies is meant e.g. intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
For the treatment of acute myeloid leukemia (AML), compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of formula (I) can be administered in combination with, e.g., farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
The term "antileukemic compounds" includes, for example, Ara-C, a pyrimidine analog, which is the 2'-alpha-hydroxy ribose (arabinoside) derivative of deoxycytidine. Also included is the purine analog of hypoxanthine, 6-mercaptopurine (6-MP) and fludarabine phosphate. Compounds which target, decrease or inhibit activity of histone deacetylase (HDAC) inhibitors such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) inhibit the activity of the enzymes known as histone deacetylases. Specific HDAC inhibitors include MS275, SAHA, FK228 (formerly FR901228), Trichostatin A and compounds disclosed in US 6,552,065, in particular, Λ/-hydroxy-3-[4-[[[2-(2-methyl-1 H-indol-3-yl)-ethyl]-amino]me- thyl]phenyl]-2E-2-propenamide, or a pharmaceutically acceptable salt thereof and Λ/-hydro- xy-3-[4-[(2-hydroxyethyl){2-(1 /-/-indol-3-yl)ethyl]-amino]methyl]phenyl]-2£-2-propenamide, or a pharmaceutically acceptable salt thereof, especially the lactate salt.
"Somatostatin receptor antagonists" as used herein refers to compounds which target, treat or inhibit the somatostatin receptor such as octreotide, and SOM230.
"Tumor cell damaging approaches" refer to approaches such as ionizing radiation. The term "ionizing radiation" referred to above and hereinafter means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4th Edition, Vol. 1 , pp. 248-275 (1993).
The term "EDG binders" as used herein refers a class of immunosuppressants that modulates lymphocyte recirculation, such as FTY720.
The term "ribonucleotide reductase inhibitors" includes, but is not limited to to pyrimidine or purine nucleoside analogs including, but not limited to, fludarabine and/or cytosine arabinoside (ara-C), 6-thioguanine, 5-fluorouracil, cladribine, 6-mercaptopurine (especially in combination with ara-C against ALL) and/or pentostatin. Ribonucleotide reductase inhibitors are especially hydroxyurea or 2-hydroxy-1 /-/-isoindole-1 ,3-dione derivatives, such as PL-1 , PL-2, PL-3, PL-4, PL-5, PL-6, PL-7 or PL-8 mentioned in Nandy et al., Acta Oncologica, Vol. 33, No. 8, pp. 953-961 (1994).
The term "S-adenosylmethionine decarboxylase inhibitors" as used herein includes, but is not limited to the compounds disclosed in US 5,461 ,076.
Also included are in particular those compounds, proteins or monoclonal antibodies of VEGF disclosed in WO98/35958, e.g. 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof, e.g. the succinate, or in WO00/09495, WO00/27820, WO00/59509, WO98/1 1223, WO00/27819 and EP 0 769 947; those as described by Prewett et al, Cancer Res, Vol. 59, pp. 5209-5218 (1999); Yuan et al., Proc Natl Acad Sci U S A, Vol. 93, pp. 14765-14770 (1996); Zhu et al., Cancer Res, Vol. 58, pp. 3209-3214 (1998); and Mordenti et al., Toxicol Pathol, Vol. 27, No. 1 , pp. 14-21 (1999); in WO00/37502 and WO94/10202; ANGIOSTATIN, described by O'Reilly et al., Cell, Vol. 79, pp. 315-328 (1994); ENDOSTATIN, described by O'Reilly et al., Cell, Vol. 88, pp. 277-285 (1997); anthranilic acid amides; ZD4190; ZD6474; SU5416; SU6668; bevacizumab; or anti-VEGF antibodies or anti-VEGF receptor antibodies, e.g. rhuMAb and RHUFab, VEGF aptamer e.g. Macugon; FLT-4 inhibitors, FLT-3 inhibitors, VEGFR-2 IgGI antibody, Angiozyme (RPI 4610) and Bevacizumab (Avastin™).
"Photodynamic therapy" as used herein refers to therapy which uses certain chemicals known as photosensitizing compounds to treat or prevent cancers. Examples of photodynamic therapy include treatment with compounds, such as e.g. VISUDYNE and porfimer sodium.
"Angiostatic steroids" as used herein refers to compounds which block or inhibit angiogenesis, such as, e.g., anecortave, triamcinolone, hydrocortisone, 1 1-α-epihydrocotisol, cortexolone, 17α-hydroxyprogesterone, corticosterone, desoxycorticosterone, testosterone, estrone and dexamethasone.
"Implants containing corticosteroids" as used herein includes, but is not limited to compounds, such as e.g. fluocinolone, dexamethasone. "Other chemotherapeutic compounds" include, but are not limited to, plant alkaloids, hormonal compounds and antagonists; biological response modifiers, preferably lymphokines or interferons; antisense oligonucleotides or oligonucleotide derivatives; shRNA or siRNA; or miscellaneous compounds or compounds with other or unknown mechanism of action.
The compounds of the invention are also useful as co-therapeutic compounds for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of inflammatory diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs. A compound of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly the invention includes a combination of a compound of the invention as hereinbefore described with an anti-inflammator or antihistamine drug substance, said compound of the invention and said drug substance being in the same or different pharmaceutical composition.
Suitable anti-inflammatory drugs include steroids, in particular glucocorticosteroids such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO02/88167, WO02/12266, WO02/100879, WO02/00679 (especially those of Examples 3, 11 , 14, 17, 19, 26, 34, 37, 39, 51 , 60, 67, 72, 73, 90, 99 and 101 ), WO03/035668, WO03/048181 , WO03/062259, WO03/064445, WO03/072592, non-steroidal glucocorticoid receptor agonists such as those described in WO00/00531 , WO02/10143, WO03/082280, WO03/082787, WO03/104195, WO04/005229;
LTB4 antagonists such LY2931 1 1 , CGS025019C, CP-195543, SC-53228, BIIL 284, ONO 4057, SB 209247 and those described in US 5451700; LTD4 antagonists such as montelu- kast and zafirlukast; PDE4 inhibitors such cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden),V-1 1294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Al mi rail Prodesfarma), PD189659 / PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in WO92/19594, WO93/19749, WO93/19750, WO93/19751 , WO98/18796, WO99/16766, WO01/13953, WO03/104204, WO03/104205, WO03/39544, WO04/000814, WO04/000839, WO04/005258, WO04/018450, WO04/018451 , WO04/018457, WO04/018465, WO04/ 018431 , WO04/018449, WO04/018450, WO04/018451 , WO04/018457, WO04/018465, WO04/019944, WO04/019945, WO04/045607 and WO04/037805; A2a agonists such as those disclosed in EP 409595A2, EP 1052264, EP 1241 176, WO94/17090, WO96/02543, WO96/02553, WO98/28319, WO99/24449, WO99/24450, WO99/24451 , WO99/38877, WO99/41267, WO99/67263, WO99/67264, WO99/67265, WO99/67266, WO00/23457, WO00/77018, WO00/78774, WO01/23399, WO01/27130, WO01/27131 , WO01/60835, WO01/94368, WO02/00676, WO02/22630, WO02/96462, WO03/086408, WO04/ 039762, WO04/039766, WO04/045618 and WO04/046083; A2b antagonists such as those described in WO02/42298; and beta-2 adrenoceptor agonists such as albuterol
(salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula (I) of WO00751 14, preferably compounds of the Examples thereof, especially a compound of formula
Figure imgf000039_0001
OH and pharmaceutically acceptable salts thereof, as well as compounds (in free or salt or solvate form) of formula (I) of WO04/16601 , and also compounds of WO04/033412. Suitable bronchodilatory drugs include anticholinergic or antimuscarinic compounds, in particular ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in WO01/041 18, WO02/51841 , WO02/53564, WO03/00840, WO03/87094, WO04/05285, WO02/00652, WO03/53966, EP 424021 , US 5171744, US 3714357, WO03/33495 and WO04/018422.
Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine as well as those disclosed in WO03/099807, WO04/026841 and JP 2004107299. Other useful combinations of compounds of the invention with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g. CCR-1 , CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1 , CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists such as Schering-Plough antagonists SC-351 125, SCH- 55700 and SCH-D, Takeda antagonists such as N-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H- benzo-cyclohepten-δ-yllcarbonyOaminolphenyll-methyOtetrahydro-N^-dimethyl^H-pyran^- amin-ium chloride (TAK-770), and CCR-5 antagonists described in US 6166037 (particularly claims 18 and 19), WO00/66558 (particularly claim 8), WO00/66559 (particularly claim 9), WO04/018425 and WO04/026873.
Therapeutic agents for possible combination are especially one or more antiproliferative, cytostatic or cytotoxic compounds, for example one or several agents selected from the group which includes, but is not limited to, an inhibitor of polyamine biosynthesis, an inhibitor of a protein kinase, especially of a serine/threonine protein kinase, such as protein kinase C, or of a tyrosine protein kinase, such as the EGF receptor tyrosine kinase, e.g. Iressa®, the VEGF receptor tyrosine kinase, e.g. PTK787 or Avastin®, or the PDGF receptor tyrosine kinase, e.g. STI571 (Glivec®), a cytokine, a negative growth regulator, such as TGF-β or IFN-β, an aromatase inhibitor, e.g. letrozole (Femara®) or anastrozole, an inhibitor of the interaction of an SH2 domain with a phosphorylated protein, antiestrogens, topoisomerase I inhibitors, such as irinotecan, topoisomerase Il inhibitors, microtubule active agents, e.g. paclitaxel or an epothilone, alkylating agents, antiproliferative antimetabolites, such as gemcitabine or capecitabine, platin compounds, such as carboplatin or cis-platin, bisphosphonates, e.g. AREDIA® or ZOMETA®, and monoclonal antibodies, e.g. against HER2, such as trastuzumab.
The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
The above-mentioned compounds, which can be used in combination with a compound of the formula (I), can be prepared and administered as described in the art, such as in the documents cited above. Thus, the invention relates in a further aspect to a combination comprising a therapeutically effective amount of a compound of formula (I) in free form or in pharmaceutically acceptable salt form and a second drug substance, for simultaneous or sequential administration.
The invention also provides, in a further aspect, a pharmaceutical preparation (composition), comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of such a compound, or a hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier and / or diluents and optionally one or more further drug substances.
The compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Topical administration is e.g. to the skin. A further form of topical administration is to the eye. Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
The invention relates also to pharmaceutical compositions comprising an effective amount, especially an amount effective in the treatment of one of the above-mentioned diseases (= disorders), of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers that are suitable for topical, enteral, for example oral or rectal, or parenteral administration and that may be inorganic or organic, solid or liquid. There can be used for oral administration especially tablets or gelatin capsules that comprise the active ingredient together with diluents, for example lactose, dextrose, mannitol, and/or glycerol, and/or lubricants and/or polyethylene glycol. Tablets may also comprise binders, for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavorings and sweeteners. It is also possible to use the pharmacologically active compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilisers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical compositions, which may, if desired, comprise other pharmacologically active substances are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectionning, dissolving or lyophilising processes, and comprise approximately from 1% to 99%, especially from approx. 1 % to approx. 20%, active ingredient(s).
The dosage of the active ingredient to be applied to a warm-blooded animal depends upon a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. The dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, for example humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 5 g, more preferably from approximately 10 mg to approximately 1.5 g per person per day, divided preferably into 1 to 3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
In a further aspect, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, as a medicament / for use as a medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases.
In a further aspect, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, as active ingredient in a medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases. In a further aspect, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, as medicament, in particular for the treatment of one or more Protein tyrosine kinase mediated diseases.
In a further aspect, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, for the manufacture of a medicament for the treatment of one or more Protein tyrosine kinase mediated diseases.
In a further aspect, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt of such a compound, for use in a method for the treatment of a subject in need thereof, especially for the treatment of a Protein tyrosine kinase mediated disease, most especially in a patient requiring such treatment.
In a further aspect, the invention relates to a method for the treatment of a disease which responds to an inhibition of a FGFR (such as FGFR3) kinase, which comprises administering a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the radicals and symbols have the meanings as defined above, especially in a quantity effective against said disease, to a warm-blooded animal requiring such treatment.
In a further aspect, the invention relates to a pharmaceutical composition comprising a compound of formula (I) as active ingredient in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. In a further aspect, the invention relates to a method of treatment of one or more Protein tyrosine kinase mediated diseases, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of compound of formula I.
In a further aspect, the invention relates to pharmaceutical compositions comprising: (a) an effective amount of compound of formula (I) and pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites thereof; and (b) one or more pharmaceutically acceptable excipients and / or diluents.
In a further aspect, the invention relates to a pharmaceutical composition for treatment of a disease, e.g. of solid or liquid tumours in warm-blooded animals, including humans, comprising a dose effective in the treatment of said disease of a compound of the formula (I) as described above or a pharmaceutically acceptable salt of such a compound together with a pharmaceutically acceptable carrier (= carrier material).
The invention also provides, in a further aspect, methods of manufacturing a compound of formula (I) and intermediates and their methods of manufacturing; such intermediates are useful for the manufacturing of a compound of formula (I). A compound of the formula (I) may be prepared by processes that, though not applied hitherto for the new compounds of the present invention where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation.
Preferably, a process for the manufacture of a compound of the formula (I) comprises either
Method A) reacting a carboxylic acid of the formula (II),
Figure imgf000044_0001
wherein the substituents are as defined for a compound of the formula (I) with an amine of the formula (III)
Figure imgf000044_0002
optionally in the prensence of a diluent (such as a polar organic solvent), optionally in the presence of a reaction aid (such as DMAP or TBTU), optionally in the presence of a base (such as an amine) to obtain a compound of formula I; or
Method B) reacting a compound of formula (X)
Figure imgf000044_0003
(X) wherein the substituents are as defined for a compound of the formula (I) and Hal represents halo (in particular bromo) with a boron compound of the formula (V)
Figure imgf000045_0001
wherein the substituents are as defined for a compound of the formula (I) and L2B represents represents a boronic acid residue or an ester thereof (such as (HO)2B-) or 4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl-), optionally in the presence of a diluent (such as an apolar organic solvent), optionally in the presence of a catalyst (such as a homogeneous Pd-catalyst), optionally in the presence of an reaction aid (such as an inorganic base) to obtain a compound of formula I;
and, if desired, converting a compound of the formula (I) obtained according to method A) or method B) into a different compound of the formula (I), and/or converting an obtainable salt of a compound of the formula (I) into a different salt thereof, and/or converting an obtainable free compound of the formula (I) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (I) from one or more different obtainable isomers of the formula I.
Method A) is particularly useful for manufacturing of compounds wherein X represents N (such as formula (I-A), (I-B), (I-C); while method B) is particular useful for manufacturing of compounds wherein X represents CH (such as formula (I-D)).
Reaction conditions
Where temperatures are given hereinbefore or hereinafter, "about" has to be added, as minor deviations from the numeric values given, e.g. variations of ±10 %, are tolerable. All reactions may take place in the presence of one or more diluents and/or solvents.
Protective gases, such as argon, may be used. The starting materials may be used in equimolar amounts; alternatively, a compound may be used in excess, e.g. to function as a solvent or to shift equilibrium or to generally accelerate reation rates. Reaction aids, such as acids, bases or catalysts may be added in suitable amounts, as known in the field, required by a reation and in line with generally known procedures. lntermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like. Intermediates may be directly used in the further reaction step or may be subject to one or more work up and/or purification steps. Additionally, intermediates may be subject to further derivatization / functionalization, as the case may be. For example, substituion of an aryl/heteroaryl ring may take place to introduce additional substituents (such as chloro, fluoro).
Starting materials may be used as commercially available, and/or subject to one or more work up and/or purification steps and/or produced in situ.
Amide forming reaction
Such reactions are generally known in the field. The reaction typically takes place in the presence of an activating agent (such as TBTU or others) which may be added in a slight excess and in the presence of a tert. amine and in the presence of one or more diluents
(such as polar aprotic diluents). Typically, the reaction takes place at r.t, reaction times may vary, good convertion rates are typically obtained after 18 hours. Further details may be found in the examples.
Suzuki-coupling
This reaction is, inter alia, useful for manufacturing of compounds of formula (I) according to method B) as described above. Reaction conditions, starting materials and catalysts for a Suzuki(-Miyaura) reaction are generally known in the field. This reaction typically takes place by palladium-catalyzed crosscoupling of organoboranes (e.g. of formula (V) or a reactive derivative thereof, whith a halogen derivative (e.g. of the formula (IV) or (X)). The reaction may be typically performed in analogy to the procedure described by K. Jones, M. Keenan, and F. Hibbert [Synlett, 1996, (6), 509-510]. Protecting groups
Protected derivatives of the compounds of the invention can be made by means known to those of ordinary skill in the art. Protecting groups are such groups that are typically no longer present in the final compounds once they are removed, while groups that remain as substituents are not protecting groups in the sense used here which are groups that are added at a starting material or intermediate stage and removed to obtain a final compound. Also in the case of conversions of a compound of the formula (I) into a different compound of the formula (I), protecting groups may be introduced and removed, if useful or required.
The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etheri- fications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by acetolysis, protonolysis, solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and below.
The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981 , in "Methoden der organischen Chemie" (Methods of organic chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H. -D. Jakubke and H. Jescheit, "Aminosauren, Peptide, Proteine" (Amino acids, peptides, proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974.
Optional Reactions and Conversions A compound of the formula (I) may be converted into a different compound of the formula (I). The following description provides a non-limiting overview of particular relevant optional reactions and conversions:
Benzyl groups: For example, in a compound of the formula (I) having a benzyl which is optionally substituted (e.g. methoxybenzyl), said benzyl moiety may be removed by hydrogenation, e.g. in the presence of a noble metal catalyst, such as palladium on coal, in an appropriate solvent, such as an alcohol, e.g. methanol, at appropriate temperatures, e.g. from 0 to 50 0C, in the case of removal from the piperazine nitrogen in the additional presence of an acid, e.g. HCI, to yield the corresponding compound wherein instead of the benzyl moiety a hydrogen is present.
N-oxides: A compound of formula (I) can be converted to a corresponding N-oxide. The reaction is typically carried out with a suitable oxidizing agent, preferably a peroxide, for example m-chloroperbenzoic acid, in a suitable solvent, e.g. halogenated hydrocarbon, typically chloroform or dichloromethane, or in a lower alkanecarboxylic acid, typically acetic acid, preferably at a temperature between O0C and the boiling temperature of the reaction mixture, especially at about room temperature. Compounds of formula (I) in unoxidized form can typically be prepared from N-oxides of compounds of formula (I) by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 800C.
Salts of compounds of formula (I) having at least one salt-forming group may be prepared in a manner known per se. For example, an acid addition salt of compounds of formula (I) with basic groups (e.g. basic nitrogen) can be typically obtained in customary manner, e.g. by treating a compound of the formula (I) with an acid or a suitable anion exchange reagent. A salt of a compound of formula (I) having acid groups may be typically formed by treating the compound with a metal compound, such as an alkali metal salt of a suitable organic carboxylic acid, e.g. the sodium salt of 2-ethylhexanoic acid, with an organic alkali metal or alkaline earth metal compound, such as the corresponding hydroxide, carbonate or hydrogen carbonate, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with a corresponding calcium compound or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used. Internal salts of compounds of formula (I) containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralization of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers. A salt of a compound of the formula (I) can be typically converted in customary manner into the free compound; a metal or ammonium salt can be converted, for example, by treatment with a suitable acid, and an acid addition salt, for example, by treatment with a suitable basic agent into a different salt. In both cases, suitable ion exchangers may be used.
Prodrug derivatives of the compounds of the invention can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be typically prepared by reacting a non-derivatized compound of the invention with a suitable carbamylating agent (e.g., 1 ,1-acyloxyalkylcarbanochloridate, para- nitrophenyl carbonate, or the like).
Solvates: Compounds of the present invention can be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.
For example, in a compound of the formula (I) wherein a substituent carries an amino or amino-Ci-C7-alkyl substituent, the amino can be converted into acylamino, e.g. Ci-C7- alkanoylamino or Ci-C7-alkanesulfonylamino, typically by reaction with a corresponding Ci-C7-alkanoylhalogenide or Ci-C7-alkanesulfonylhalogenide, e.g. a corresponding chloride, in the presence of a tertiary nitrogen base, such as triethylamine or pyridine, in the absence or presence of an appropriate solvent, such a methylene chloride, for example at temperatures in the range from -20 to 50 0C, e.g. at about room temperature.
In a compound of the formula (I) wherein a substituent carries a cyano substituent, the cyano may be converted to an aminomethyl group, e.g. by hydrogenation in the presence of an appropriate metal catalyst, such as Raney Nickel or Raney Cobalt, in an appropriate solvent, e.g. a lower alkanol, such as methanol and/or ethanol, for example at temperatures in the range from -20 to 50 0C, e.g. at about room temperature.
In a compound of the formula (I) wherein a substituent carries a carboxyl group (- COOH), the latter can be converted into an amide group, e.g. an N-Ci-C7-alkyl-carba- moyl group, typically by reaction with the corresponding amine, e.g. in the presence of a coupling agent, that forms a preferred reactive derivative of the carboxyl group in situ, for example dicyclohexylcarbodiimide/i-hydroxybenzotriazole (DCC/ HOBT); bis(2-oxo-3-oxaz- olidinyl)phosphinic chloride (BOPCI); O-(1 ,2-dihydro-2-oxo-1-pyridyl)-Λ/,Λ/,Λ/',Λ/-tetramethyl- uronium tetrafluoroborate (TPTU); O-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU); (benzotriazol-1 -yloxy)-tripyrrolidinophosphonium-hexafluoro- phosphate (PyBOP), O-(1 H-6-chlorobenzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate, 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride/hy- droxybenzotriazole or/1-hydroxy-7-azabenzotriazole (EDC/HOBT or EDC/HOAt) or HOAt alone, or with (1-chloro-2-methyl-propenyl)-dimethylamine. For review of some other possible coupling agents, see e.g. Klauser; Bodansky, Synthesis (1972), 453-463. The reaction mixture is preferably stirred at a temperature of between approximately -20 and 50 0C, especially between 0 0C and 30 0C, e.g. at room temperature.
Salts of a compound of formula (I) with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula (I) may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of formula I) may also be converted into a salt with one acid molecule per compound (for example a monohalogenide); this may be typically done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from 130 to 1700C, one molecule of the acid being expelled per molecule of a compound of formula I. Salts can usually be converted to free compounds, e.g. by treating with suitable basic compounds, for example with alkali metal carbonates, alkali metal hydrogencarbonates, or alkali metal hydroxides, typically K2CO3 or sodium NaOH.
Stereoisomeric mixtures, e.g. mixtures of diastereomers, can be separated into their corresponding isomers in a manner known per se by means of suitable separation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula (I) itself. Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in J. Jacques, A. Collet, S. H. Wilen, "Enantiomers, Racemates and Resolutions", Wiley, 1981.
It should be emphasized that reactions analogous to the conversions mentioned in this chapter may also take place at the level of appropriate intermediates (and are thus useful in the preparation of corresponding starting materials).
Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as disclosed in the Examples hereinafter.
One of skill in the art will appreciate that the above transformations are only representative of methods for preparation of the compounds of the present invention, and that other well known methods can similarly be used.
Starting materials:
The starting materials of the formulae II, III, IV and V, as well as other starting materials mentioned herein, e.g. below, can be prepared according to or in analogy to methods that are known in the art, are known in the art and/or are commercially available. Novel starting materials, as well as processes for the preparation thereof, are likewise an embodiment of the present invention. In the preferred embodiments, such starting materials are used and the reaction chosen are selected so as to enable the preferred compounds to be obtained. Wherein the starting materials and intermediates R1, R2, RA1, RA2, RB1, RB1, X, ring A, ring B, m and n are used ("the substituents of formula (I)"), these symbols preferably have the meanings given for a compound of the formula (I), if not indicated otherwise. In the starting materials (including intermediates), which may also be used and/or obtained as salts where appropriate and expedient, the substituents are preferably as defined for a compound of the formula I.
Compounds of the formula (II) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (II) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation. A process for the manufacture of a compound of the formula (II) comprises method A), step 1 : reacting first a compound of formula (IV)
Figure imgf000052_0001
wherein the substituents are as defined for a compound of the formula (I) and Hal represents halo (in particular bromo) with a boron compound of the formula (V)
Figure imgf000052_0002
wherein the substituents are as defined for a compound of the formula (I) and L2B represents represents a boronic acid residue or an ester thereof (such as (HO)2B-) or
4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl-), optionally in the presence of a diluent (such as an apolar organic solvent), optionally in the presence of a catalyst (such as a homogeneous Pd-catalyst), optionally in the presence of an reaction aid (such as an inorganic base); step 2: converting the thus obtained compound, optionally after purification or isolation, with
CuCN, optionally in the presence of a polar organic solvent (such as NMP) into the corresponding cyano derivative ; step 3: hydrolysing the thus obtained compound, optionally after purification or isolation, optionally in the presence of an polar organic solvent, to obtain a compound of formula (II);
or, method B), hydrolizing an ester of formula (NX)
Figure imgf000053_0001
wherein the substituents are as defined for a compound of the formula (I) and R" represents lower alkyl (in particular ethyl) under basic conditions, optionally in the prsende of a diluent, to obtain a compound of formula (II);
and, if desired, converting a compound of the formula (II) obtained into a different compound of the formula (II), and/or converting an obtainable salt of a compound of the formula (II) into a different salt thereof, and/or converting an obtainable free compound of the formula (II) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (II) from one or more different obtainable isomers of the formula (II).
The subsequent conversion of a compound of formula (II) into another compound of formula (II) is further illustrated by the following scheme.
Figure imgf000053_0002
In this scheme, the substituents have the meaning as defined herein. Thus, compounds of formula (II), in particular wherein ring B represents phenyl, a halogenation step may take place once a compound of formula (II) is formed. Such subsequent reaction step
R? R1
(halogenation step) is particular suitable if a substituent -R -R (such as fluoro or chloro) is to be introduced in one or both of the ortho-position(s) of ring B. Thus, the invention relates also to a process of manufacturing a compound of formula (II) wherein a Suzuki- coupling reation as described above is followed by a substitution reaction, in particular a halogenation reaction of ring B.
Compounds of the formula (III) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (III) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation. A process for the manufacture of a compound of the formula (III) comprises the step of reducing a compound of formula (IX)
Figure imgf000054_0001
wherein the substituents are as defined for a compound of the formula (I) with a reducing agent, optionally in the presence of a diluent
and, if desired, converting a compound of the formula (III) obtained into a different compound of the formula (III), and/or converting an obtainable salt of a compound of the formula (III) into a different salt thereof, and/or converting an obtainable free compound of the formula (III) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (III) from one or more different obtainable isomers of the formula (III).
Compounds of the formula (IV) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (IV) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation. A process for the manufacture of a compound of the formula (IV) wherein X represents N, comprises the step of reacting a compound of formula (Vl) Q P )— (
H R1' (Vl) wherein R1" represents either R1 or R2 as defined for a compound of the formula (I) and with a compound of formula (VII),
Figure imgf000055_0001
wherein Hal represents halo, in particular bromo, optionally in the presence of a diluent
and, if desired, converting a compound of the formula (IV) obtained into a different compound of the formula (IV), and/or converting an obtainable salt of a compound of the formula (IV) into a different salt thereof, and/or converting an obtainable free compound of the formula (IV) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (IV) from one or more different obtainable isomers of the formula (IV).
Compounds of the formula (V) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (V) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation.
A process for the manufacture of a compound of the formula (V) comprises the step of reacting a compound of formula (XIII)
Figure imgf000055_0002
wherein the substituents are as defined for a compound of the formula (I) and hal represents halogen, in particular bromo, first with a lithiation agent (such as butyllitium), optionally in the presence of a diluent, followed by reaction with a boronic acid or derivative thereof (such as trimethylboranate or bis-pinacolate-diboron)
and, if desired, converting a compound of the formula (V) obtained into a different compound of the formula (V), and/or converting an obtainable salt of a compound of the formula (V) into a different salt thereof, and/or converting an obtainable free compound of the formula (V) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (V) from one or more different obtainable isomers of the formula (V).
Compounds of the formula (X) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (X) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation.
A process for the manufacture of a compound of the formula (X) comprises the step of reacting a compound of formula (Xl)
Figure imgf000056_0001
wherein the substituents are as defined for a compound of the formula (I) (in particular wherein X represents CH) and hal represents halo (in particular bromo) with an amine of formula (III)
Figure imgf000056_0002
wherein the substituents are as defined for a compound of the formula (I), optionally in the presence of a diluent (such as a polor organic solvent), optionally in the presence of a reaction aid (such as DMAP or TBTU), optionally in the presence of a base (such as an amine) to obtain a compound of formula (X)
and, if desired, converting a compound of the formula (X) obtained into a different compound of the formula (X), and/or converting an obtainable salt of a compound of the formula (X) into a different salt thereof, and/or converting an obtainable free compound of the formula (X) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (X) from one or more different obtainable isomers of the formula (X).
This process is particular useful for compounds of formula (X), weherein X represents CH. Compounds of the formula (Xl) are known or may be prepared by processes that, though not applied hitherto for the compounds of the formula (Xl) where they thus form new processes, are known per se, the following scheme illustrates methods for such preparation.
A process for the manufacture of a compound of the formula (Xl) comprises the step of oxidizing a compound of formula (XII)
Figure imgf000057_0001
wherein the substituents are as defined for a compound of the formula (I) (in particular wherein X represents CH) and hal represents halo (in particular bromo) with an oxidizing agent (such as KMnO4) optionally in a diluent
and, if desired, converting a compound of the formula (Xl) obtained into a different compound of the formula (Xl), and/or converting an obtainable salt of a compound of the formula (Xl) into a different salt thereof, and/or converting an obtainable free compound of the formula (Xl) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (Xl) from one or more different obtainable isomers of the formula (Xl).
This process is particular useful for compounds of formula (X), weherein X represents CH.
The following examples illustrate the invention without limiting the scope thereof.
Temperatures are measured in degrees Celsius. Unless otherwise indicated, the reactions take place at rt. Microwave Apparatus: Emrys Optimizer (Biotage)
Analytical HPLC conditions are as follows:
System 1 : Linear gradient 20-100% solvent A in 5 min + 1.5 min 100% solvent A; detection at 215 nm, flow rate 1 mL/min at 300C. Column: Nucleosil 100-3 C18 (70 x 4.0 mm). Solvent A = CH3CN + 0.1 % TFA; Solvent B = H2O + 0.1% TFA. System 2: 40% Solvent A for 5 min and then linear gradient 40-100% solvent A in 5 min + 5 min 100% solvent A, flow rate 0.8 mL/min. Column: C18 XDB (250 x 4.6 mm). Solvent A = CH3CN; Solvent B = 20 mM NH4OAc in H2O.
System 3: Linear gradient 30-100% solvent A in 4 min + 2 min 100% solvent A; flow rate 0.8 mL/min. Column: Hypersil C18 (250 x 4.6 mm). Solvent A = CH3CN; Solvent B = H2O + 0.1% TFA.
The following Abbreviations and Acronyms are used:
AcOH acetic acid
BoC2O tert-butoxycarbonyl anhydride bp boiling point brine saturated solution of NaCI in water
CH3CN acetonitrile
Cs2CO3 cesium carbonate
CuCN copper (I) cyanide
DCM dichloromethane cone. concentrated
DIEA diisopropylethylamine
DMAP 4-(dimethylamino) pyridine
DME 1 ,2-dimethoxyethane
DMF dimethyl formamide
DMP 1 ,3-dimethyl-3,4,5,6-tetrahydro-2-(1 H)-pyrimidinone
DMSO dimethylsulfoxide equiv equivalent(s)
Et2O diethyl ether
EtOAc ethyl acetate
EtOH ethanol h hour(s)
Hex hexane
HCI hydrochloric acid
H2O water
HPLC high pressure liquid chromatography
KOH potassium hydroxyde
L liter(s) LiAIH4 lithium aluminum hydride
LiOH lithium hydroxyde mCPBA m-cloroperbenzoic acid
Me methyl
MeOH methanol mL milliliter(s) min minute(s) m.p. melting point
MPLC medium pressure liquid chromatography
MS mass spectrum
NaBH4 sodium borohydride
Na2CO3 sodium carbonate
NaH sodium hydride
NaHCO3 sodium bicarbonate
NaOH sodium hydroxyde
Na2SO4 sodium sulfate
NBS N-bromosuccinimide
NH4OAc ammonium acetate
NMP 1 -methyl-2-pyrrolidone
NMR Nuclear Magnetic Resonance
PdCI2(dppf) [1 ,1 '-bis(diphenylphosphino) ferrocene]d
Pd(PPh3)4 tetrakis(triphenylphosphine) palladium(O) Pd(PhCN)2CI2Bis(benzonitrile)palladium(ll)chloride
Ph phenyl
PPTS p-toluensulfonic acid
Rf ratio of fronts (TLC) rt room temperature
SelectFluor 1 -chloromethyl-4-fluoro-1 ,4-diazobicyclo[2.2.2]octane bis(tetrafluorol
TBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
TFA CF3COOH
THF tetrahydrofuran
TLC thin layer chromatography tR time of retention
Wt. weight For convenience, the following synthetic schemes are provided, wherein scheme 1 relates to examples 1 - 81 scheme 2 relates to examples 82 - 84 scheme 3 relates to examples 85 - 87 scheme 4 relates to examples 88 - 96 scheme 5 relates to examples 174-178 schemes 6 and 7 relate to examples 179-187
40% aq glyoxal / EtOH
Figure imgf000060_0001
Figure imgf000060_0002
Figure imgf000060_0003
Figure imgf000060_0004
Example 1
Figure imgf000060_0005
THF
Figure imgf000060_0006
Figure imgf000060_0007
Scheme 1
Figure imgf000061_0001
Figure imgf000061_0002
Step 83.1 Step 82.1
Figure imgf000061_0003
Scheme 2
Figure imgf000062_0001
Figure imgf000062_0002
KOH / Ethylene Glycol / H2O
Figure imgf000062_0003
Example 85
Scheme 3
Figure imgf000063_0001
Figure imgf000063_0002
KOH /Ethylene Glycol / H2O KOH /Ethylene Glycol /H2O
Figure imgf000063_0003
Step 391
Figure imgf000063_0004
Example 88 Example 94
Scheme 4
Figure imgf000064_0001
LiOH, THF
Figure imgf000064_0002
Scheme 5
EtOH 40% aq glyoxal / EtOH
Figure imgf000065_0001
Figure imgf000065_0002
Figure imgf000065_0003
Figure imgf000065_0004
Example 180
Scheme 6
Y NH
BoC2O, NaOH Acetone, H2O
Figure imgf000065_0005
Step 1.9
Step 1.8
Scheme 7 Example 1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl- piperazin-1 -vD-phenyli-amide
Figure imgf000066_0001
A mixture of propylphosphonic anhydride (50% in DMF, 0.31 ml_, 0.53 mmol, 2 equiv), 8- (2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (100 mg, 0.26 mmol) (Step 1.1 ), 4-(4-ethylpiperazin-1-yl)-aniline (Step 1.9) (65 mg, 0.32 mmol, 1.2 equiv), DMAP (2 mg), and Et3N (0.37 ml_, 2.65 mmol, 10 equiv) in DMF (2.0 ml_), was stirred for 18 h at rt, under an argon atmosphere. The reaction mixture was diluted with EtOAc and H2O. The aqueous layer was separated and extracted with EtOAc. The combined organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by trituration in Et2O to afford the title compound as a yellow solid: ES-MS: 565.9 [M+H]+; tR= 4.26 min (System 1 ).
Step 1.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid Sulfuryl chloride (1.7 ml_, 21.3 mmol, 2 equiv) was added dropwise to a cold (5°C) suspension of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 1.2) (3.3 g, 10.6 mmol) in CH3CN (30 ml_). The reaction mixture was stirred at 5°C for 2 h, quenched by addition of H2O, and concentrated. Trituration of the residue in H2O provided 4.0 g of the title compound as a white solid: ESI-MS: 378.9 [M+H]+; tR= 4.54 min (System 1 ).
Step 1.2: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
KOH (6.0 g, 107 mmol, 10 equiv) was added to 8-(3,5-dimethoxy-phenyl)-quinoxaline-5- carbonitrile (Step 1.3) (3.12 g, 10.7 mmol) in ethylene glycol (30 ml_). The reaction mixture was stirred at 1500C for 3 h (a solution was obtained), allowed to cool to rt, diluted with Et2O/ H2O, and extracted with Et2O. The aqueous phase was acidified to pH 5 by addition of HCI. Vacuum filtration of the resulting suspension afforded 3.3 g of the title compound as a yellow solid: ESI-MS: 31 1.0 [M+H]+; tR= 4.34 min (System 1 ).
Step 1.3: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carbonitrile A mixture of 5-bromo-8-(3,5-dimethoxy-phenyl)-quinoxaline (Step 1.4) (4.54 g, 13.2 mmol) and CuCN (1.54 g, 17.1 mmol, 1.3 equiv) in NMP (50 mL) was stirred for 2 h at 1800C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with EtOAc (10% aqueous solution of ethylenediamine) (150 ml_), and filtered to afford 1.19 g (batch 1 ) of the title compound as a yellow solid. The filtrate was extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in EtOAc to provide 2.31 g (batch 2) of the title compound: ESI- MS: 292.1 [M+H]+; tR= 4.53 min (System 1 ).
Step 1.4: 5-Bromo-8-(3,5-dimethoxy-phenyl)-quinoxaline
A mixture of 3,5-dimethoxyphenylboronic acid (Step 1.8) (3.38 g, 18.6 mmol) in EtOH (15 ml.) was added dropwise to a mixture of 5,8-dibromo-quinoxaline (Step 1.5) (10.7 g, 37.1 mmol, 2 equiv), PdCI2(dppf) (530 mg, 0.7 mmol, 0.03 equiv), Na2CO3 (2 M solution in H2O, 37 ml_, 74.3 mmol, 4 equiv) in toluene (100 ml.) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 105 0C for 2 h, allowed to cool to rt, diluted with EtOAc and H2O, filtered through a pad of celite and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by trituration in DCM, followed by silica gel column chromatography (Hex/EtOAc, 4:1 ) to afford 4.54 g of the title compound as a yellow solid: ES-MS: 345.0 [M+H]+; tR= 5.13 min (System 1 ); Rf = 0.17 (Hex/EtOAc, 4:1 ).
Step 1.5: 5,8-Dibromo-quinoxaline
A 40% aqueous solution of glyoxal (8.8 M, 6.3 ml_, 55.1 mmol, 1.3 equiv) was added to a suspension of 3,6-dibromo-benzene-1 ,2-diamine (Step 1.6) (1 1.3 g, 42.4 mmol) in EtOH (280 ml_). The reaction mixture was heated to reflux for 3 h and allowed to cool to rt overnight. Vacuum filtration of the reaction mixture afforded 9.7 g of the title compound as a yellow solid: APCI-MS: 286.2 / 288.1 / 290.1 [M-1]"; tR= 4.40 min (System 1 ).
Step 1.6: 3,6-Dibromo-benzene-1 ,2-diamine
NaBH4 (26 g, 680 mmol, 10 equiv) was added portionwise (2h) to a vigorously stirred suspension of 4,7-dibromo-benzo[1 ,2,5]thiadiazole (Step 1.7) (20 g, 68.0 mmol) in EtOH (400 ml_), under a nitrogen atmosphere and keeping the internal temperature below 15°C. The reaction mixture was allowed to warm to 300C, stirred for 1 h, cooled to 5°C, quenched by addition of H2O (50 ml_), and concentrated. The residue was diluted with Et2O/H2O. The resulting suspension was filtered and the filtrate extracted with Et2O. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in hexane to provide 12 g of the title compound as a white solid: ESI-MS: 262.9 / 264.9 / 266.9 [M-H]"; tR= 4.20 min (System 1 ).
Step 1.7: 4,7-Dibromo-benzo[1 ,2,51thiadiazole Bromine (18.6 ml_, 265 mmol, 1.2 equiv) was added to a refluxing solution of 1 ,2,5- benzothiazole (30 g, 220 mmol) in HBr (48% in H2O, 150 ml_). The reaction mixture was stirred for 4 h at reflux and allowed to cool to rt. The resulting solid was collected by vacuum filtration, washed with H2O, dried under vacuum, and triturated in MeOH to afford 63 g of the title compound as an off-white solid: 1H NMR (400 MHz, DMSO-c/6) δ(ppm): 8.00 (s, 2H); tR= 5.05 min (System 1 ).
Step 1.8: 3,5-dimethoxyphenylboronic acid f-BuLi (1.7 M in pentatne, 63 ml_, 106 mmol, 2.1 equiv) was added dropwise to a cold (-
78°C) solution of 3,5-dimethoxy-bromobenzene (1 1 g, 50.7 mmol) in THF (400 ml_), under an argon atmosphere. The yellow mixture si stirred for 45 min at -78°C. Trimethyl borate (20 ml_, 179 mmol, 3.5 equiv) was then added. The colorless reaction mixture was allowed to warm to 00C, quenched by addition of a saturated solution of NH4CI (5 ml_), and concentrated. The residue was diluted with EtOAc/NH4CI (saturated aqueous solution), and extracted with EtOAc. The organic phase was dried (Na2SO4), filtered and concentrated. The residue was triturated in Et2O to provide 6.8 g of the title compound as a white solid: ESI-MS: 183.1 [M+H]+; tR= 2.70 min (System 1 ).
Step 1.9: 4-(4-Ethylpiperazin-1-yl)-aniline
A suspension of 1-ethyl-4-(4-nitro-phenyl)-piperazine (Step 1.10) (6.2 g, 26.35 mmol) and Raney nickel (2 g) in MeOH (120 ml.) was stirred for 7 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 5.3 g of the title compound as a violet solid: ESI-MS: 206.1 [M+H]+; TLC: Rf = 0.15 (DCM/MeOH + 1 % NH3 aq, 9:1 ).
Step 1.10: 1-Ethyl-4-(4-nitro-phenyl)-piperazine
A mixture of 1-bromo-4-nitrobenzene (6 g, 29.7 mmol) and 1-ethylpiperazine (7.6 ml_, 59.4 mmol, 2 equiv) was heated to 800C for 15 h. After cooling to rt, the reaction mixture was diluted with H2O and DCM/MeOH (9:1 , v/v). The aqueous layer was separated and extracted with DCM/MeOH, 9:1. The organic phase was washed with brine, dried (sodium sulfate), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCIWMeOH + 1 % NH3 aq, 9:1 ) afforded 6.2 g of the title compound as a yellow solid: ESI-MS: 236.0 [M+H]+; tR= 2.35 min (purity: 100%, system 1 ); TLC: Rf = 0.50 (DCM/MeOH + 1 % NH3 aq, 9:1 ).
Example 2: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl- piperazin-1 -vD-phenyli-amide
Figure imgf000069_0001
The title compound was prepared in analogy to the procedure described in Examplei but using 3-(4-ethylpiperazin-1-yl)-aniline (Step 2.1 ). Purification of the crude product by silica gel column chromatography (DCM/MeOH/NH3 aq, 96.5:2.5:1 ) afforded 147 mg of the title compound as a yellow solid: ESI-MS: 565.9 / 567.9 [M+H]+; tR= 4.35 min (System 1 ); TLC: Rf = 0.30 (DCM/MeOH/NH3 aq, 96.5:2.5:1 ).
Step 2.1 : 3-(4-Ethylpiperazin-1-yl)-aniline The title compound was prepared in analogy to the procedure described in Step 1.9 but using 1-ethyl-4-(3-nitro-phenyl)-piperazine (Step 2.2). Title compound: ESI-MS: 206.2 [M+H]+; tR= 2.49 min (System 1 ).
Step 2.2: 1-Ethyl-4-(3-nitro-phenyl)-piperazine A mixture of 2-fluoro-4-nitrobenzene (3.2 mL, 29.7 mmol) and 1-ethylpiperazine (7.6 mL, 59.4 mmol, 2 equiv) was heated to reflux for 1 17 h. After cooling to rt, the reaction mixture was diluted with H2O and DCM/MeOH, 9:1. The aqueous layer was separated and extracted with DCM/MeOH, 9:1. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCM/MeOH, 1 :0 → 95:5) afforded 6 g of the title compound as a brown oil: ESI-MS: 236.0 [M+H]+; tR= 2.49 min (System 1 ); TLC: Rf = 0.26 (DCM/MeOH, 95:5). xample 3: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A-
Figure imgf000070_0001
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-aminobenzamide. Purification of the crude product by silica gel column chromatography (DCIWMeOH, 95:5), followed by trituration in EtOAc, afforded the title compound as a white solid: ESI-MS: 496.9 / 498.9 [M+H]+; tR= 4.72 min (System 1 ); TLC: Rf = 0.17 (DCM/MeOH, 96:5).
Example 4: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- morpholin-4-yl-phenyl)-amide
Figure imgf000070_0002
The title compound was prepared in analogy to the procedure described in Example 1 but using N-(4-aminophenyl)-morpholine. Purification of the crude product by silica gel column chromatography (DCM/MeOH, 97.5:2.5) afforded the title compound as a red solid: ESI-MS: 538.9 / 540.9 [M+H]+; tR= 4.61 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH, 97.5:2.5).
Example 5: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2- dimethylamino-ethoxy)-phenyl1-amide
Figure imgf000070_0003
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(2-dimethylamino-ethoxy)-phenylamine (Step 5.1 ). Purification of the crude product by silica gel column chromatography (DCM/MeOH/NH3 aq, 96.5:2.5:1 ) afforded the title compound as a red solid: ESI-MS: 540.8 / 542.7 [M+H]+; tR= 4.19 min (System 1 ); TLC: Rf = 0.41 (DCM/MeOH/NH3 aq, 96.5:2.5:1 ). Step 5.1 : 4-(2-Dimethylamino-ethoxy)-phenylamine i-Chloro-2-dimethylaminoethane hydrochloride (2 g, 21.9 mmol, 1.2 equiv) was added in one portion to a mixture of 4-aminophenol (2 g, 18.3 mmol) and finely powdered sodium hydroxide (1.8 g, 45.8 mmol, 2.5 equiv) in DMF (27 ml_), under an argon atmosphere. The reaction mixture was stirred for 17 h at rt. The resulting dark suspension was filtered. The filtrate was diluted with DCM (200 ml) and washed with brine (2 x 50 ml_). The organic phase was dried (Na2SO4), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCM/MeOH, 7:3) provided 3 g of the title compound as a brown solid: API-MS: 181.2 [M+H]+; TLC: Rf = 0.18 (DCM/MeOH, 7:3).
Example 6: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- carbamoyl-pyridin-2-yl)-amide
Figure imgf000071_0001
The title compound was prepared in analogy to the procedure described in Example 1 but using 6-aminonicotinamide. Purification of the crude product by silica gel column chromatography (DCM/MeOH, 97.5:2.5), followed by trituration in EtOAc, afforded the title compound as a yellow solid: ESI-MS: 497.9 / 499.9 [M+H]+; tR= 4.59 min (System 1 ); TLC: Rf = 0.12 (DCM/MeOH, 97.5:2.5).
Example 7: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-hvdroxy- phenvP-amide
Figure imgf000071_0002
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-aminophenol. Purification of the crude product by silica gel column chromatography (DCM/MeOH, 95:5), followed by trituration in DCM, afforded the title compound as a yellow solid: ESI-MS: 469.9 / 471.9 [M+H]+; tR= 4.71 min (System 1 ); TLC: Rf = 0.44 (DCM/MeOH, 95:5). xample 8: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-
Figure imgf000072_0001
A mixture of 4-(4-{[8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonyl]-amino}- phenyl)-piperazine-1-carboxylic acid tert-butyl ester (Step 8.1 ) (137 mg, 0.22 mmol) and a 4 N solution of HCI in dioxane (5 ml.) was stirred for 1 h at rt. The reaction mixture was diluted with DCM and H2O. The aqueous layer was separated and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in Et2O to afford 95 mg of the title compound as a red solid: ESI-MS: 537.9 / 539,9 [M+H]+; tR= 4.01 min (System 1 ).
Step 8.1 : 4-(4-{[8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonyl1-amino)- phenyl)-piperazine-1-carboxylic acid tert-butyl ester
The title compound was prepared in analogy to the procedure described in Examplei but using 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (Step 8.2). After workup with DCM and H2O, trituration of the crude product in Et2O afforded the title compound as a yellow solid: ES-MS: 637.9 / 639.9 [M+H]+; tR= 5.31 min (System 1 ).
Step 8.2: 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester A suspension of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (Step 8.3) (1.26 g, 4.1 mmol) and palladium on carbon (200 mg) in MeOH (30 ml.) was stirred for 30 min at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 1.1 g of the title compound as a pink solid: ESI-MS: 278.2 [M+H]+; tR= 2.85 min (System 1 ).
Step 8.3: 4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
Di-te/f-butyl-dicarbonate (1 M in THF, 5.8 ml_, 5.8 mmol, 1.2 equiv) was added to a solution of 1-(4-nitro-phenyl)-piperazine (1 g, 4.8 mmol) and triethylamine (1.0 ml_, 7.2 mmol, 1.5 equiv) in THF (20 ml_). The reaction mixture was stirred for 15 min at rt, quenched by addition of H2O (0.5 ml_), and concentrated. The residue was diluted with EtOAc, washed with a saturated aqueous solution of NH4CI, H2O and brine, dried (sodium sulfate), filtered and concentrated. Trituration of the crude product in Et2O afforded 1.26 g of the title compound as a yellow solid: ES-MS: 308.1 [M+H]+; tR= 5.00 min (System 1 ).
Example 9: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1-yl)-phenyl1-amide
Figure imgf000073_0001
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(4-methylpiperazin-1-yl)-aniline (WO2006000420). Title compound: ESI-MS: 551.8 / 553.9 [M+H]+; tR= 4.17 min (System 1 ).
Example 10: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- isopropyl-piperazin-i-vD-phenyli-amide
Figure imgf000073_0002
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(4-isopropylpiperazin-1-yl)-aniline (WO2006000420). Title compound: ESI-MS: 579.9 / 581.9 [M+H]+; tR= 4.37 min (System 1 ).
Example 1 1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- isopropyl-piperazin-1-ylmethyl)-phenyl1-amide
Figure imgf000073_0003
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(4-isopropyl-piperazin-1-ylmethyl)-phenylamine (Step 1 1.1 ). Title compound: ESI- MS: 593.8 / 595.8 [M+H]+; tR= 3.73 min (System 1 ).
Step 1 1.1 : 4-(4-lsopropyl-piperazin-1-ylmethyl)-phenylamine A suspension of 1-isopropyl-4-(4-nitro-benzyl)-piperazine (Step 1 1.2) (5.7 g, 21.65 mmol) and Raney Nickel (2 g) in MeOH (100 ml.) was stirred for 6 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 4.9 g of the title compound as a white solid: ESI-MS: 234.2.
Step 1 1.2: 1-lsopropyl-4-(4-nitro-benzyl)-piperazine
A mixture of 4-nitrobenzylchloride (4.1 g, 23.90 mmol), N-isopropylpiperazine (3.6 g, 28.67 mmol, 1.2 equiv), potassium carbonate (6.5 g, 47.79 mmol, 2 equiv) and acetone (82 ml) was stirred for 16 h at reflux. The reaction mixture was allowed to cool, was then filtered and concentrated. The residue was purified by silica gel column chromatography
(DCM/MeOH + 1 % NH3 aq, 9:1 ) to afford 5.7 g of the title compound: ESI-MS: 264.1 [M+H]+; TLC: tR= 1.73 min (System 1 ); TLC: Rf = 0.34 (DCM/MeOH + 1 % NH3 aq, 9:1 ).
Example 12: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- ethyl-piperazin-1-ylmethyl)-phenyl1-amide
Figure imgf000074_0001
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(4-ethyl-piperazin-1-ylmethyl)-phenylamine. Title compound: ESI-MS: 579.8 / 581.8 [M+H]+; tR= 3.66 min (System 1 ).
Step 12.1 : 4-(4-Ethyl-piperazin-1-ylmethyl)-phenylamine
The title compound was prepared in analogy to the procedure described in Step 1 1.1 but using 1-ethyl-4-(4-nitro-benzyl)-piperazine (Step 12.2): ESI-MS: 220.1 [M+H]+; TLC: Rf = 0.08 (DCM/MeOH + 1 % NH3 aq, 9:1 ).
Step 12.2: 1-Ethyl-4-(4-nitro-benzyl)-piperazine
The title compound was prepared in analogy to the procedure described in Step 1 1.2. The title compound: ESI-MS: 250.1 [M+H]+; TLC: Rf = 0.31 (DCM/MeOH + 1 % NH3 aq, 9:1 ). xample 13: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2-
Figure imgf000075_0001
The title compound was prepared in analogy to the procedure described in Example 1 but using 4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (WO2005047273). The title compound: ESI- MS: 566.8 / 568.8 [M+H]+; tR= 4.37 min (System 1 ).
Example 14: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (1 H- imidazol-2-vD-amide
Figure imgf000075_0002
A mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-yl]-amide (Step 14.1 ) (0.527 g, 0.82 mmol), 5 N HCI (7 ml_), and EtOH (4 ml.) was stirred at 65°C for 10 h. The reaction mixture was allowed to cool to rt, basified by addition of a saturated aqueous solution of Na2CO3, and extracted with DCM. The combined organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) to afford 0.288 g of the title compound as a yellow solid: ESI- MS: 443.9 / 445.9 [M+H]+; tR= 3.74 min (System 1 ); TLC: Rf = 0.30 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 14.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-yl1-amide
A mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 1.1 ) (0.400 g, 1.06 mmol), 1-(2-trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-ylamine (Step 14.2) (0.270 g, 1.27 mmol, 1.2 equiv), TBTU (408 mg, 1.27 mmol, 1.2 equiv), DIEA (0.74 ml_, 4.23 mmol, 4.0 equiv) in DMF (5 ml.) was stirred for 2 h at rt, diluted with EtOAc and H2O, and extracted with EtOAc.washed with a saturated aqueous solution of NaHCO3, H2O, and brine. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH, 95:5) to afford 0.518 g of the title compound as a yellow foam: ES-MS: 573.8 / 575.8 [M+H]+; tR= 5.03 min (System 1 ); Rf = 0.19 (DCM2/MeOH, 95:5).
Step 14.2: 1-(2-Trimethylsilanyl-ethoxymethyl)-1 H-imidazol-2-ylamine A suspension of 2-nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1 H-imidazole (Step 14.3) (1.84 g, 7.57 mmol) and palladium on carbon (200 mg) in MeOH (30 ml.) was stirred for 40 min at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 1.55 g of the title compound: ESI-MS: 214.1 [M+H]+; tR= 3.26 min (System 1 ).
Step 14.3: 2-Nitro-1-(2-trimethylsilanyl-ethoxymethyl)-1 H-imidazole
A suspension of 2-nitroimidazole (0.885 g, 7.8 mmol) and sodium hydride (60% dispersion in mineral oil, 0.440 g, 1 1.0 mmol, 1.4 equiv) in THF (20 ml.) was stirred for 1.5 h at 5°C, under an argon atmosphere. 2-(Trimethylsilyl)ethoxymethyl chloride (1.5 ml_, 8.6 mmol, 1.1 equiv) was then added. The reaction mixture was stirred for 2.5 h at 5°C, quenched by addition of a saturated aqueous solution of NH4CI, and extracted with EtOAc. The combined organic phase was washed with H2O and brine, dried (sodium sulfate), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:1 ) to afford 1.76 g of the title compound as a yellow oil: ES-MS: 244.1 [M+H]+; tR= 4.63 min (System 1 ); TLC: Rf = 0.19 (Hex/EtOAc, 3:1 ).
Example 15: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (2H- pyrazol-3-vD-amide
Figure imgf000076_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-nitro-1 H-pyrazole [Janssen, J. W. A. M.; Koeners, H. J.; Kruse, C. G.; Habrakern, Clarisse L. Gorlaeus Lab., Univ. Leiden, Leiden, Neth. Journal of Organic Chemistry (1973), 38(10), 1777-82] instead of 2-nitroimidazole in Step 14.3. The title compound: ESI- MS: 443.9 / 445.9 [M+H]+; tR= 4.42 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 16: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (3H- imidazol-4-yl)-amide
Figure imgf000077_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 4-nitro-imidazole instead of 2-nitroimidazole in Step 14.3. The title compound: ESI- MS: 443.9 / 445.9 [M+H]+; tR= 3.66 min (System 1 ); TLC: Rf = 0.14 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 17: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4H- ri ,2,41triazol-3-yl)-amide
Figure imgf000077_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 3-nitro-1 ,2,4-triazole instead of 2-nitroimidazole in Step 14.3. Trituration of the crude product in DCM afforded the title compound: ESI-MS: 444.9 / 446.9 [M+H]+; tR= 4.24 min (System 1 ).
Example 18: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- diethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000077_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, diethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine (Step 18.1 ) instead of 2-nitroimidazole in Step 14.3. The title compound: ESI-MS: 443.9 / 445.9 [M+H]+; tR= 4.42 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ). Step 18.1 : Diethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine
Formaldehyde (36% in H2O, 1.O mL, 13.3 mmol, 1.5 equiv) and diethyl amine (0.92 mL, 8.8 mmol) were added sequentially to a suspension of 2-nitro-imidazole (1 g, 8.8 mmol) in EtOH (20 mL). The resulting mixture was heated to reflux for 18 h, allowed to cool to rt, and concentrated. Trituration of the residue in Et2O afforded an impure sample of the title compound which was used without further purification.
Example 19: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- pyrrolidin-1 -ylmethyl-1 H-imidazol-2-yl)-amide
Figure imgf000078_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, 2-nitro-4-pyrrolidin-1 -ylmethyl-1 H-imidazole (Step 19.1 ) instead of 2-nitroimidazole in Step 14.3. The title compound: ESI-MS: 526.9 / 528.9 [M+H]+; tR= 3.48 min (System 1 ); TLC: Rf = 0.30 (DCM/MeOH/NH3 aq, 89:10:1 ).
Step 19.1 : 2-Nitro-4-pyrrolidin-1-ylmethyl-1 H-imidazole
The title compound was prepared in analogy to the procedure described in Step 18.1 but using pyrrolidine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 20: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000078_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, 1-methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 20.1 ) instead of 2- nitroimidazole in Step 14.3. The title compound: ESI-MS: 555.8 / 557.8 [M+H]+; tR= 3.22 min (System 1 ). Step 20.1 : 1-Methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine The title compound was prepared in analogy to the procedure described in Step 18.1 but using 1-methylpiperazine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 21 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- ethyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000079_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, 1-ethyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 21.1 ) instead of 2- nitroimidazole in Step 14.3. The title compound: ESI-MS: 569.8 / 571.8 [M+H]+; tR= 3.29 min (System 1 ).
Step 21.1 : 1-Ethyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine
The title compound was prepared in analogy to the procedure described in Step 18.1 but using 1-ethylpiperazine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 22: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000079_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine (Step 22.2) instead of 2-nitroimidazole in Step 14.3. The title compound: ESI-MS: 500.9 / 502.8 [M+H]+; tR= 3.35 min (System 1 ); TLC: Rf = 0.40 (DCM/MeOH/NH3 aq, 89:10:1 ). Step 22.1 : Dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine
The title compound was prepared in analogy to the procedure described in Step 18.1 but using dimethyl amine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 23: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- morpholin-4-ylmethyl-1 H-imidazol-2-yl)-amide
Figure imgf000080_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, 4-(2-nitro-1 H-imidazol-4-ylmethyl)-morpholine (Step 23.1 ) instead of 2-nitroimidazole in Step 14.3. The title compound: ESI-MS: 542.9 / 544.9 [M+H]+; tR= 3.42 min (System 1 ); TLC: Rf = 0.23 (DCM/MeOH/NH3 aq, 89:10:1 ).
Step 23.1 : 4-(2-Nitro-1 H-imidazol-4-ylmethyl)-morpholine
The title compound was prepared in analogy to the procedure described in Step 18.1 but using morpholine instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 24: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-oxo- 1 ,6-dihydro-pyridin-3-yl)-amide
Figure imgf000080_0002
The title compound was prepared in analogy to the procedure described in Example 1 but using 5-amino-pyridin-2-ol (Step 24.1 ) and stirring the reaction mixture for 40 h at rt. Title compound: ESI-MS: 470.8 / 472.8 [M+H]+; tR= 4.28 min (System 1 ) ; TLC: Rf = 0.17 (DCM/MeOH, 95:5).
Step 24.1 : 5-Amino-pyridin-2-ol A suspension of 2-hydroxy-5-nitropyridine (5 g, 35.7 mmol) and palladium on carbon (500 mg) in MeOH (100 mL) was stirred for 1 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 3.8 g of the title compound: ESI-MS: 110.8 [M+H]+.
Example 25: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazine-1-carbonyl)-pyridin-2-yl1-amide
Figure imgf000081_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using (6-amino-pyridin-3-yl)-(4-methyl-piperazin-1-yl)-methanone (Step 25.1 ) (2.4 equiv) and 2.4 equiv of TBTU. Title compound: ESI-MS: 580.8 / 582.8 [M+H]+; tR= 3.86 min (System 1 ); TLC: Rf = 0.29 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 25.1 : (6-Amino-pyridin-3-ylH4-methyl-piperazin-1-yl)-methanone The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-amino-nicotinic acid and 1-methylpiperazine. The reaction mixture was stirred overnight at 00C. DCM was used for dilution and extraction instead of EtOAc. The dried organic phase was concentrated to afford an impure sample of the title compound which was used without further purification.
Example 26: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000081_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2 equiv of 5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 26.1 ) and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 580.8 / 582.8 [M+H]+; tR= 3.63 min (System 1 ); TLC: Rf = 0.31 (DCM/MeOH/NH3 aq, 94:5:1 ). Step 26.1 : 5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride A mixture of [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 26.2) (0.75 g, 2.8 mmol) and a 4 N solution of HCI in dioxane (20 ml.) was stirred for 72 h at rt and concentrated to afford 660 mg of the title compound as a white solid: ESI-MS: 221.1 [M+H]+; tR= 0.80 min (System 1 ).
Step 26.2: [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester A mixture of methanesulfonic acid 6-tert-butoxycarbonylamino-pyridin-3-ylmethyl ester (Step 26.3) (0.8 g, 2.6 mmol), N-ethylpiperazine (0.37 ml_, 2.9 mmol, 1.1 equiv), cesium carbonate (1 g, 3.2 mmol, 1.2 equiv), and DMF (I O ml) was stirred for 2 h at rt, diluted with EtOAc and H2O, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to provide a yellow solid. Trituration in Et2O afforded 0.75 g of the title compound as a white solid: ES-MS: 321.2 [M+H]+.
Step 26.3: Methanesulfonic acid 6-tert-butoxycarbonylamino-pyridin-3-ylmethyl ester
Methanesulfonic anhydride (0.854 g, 4.9 mmol, 1.1 equiv) was added portionwise to a cold (5°C) mixture of (5-hydroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl ester (Step 26.4) (1 g, 4.5 mmol) and triethylamine (0.75 ml_, 5.4 mmol, 1.2 equiv) in DCM (20 ml_), under an argon atmosphere. The reaction mixture was allowed to stir for 1 h at 5°C, diluted with EtOAc and H2O, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to provide 1.25 g of the title compound as a white solid: tR= 2.60 min (System 1 ).
Step 26.4: (5-Hvdroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl Lithium aluminium hydride (1.6 g, 40.9 mmol, 1.1 equiv) was added portionwise to a cold (5°C) solution of θ-tert-butoxycarbonylamino-nicotinic acid ethyl ester (Step 26.5) (9.9 g, 37.2 mmol) in THF (250 ml_), under an argon atmosphere. The reaction mixture was stired for 1 h at 5°C and quenched by sequential addition of H2O (4 ml_), 15% NaOH aqueous solution (4 ml.) and H2O (12 ml_). The resulting mixture was filtered through a pad of celite and concentrated. The residue was diluted with EtOAc and H2O, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by trituration in Et2O to provide 5 g of the title compound as a white solid: ESI-MS: 223.0 [M-H]"; tR= 1.75 min (System 1 ). Step 26.5: θ-tert-Butoxycarbonylamino-nicotinic acid ethyl ester
A solution of di-te/f-butyl dicarbonate (1.7 g, 7.8 mmol, 1.3 equiv) in CH3CN (20 mL) is added dropwise to a suspension of ethyl 6-aminonicotinate (1 g, 6.0 mmol) and DMAP (73 mg, 0.6 mmol, 0.1 equiv) in CH3CN (10 mL) at rt. The reaction mixture was stirred for 4h at rt and concentrated. The residue was diluted with EtOAc and H2O, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 4:1 ) to afford 1.18 g of the title compound as a white solid: ES-MS: 265.1 [M-H]"; tR= 4.61 min (System 1 ); Rf = 0.50 (Hex/EtOAc, 4:1 ).
Example 27: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- diethylaminomethyl-pyridin-2-yl)-amide
Figure imgf000083_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-diethylaminomethyl-pyridin-2-ylamine (prepared as described in Example 26 but using diethylamine in Step 26.2) and stirring the reaction mixture overnight at rt. Title compound: ESI-MS: 539.9 / 541.8 [M+H]+; tR= 5.55 min (System 1 ); TLC: Rf = 1.0 (DCM/MeOH/NH3 aq, 89:10:1 ).
Example 28: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- dimethylaminomethyl-pyridin-2-yl)-amide
Figure imgf000083_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-dimethylaminomethyl-pyridin-2-ylamine hydrochloride (prepared as described in Example 26 but using dimethylamine hydrochloride in Step 26.2) and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 511.9 / 513.9 [M+H]+; tR= 3.96 min (System 1 ); TLC: Rf = 0.56 (DCM/MeOH/NH3 aq, 91 :8:1 ). xample 29: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-
Figure imgf000084_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-morpholin-4-ylmethyl-pyridin-2-ylamine hydrochloride (prepared as described in Example 26 but using morpholine in Step 26.2) and stirring the reaction mixture for 18 h at rt. Title compound: ESI-MS: 553.9 / 555.8 [M+H]+; tR= 3.98 min (System 1 ); TLC: Rf = 0.61 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Example 30: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- pyrrolidin-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000084_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-pyrrolidin-1-ylmethyl-pyridin-2-ylamine hydrochloride (2 equiv, prepared as described in Example 26 but using pyrrolidine in Step 26.2) and stirring the reaction mixture for 21 h at rt. Title compound: ESI-MS: 537.9 / 539.9 [M+H]+; tR= 4.16 min (System 1 ); TLC: Rf = 0.50 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Example 31 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000084_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (prepared as described in Example 26 but using N-methylpiperazine in Step 26.2), 2.4 equiv of TBTU and stirring the reaction mixture for 22 h at rt. Title compound: ESI-MS: 566.8 / 568.8 [M+H]+; tR= 3.62 min (System 1 ); TLC: Rf = 0.41 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Example 32: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4,5-bis- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000085_0001
A mixture of formaldehyde (36% in H2O, 60 μl_, 0.84 mmol, 9.3 equiv), dimethyl amine (40% in H2O, 66 μl_, 0.54 mmol, 6 equiv) and 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline- 5-carboxylic acid (1 H-imidazol-2-yl)-amide (Example 14) (40 mg, 0.09 mmol) in n-butanol (2 ml.) was heated to reflux for 1.5 h, allowed to cool to rt, and concentrated. The residue was diluted with DCM and an aqueous saturated solution of NaHCO3. The layers were separated and the aqueous phase was extracted with DCM. The combined organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 91 :8:1 ), followed by trituration in Et2O, to afford 9 mg of the title compound as a yellow solid: ES-MS: 557.8 / 559.8 [M+H]+; tR= 3.15 min (System 1 ); TLC: Rf = 0.09 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Example 33: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- isopropyl-piperazin-1-yl)-pyridin-3-vπ-amide
Figure imgf000085_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylaniline (Step 33.1 ) and stirring the reaction mixture for 17 h at rt. Title compound: ESI-MS: 580.8 / 582.8 [M+H]+; tR= 3.75 min (System 1 ); TLC: Rf = 0.37 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 33.1 : 6-(4-lsopropyl-piperazin-1-yl)-pyridin-3-vlaniline A mixture of 1-isopropyl-4-(4-nitro-phenyl)-piperazine (Step 33.2) (1.58 g, 6.32 mmol), iron (1.4 g, 25.3 mmol, 4 equiv), EtOH (20 ml_), H2O (5 ml.) and AcOH (2.5 ml.) was stirred for 2 h at 900C. The reaction mixture was allowed to cool to rt, basified by addition of aqueous NH3, filtered through a pad of celite. The filtrate was concentrated (to remove EtOH), extracted with EtOAc and DCM, saturated with NaCI and extracted with DCM. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCM/MeOH/NH3 aq, 91 :8:1 ) afforded 1.1 g of the title compound as a purple solid: ESI-MS: 221.1 [M+H]+; TLC: Rf = 0.20 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Step 33.2: 1-lsopropyl-4-(5-nitro-pyridin-2-yl)-piperazine
1-lsopropylpiperazine (1.8 ml_, 12.7 mmol, 2 equiv) was added to a cold (5°C) solution of 2- chloro-5-nitropyridine (1 g, 6.3 mmol,) in DCM (5 ml_). The reaction mixture was allowed to warm to rt, stirred for 16 h, diluted with DCM and H2O. The aqueous layer was separated and extracted with DCM. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated to provide 1.58 g of he title compound as a yellow solid: ESI-MS: 251.2 [M+H]+; tR= 2.20 min.
Example 34: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- ethyl-piperazin-1-yl)-pyridin-3-yl1-amide
Figure imgf000086_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-(4-ethylpiperazin-1-yl)-pyridin-3-ylaniline (prepared as described in Example 33 but using N-ethyl-piperazine in Step 33.2) and stirring the reaction mixture for 72 h at rt. Title compound: ESI-MS: 566.8 / 568.8 [M+H]+; tR= 3.66 min (System 1 ); TLC: Rf = 0.37 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 35: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [2-(4- isopropyl-piperazin-1-yl)-pyrimidin-5-yl1-amide
Figure imgf000087_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-(4-isopropyl-piperazin-1-yl)-pyrimidin-5-ylamine (Step 35.1 ) and stirring the reaction mixture for 72 h at rt. Title compound: ESI-MS: 581.7 / 583.7 [M+H]+; tR= 4.18 min (System 1 ); TLC: Rf = 0.62 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 35.1 : 2-(4-lsopropyl-piperazin-1-yl)-pyrimidin-5-ylamine
The title compound was prepared in analogy to the procedure described in Step 33.1 but using 2-(4-isopropyl-piperazin-1-yl)-5-nitro-pyrimidine (Step 35.2) and stirring the reaction mixture for 1.5 h. The title compound: ESI-MS: 222.1 [M+H]+; TLC: Rf = 0.13 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 35.2: 2-(4-lsopropyl-piperazin-1-yl)-5-nitro-pyrimidine
1-lsopropylpiperazine (1.8 mL, 12.7 mmol, 2 equiv) was added to a cold (5°C) solution of 2- chloro-5-nitropyrimidine (1 g, 6.3 mmol,) in DCM (5 mL). The reaction mixture was stirred for
20 min at 5°C and then diluted with DCM and H2O. The aqueous layer was separated and extracted with DCM. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated to provide 1.41 g of the title compound as a beige solid: ESI-MS: 252.2
[M+H]+; tR= 1.89 min.
Example 36: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [2-(4- ethyl-piperazin-1-yl)-pyrimidin-5-yl1-amide
Figure imgf000087_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-(4-ethyl-piperazin-1-yl)-pyrimidin-5-ylamine (prepared as described in Example 35 but using N-ethyl-piperazine in Step 35.2) and stirring the reaction mixture for 72 h at rt. Title compound: ESI-MS: 567.9 / 569.9 [M+H]+; tR= 4.11 min (System 1 ); TLC: Rf = 0.56 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 37: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {6- [methyl-(1-methyl-piperidin-4-yl)-amino1-pyridin-3-yl)-amide
Figure imgf000088_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using N-methyl-N-(1-methyl-piperidin-4-yl)-benzene-1 ,4-diamine [prepared as described in Example 33 but using methyl-(1-methyl-piperidin-4-yl)-amine in Step 33.2 and stirring the corresponding reaction mixture for 15 h at rt] and stirring the reaction mixture for 3 days at rt. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.46 min (System 1 ); TLC: Rf = 0.18 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 38: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {6-[(2- dimethylamino-ethyl)-methyl-amino1-pyridin-3-yl)-amide
Figure imgf000088_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-amino-2-[N-(2-dimethylamino-ethyl)-N-methyl]-pyridine (prepared as described in Example 33 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 33.2 and stirring the corresponding reaction mixture for 15 h at rt) and stirring the reaction mixture for 3 days at rt. Title compound: ESI-MS: 554.8 / 557.0 [M+H]+; tR= 3.58 min (System 1 ).
Example 39: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000088_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-(4-methyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (Step 39.1 ), and stirring the reaction mixture for 3 h at rt. The crude product was purified by trituration with Et2O. Title compound: ESI-MS: 566.9 / 569.1 [M+H]+; tR= 3.44 min (System 1 ).
Step 39.1 : 6-(4-Methyl-piperazin-1-ylmethyl)-pyridin-3-ylamine A suspension of 1-methyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine (Step 39.2) (0.529 g, 2.24 mmol) and Raney nickel (0.1 g) in MeOH (10 ml.) was stirred for 1 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 0.448 g of the title compound as an off-white solid: ESI-MS: 207.2 [M+H]+.
Step 39.2: 1-Methyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine
Sodium triacetoxyborohydride (1.4 g, 6.6 mmol, 2 equiv) was added portionwise to a cold (5°C) solution of 5-nitro-pyridine-2-carbaldehyde (Step 39.3) (0.5 g, 3.3 mmol) and N- methyl-piperazine (0.4 ml_, 3.6 mmol, 1.1 equiv) in DCM (10 ml_). The reaction mixture was allowed to warm to rt, stirred for 16 h, diluted with DCM and saturated solution of NaHCO3, and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 91 :8:1 ) to provide 0.532 g of the title compound as a yellow solid: ESI-MS: 237.2 [M+H]+; TLC: Rf = 0.31 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Step 39.3: 5-Nitro-pyridine-2-carbaldehyde
Diisobutylaluminium hydride (1 M in DCM, 44 ml_, 44 mmol, 1.3 equiv) was added dropwise to a cold (-780C) solution of δ-nitro-pyridine^-carboxylic acid ethyl ester (step 39.4) (6.56 g, 33.5 mmol) in DCM (130 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to 5°C, quenched by addition of an aqueous solution of potassium sodium tartrate, diluted with DCM and H2O, stirred for 16 h at rt, and filtered through a pad of celite. The filtrate was extracted several times with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by by silica gel column chromatography (EtOAc/Hex, 1 :1 ) to provide 2.54 g of the title compound as a beige solid: ESI-MS: 151.1 [M-H]".
Step 39.4: δ-Nitro-pyridine^-carboxylic acid ethyl ester
A mixture of δ-nitro-pyridine^-carboxylic acid (Step 39.5) (5.74 g, 34.2 mmol), H2SO4 (1 ml.) and EtOH (50 ml.) was stirred for 1.5 h at reflux. The residue was diluted with EtOAc and saturated solution of NaHCO3. The aqueous layer was separated and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 6.1 g of the title compound as a white solid: ES-MS: 197.1 [M+H]+; tR= 3.22 min (System 1 ).
Step 39.5: δ-Nitro-pyridine^-carboxylic acid A mixture of 2-bromo-5-nitro-pyridine (5.8 g, 28.6 mmol) and CuCN (3.3 g, 37.1 mmol, 1.3 equiv) in DMF (50 ml.) was stirred at reflux for 15 min, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with Et2O and H2O. The aqueous layer was separated and extracted with Et2O. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was treated with 6N HCI (50 ml.) for 1.5 h at reflux. The mixture was poured onto H2O (200 ml_). The resulting white solid was collected by vacuum filtration and dried to provide 3.1 g of the title compound: ESI-MS: 167.0 [M-H]"; tR= 1.59 min.
Example 40: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- ethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000090_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-(4-ethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (prepared as described in Example 39 but using N-ethyl-piperazine in Step 39.2), and stirring the reaction mixture for 16 h at rt. The crude product was purified by trituration with Et2O. Title compound: ESI-MS: 580.9 / 583.1 [M+H]+; tR= 3.53 min (System 1 ).
Example 41 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- PVrrolidin-1-ylmethyl-pyridin-3-yl)-amide
Figure imgf000090_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-pyrrolidin-1-ylmethyl-pyridin-3-ylamine (prepared as described in Example 39 but using pyrrolidine in Step 39.2), and stirring the reaction mixture for 1 h at rt. Title compound: ESI-MS: 538.0 / 540.1 [M+H] ; tR= 4.22 min (System 1 ); TLC: Rf = 0.35 (DCM/MeOH/NH3 q, 94:5:1 ).
Example 42: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- diethylaminomethyl-pyridin-3-yl)-amide
Figure imgf000091_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-diethylaminomethyl-pyridin-3-ylamine (prepared as described in Example 39 but using diethylamine in Step 39.2), and stirring the reaction mixture for 18 h at rt. The crude product was purified by trituration with Et2O. Title compound: ESI-MS: 540.0 / 542.1 [M+H]+; tR= 4.30 min (System 1 ).
Example 43: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- morpholin-4-ylmethyl-pyridin-3-yl)-amide
Figure imgf000091_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-morpholin-4-ylmethyl-pyridin-3-ylamine (prepared as described in Example 39 but using morpholine in Step 39.2), and stirring the reaction mixture for 18 h at rt. The crude product was purified by trituration with Et2O. Title compound: ESI-MS: 553.9 / 556.1 [M+H]+; tR= 4.30 min (System 1 ).
Example 44: 8-(2-Fluoro-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino-ethoxy)- phenyli-amide
Figure imgf000091_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture overnight and using 4-(2-dimethylamino-ethoxy)-phenylamine (Step 5.1 ) and 8-(2-fluoro-phenyl)-quinoxaline-5-carboxylic acid. The latter compound was prepared as described in Steps 1.2 - 1.7 but using 2-fluorophenylboronic acid in Step 1.4. Title compound: ESI-MS: 431.0 [M+H]+; tR= 3.93 min (System 1 ); TLC: Rf = 0.29 (DCM/MeOH/NH3 aq, 96:3:1 ).
Example 45: 8-(2-Fluoro-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000092_0001
The title compound was prepared in analogy to the procedure described in Example 14 but using 8-(2-fluoro-phenyl)-quinoxaline-5-carboxylic acid (Example 44) in Step 14.1. Title compound: ESI-MS: 334.0 [M+H]+; tR= 3.39 min (System 1 ); TLC: Rf = 0.54 (DCM/MeOH, 9:1 ).
Example 46: 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-vD- phenyli-amide
Figure imgf000092_0002
The title compound was prepared in analogy to the procedure described in in Step 14.1 but stirring the reaction mixture overnight and using 4-(4-methylpiperazin-1-yl)-aniline (WO2006000420) and 8-naphthalen-1-yl-quinoxaline-5-carboxylic acid. The latter compound was synthesized as described in Steps 1.2-1.7 but using 1-naphtylboronic acid in Step 1.4. Title compound: ESI-MS: 474.0 [M+H]+; tR= 4.34 min (System 1 ); TLC: Rf = 0.45 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 47: δ-Naphthalen-i-yl-quinoxaline-δ-carboxylic acid (5-diethylaminomethyl-pyridin- 2-vD-amide
Figure imgf000093_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture overnight and using 5-diethylaminomethyl-pyridin-2-ylamine (Example 27) and 8-naphthalen-1-yl-quinoxaline-5-carboxylic acid (Example 46). Title compound: ESI-MS: 462.0 [M+H]+; tR= 4.35 min (System 1 ); TLC: Rf = 0.72 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Example 48: δ-Naphthalen-i-yl-quinoxaline-δ-carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
Figure imgf000093_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 72 h at rt and using 3 equiv of 5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-ylamine hydrochloride (Example 31 ), TBTU (2.4 equiv) and 8- naphthalen-1-yl-quinoxaline-5-carboxylic acid (Example 46). Title compound: ESI-MS: 489.1 [M+H]+; tR= 3.73 min (System 1 ); TLC: Rf = 0.08 (DCM/MeOH, 9:1 ).
Example 49: 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000093_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-naphthalen-1-yl-quinoxaline-5-carboxylic acid (Example 46). Title compound: ESI- MS: 366.1 [M+H]+; tR= 3.88 min (System 1 ); TLC: Rf = 0.43 (DCM/MeOH, 9:1 ).
Example 50: 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1-vD- pyridin-3-yli-amide
Figure imgf000094_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 20 h at rt and using 6-(4-methylpiperazin-1-yl)-pyridin-3- ylamine (prepared as described in Example 33 but using N-methyl-piperazine in Step 33.2) and 8-naphthalen-1-yl-quinoxaline-5-carboxylic acid (Example 46). Title compound: ESI-MS: 475.0 [M+H]+; tR= 3.76 min (System 1 ).
Example 51 : 8-Naphthalen-1-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1- ylmethyl)-1 H-imidazol-2-yl1-amide
Figure imgf000094_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-naphthalen-1-yl-quinoxaline-5-carboxylic acid (Example 46) in Step 14.1 , Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2 and 1- methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3. Title compound: ESI-MS: 478.1 [M+H]+; tR= 3.36 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH, 9:1 ).
Example 52: 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1-vD- phenyli-amide
Figure imgf000094_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-(4-ethylpiperazin-1-yl)-aniline (Step 2.1 ) and 8-isoquinolin-4-yl-quinoxaline-5- carboxylic acid. The latter compound was synthesized as described in Steps 1.2-1.7 but using 4-isoquinolineboronic acid in Step 1.4. Title compound: ESI-MS: 489.2 [M+H]+; tR= 1 1.28 min (System 2). Example 53: δ-lsoquinolin^-yl-quinoxaline-δ-carboxylic acid [4-(4-ethyl-piperazin-1-yl)- phenyli-amide
Figure imgf000095_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(4-ethylpiperazin-1-yl)-aniline (Step 1.9) and 8-isoquinolin-4-yl-quinoxaline-5- carboxylic acid (Example 52). Title compound: ESI-MS: 489.1 [M+H]+; tR= 10.58 min (System 2).
Example 54: δ-lsoquinolin^-yl-quinoxaline-δ-carboxylic acid [4-(2-dimethylamino-ethoxy)- phenyli-amide
Figure imgf000095_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(2-dimethylamino-ethoxy)-phenylamine (Step 5.1 ) and 8-isoquinolin-4-yl- quinoxaline-5-car-boxylic acid (Example 52). Title compound: ESI-MS: 464.1 [M+H]+; tR= 8.23 min (System 2).
Example 55: 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000095_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-isoquinolin-4-yl-quinoxaline-5-carboxylic acid (Example 52) in Step 14.1. Title compound: ESI-MS: 367.0 [M+H]+; TLC: Rf = 0.17 (DCM/MeOH, 95:5).
Example 56: 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
Figure imgf000096_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 17 h at rt, using 2 equiv of 5-(4-methyl-piperazin-1-ylmethyl)- pyridin-2-ylamine hydrochloride (Example 31 ), TBTU (2 equiv) and 8-isoquinolin-4-yl- quinoxaline-5-carboxylic acid (Example 52). Title compound: ESI-MS: 490.0 [M+H]+; tR= 2.21 min (System 1 ); TLC: Rf = 0.17 (DCIWMeOH, 9:1 ).
Example 57: δ-lsoquinolin^-yl-quinoxaline-δ-carboxylic acid [6-(4-methyl-piperazin-1-yl)- pyridin-3-yli-amide
Figure imgf000096_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 20 h at rt and using 6-(4-methylpiperazin-1-yl)-pyridin-3- ylamine (prepared as described in Example 33 but using N-methyl-piperazine in Step 33.2) and 8-isoquinolin-4-yl-quinoxaline-5-carboxylic acid (Example 52). Title compound: ESI-MS: 476.1 [M+H]+; tR= 1.98 min (System 1 ).
Example 58: 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1- ylmethyl)-1 H-imidazol-2-yl1-amide
Figure imgf000096_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using 1-methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 20.1 ) instead of 2- nitroimidazole in Step 14.3, Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 8-isoquinolin-4-yl-quinoxaline-5-carboxylic acid (Example 52) in Step 14.1. Title compound: ESI-MS: 479.0 [M+H]+; TLC: Rf = 0.16 (DCM/MeOH, 9:1 ). Example 59: δ-Benzofbithiophen-S-yl-quinoxaline-δ-carboxylic acid [5-(4-methyl-piperazin- 1 -ylmethyl)-pyridin-2-yl1-amide
Figure imgf000097_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture at rt overnight and using 2 equiv of 5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-ylamine hydrochloride (Example 31 ), TBTU (2 equiv) and 8- benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid. The carboxylic acid was synthesized as described in Steps 1.2-1.7 but using benzothiophene-3-boronic acid in Step 1.4. Title compound: ESI-MS: 494.9 [M+H]+; tR= 3.77 min (System 1 ); TLC: Rf = 0.17 (DCIWMeOH, 9:1 ).
Example 60: δ-Benzofbithiophen-S-yl-quinoxaline-δ-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000097_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid (Example 59) in Step 14.1. Title compound: ESI-MS: 372.0 [M+H]+; tR= 3.88 min (System 1 ); TLC: Rf = 0.57 (DCM/MeOH, 9:1 ).
Example 61 : 8-Benzo[b1thiophen-3-yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin- 1 -yl)-pyridin-3-yl1-amide
Figure imgf000097_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 20 h at rt, using 6-(4-methylpiperazin-1-yl)-pyridin-3-ylamine (prepared as described in Example 33 but using N-methyl-piperazine in Step 33.2) and 8- benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid (Example 59). Title compound: ESI-MS: 481.0 [M+H]+; tR= 3.81 min (System 1 ); TLC: Rf = 0.40 (DCM/MeOH, 9:1 ). Example 62: δ-Benzofbithiophen-S-yl-quinoxaline-δ-carboxylic acid [4-(4-methyl-piperazin-
1 -ylmethvD-1 H-imidazol-2-yli-amide
Figure imgf000098_0001
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for 20 h at 65°C, using 1-methyl-4-(2-nitro-1 H-imidazol-4- ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3, Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 8- benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid (Example 59) in Step 14.1. Title compound: ESI-MS: 484.0 [M+H]+; tR= 3.36 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH, 9:1 ).
Example 63: 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl- piperazin-1 -yl)-phenyll-amide
Figure imgf000098_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-(4-ethylpiperazin-1-yl)-aniline (Step 2.1 ) and 8-(2-chloro-5-methoxy-phenyl)- quinoxaline-5-carboxylic acid. The latter compound was synthesized as described in Steps 1.2-1.7 but using 2-chloro-4-methoxyphenylboronic acid in Step 1.4. Title compound: ESI- MS: 502.1 [M]+; tR= 3.57 min (System 3).
Example 64: 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl- piperazin-1 -vD-phenyli-amide
Figure imgf000098_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(4-ethylpiperazin-1-yl)-aniline (Step 1.9) and 8-(2-chloro-5-methoxy-phenyl)- quinoxaline-5-carboxylic acid (Example 63). Title compound: ESI-MS: 502.1 [M]+; tR= 3.50 min (System 3).
Example 65: 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2- dimethylamino-ethoxy)-phenyl1-amide
Figure imgf000099_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(2-dimethylamino-ethoxy)-phenylamine (Step 5.1 ) and 8-(2-chloro-5-methoxy- phenyl)-quinoxaline-5-carboxylic acid (Example 63). Title compound: ESI-MS: 476.9 [M]+; tR= 3.43 min (System 3).
Example 66: 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2- vD-amide
Figure imgf000099_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2-chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid (Example 63) in Step 14.1. Title compound: ESI-MS: 380.0 [M+H]+; tR= 3.61 min (System 1 ); TLC: Rf = 0.36 (DCM/MeOH, 95:5).
Example 67: 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin- 1 -ylmethyl)-pyridin-2-yl1-amide
Figure imgf000099_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture at rt overnight, using 2 equiv of 5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-ylamine hydrochloride (Example 31 ), TBTU (2 equiv) and 8-(4-methyl- thiophen-3-yl)-quinoxaline-5-carboxylic acid. The carboxylic acid was synthesized as described in Steps 1.2-1.7 but using 4-methyl-3-thiopheneboronic acid in Step 1.4. Title compound: ESI-MS: 459.1 [M+H]+; tR= 3.41 min (System 1 ); TLC: Rf = 0.25 (DCIWMeOH, 9:1 ).
xample 68: 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-
Figure imgf000101_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 20 h at rt, using 6-(4-methylpiperazin-1-yl)-pyridin-3-ylamine (prepared as described in Example 33 but using N-methyl-piperazine in Step 33.2) and 8-(4- methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (Example 67). Title compound: ESI-MS: 445.0 [M+H]+; tR= 3.42 min (System 1 ).
Example 69: 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-
1 -ylmethvD-1 H-imidazol-2-yli-amide
Figure imgf000101_0002
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for 16 h at 600C, using 1-methyl-4-(2-nitro-1 H-imidazol-4- ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3, Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 8-(4-methyl- thiophen-3-yl)-quinoxaline-5-carboxylic acid (Example 67) in Step 14.1. Title compound: ESI-MS: 448.0 [M+H]+; tR= 3.00 min (System 1 ); TLC: Rf = 0.14 (DCM/MeOH, 9:1 ).
Example 70: 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)- amide
Figure imgf000101_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(4-methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (Example 67) in Step 14.1. Title compound: ESI-MS: 336.1 [M+H]+; tR= 3.47 min (System 1 ); TLC: Rf = 0.66 (DCM/MeOH, 9:1 ). Example 71 : 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1- vD-phenyli-amide
Figure imgf000102_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-(4-ethylpiperazin-1-yl)-aniline (Step 2.1 ) and 8-(2,6-dimethyl-phenyl)-quinoxaline-5- carboxylic acid. The carboxylic acid was synthesized as described in Steps 1.2-1.7 but using 2,6-dimethylphenylboronic acid and Pd(PPh3)4 in Step 1.4. Title compound: ESI-MS: 466.2 [M+H]+; tR= 3.74 min (System 3).
Example 72: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1- vD-phenyli-amide
Figure imgf000102_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(4-ethylpiperazin-1-yl)-aniline (Step1.9) and 8-(2,6-dimethyl-phenyl)-quinoxaline-5- carbox-ylic acid (Example 71 ). Title compound: ESI-MS: 466.2 [M+H]+; tR= 3.67 min (System 3).
Example 73: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino- ethoxy)-phenyl1-amide
Figure imgf000102_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(2-dimethylamino-ethoxy)-phenylamine (Step 5.1 ) and 8-(2,6-dimethyl-phenyl)- quinoxaline-5-carboxylic acid (Example 71 ). Title compound: ESI-MS: 441.1 [M+H]+; tR= 3.52 min (System 3). Example 74: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000103_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Example 71 ) in Step 14.1. Title compound: ESI-MS: 344.1 [M+H]+; tR= 3.62 min (System 1 ); TLC: Rf = 0.50 (DCIWMeOH, 95:5).
Example 75: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-yl1-amide
Figure imgf000103_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 2 days at rt, using 2 equiv of 5-(4-methyl-piperazin-1- ylmethyl)-pyridin-2-ylamine hydrochloride (Example 31 ), TBTU (2 equiv) and 8-(2,6- dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Example 71 ). Title compound: ESI-MS: 467.1 [M+H]+; tR= 3.55 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH, 9:1 ).
Example 76: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1- yl)-pyridin-3-yl1-amide
Figure imgf000103_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but stirring the reaction mixture for 20 h at rt, using 6-(4-methylpiperazin-1-yl)-pyridin-3-ylamine (prepared as described in Example 33 but using N-methyl-piperazine in Step 33.2) and 8- (2,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Example 71 ). Title compound: ESI-MS: 453.1 [M+H]+; tR= 3.55 min (System 1 ). Example 77: 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1- ylmethyl)-1 H-imidazol-2-yl1-amide
Figure imgf000104_0001
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for at 600C overnight, using 1-methyl-4-(2-nitro-1 H-imidazol-4- ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3 and 8-(2,6- dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Example 71 ), and using Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. Title compound: ESI-MS: 456.1 [M+H]+; tR= 3.18 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH, 9:1 ).
Example 78: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3- ylamide
Figure imgf000104_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-aminopyridine and stirring the reaction mixture for 16 h at rt. Title compound: ESI- MS: 455.0 / 456.9 [M+H]+; tR= 3.76 min (System 1 ); TLC: Rf = 0.35 (DCM/MeOH/NH3 aq, 96:3:1 ).
Example 79: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-2- ylamide
Figure imgf000104_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-aminopyridine (2 equiv), TBTU (4 equiv) and stirring the reaction mixture for 16 h at rt. Title compound: ESI-MS: 455.0 / 456.9 [M+H]+; tR= 4.47 min (System 1 ); TLC: Rf = 0.61 (DCM/MeOH/NH3 aq, 96:3:1 ). Example 80: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-methyl- pyridin-2-yl)-amide
Figure imgf000105_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-amino-5-methylpyridine (2 equiv), TBTU (4 equiv) and stirring the reaction mixture for 4 days at rt. Title compound: ESI-MS: 469.0 / 470.9 [M+H]+; tR= 4.48 min (System 1 ).
Example 81 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
Figure imgf000105_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using N-(6-amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2) and stirring the reaction mixture for 4 days at rt. Title compound: ESI-MS: 569.0 / 571.2 [M+H]+; tR= 3.44 min (System 1 ); TLC: Rf = 0.19 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 82: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-3-ylamide
Figure imgf000105_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-aminopyridine, 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carboxylic acid (Step 82.1 ) and stirring the reaction mixture for 12 h at rt. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.24 min (System 1 ); TLC: Rf = 0.38 (DCM/MeOH, 9:1 ). Step 82.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1-ylmethyl)- quinoxaline-5-carboxylic acid
A solution of KOH (0.818 g, 14.6 mmol, 10 equiv) in H2O (20 ml.) was added to 710 mg (1.46 equiv) of a mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl- piperazin-1-ylmethyl)-quinoxaline-5-carbonitrile (Step 82.2) (710 mg, 1.46 mmol) in ethylene glycol (20 ml_). The reaction mixture was stirred at 1500C for 3 h, allowed to cool to rt and washed with EtOAc (2 x 100 ml_). The aqueous layer was acidified to pH 3-4 by addition of 1 N HCI. The resulting suspension was filtered. The filtrate contains 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 -ylmethyl)-quinoxaline-5-carboxylic acid (Step 83.1 ). The residue in the filter was triturated in 1 N HCI (3 mL) and filtered. The filtrate was basified to pH 5 and extracted with DCM (2 x 100 mL). The organic layer was dried (Na2SO4), filtered and concentrated to afford 190 mg of the title compound as a white solid: ES-MS: 505.0 / 506.6 [M+H]+; tR= 3.46 min (System 1 ).
Step 82.2: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carbonitrile N-Ethylpiperazine (0.308 mL, 2.43 mmol, 1.1 equiv) was added to a mixture of 3- bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile and 2- bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 82.3) (1 g, 2.21 mmol) and Cs2CO3 (3.52 g, 20 mmol, 1.5 equiv) in DMF (50 mL). The reaction mixture was stirred for 10 min at rt, quenched by addition of a saturated aqueous solution of NaHCO3 (150 mL) and extracted with EtOAc (2 x 300 mL). The organic phase was washed with a saturated aqueous solution of NaHCO3 (150 mL), dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH, 1 :0 → 95:5) to afford 0.71 g of a mixture of 8-(2,6-dichloro-3,5-dimethoxy- phenyl)-3-(4-ethyl-piperazin-1 -ylmethyl)-quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-2-(4-ethyl-piperazin-1-ylmethyl)-quinoxaline-5-carbonitrile
Step 82.3: 3-Bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile and 2-bromomethyl-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile A mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile (Step 82.4) (4.93 g, 13.2 mmol) and NBS (3.52 g, 20 mmol, 1.5 equiv) in DMF (100 ml.) was stirred at 800C for 3 h. Further NBS (2.35 g, 1 equiv) was added and the reaction mixture was stirred at 100° for 2 h, allowed to cool to rt, quenched by addition of a saturated aqueous solution of NaHCO3 (250 ml.) and extracted with EtOAc (2 x 300 ml_). The organic phase was washed with a saturated aqueous solution of NaHCO3 (150 ml_), dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 9:1 →7:3) to afford 2.37g of a mixture of 3-bromomethyl-8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carbonitrile and 2-bromomethyl-8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carbonitrile.
Step 82.4: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8- (2,6-dichloro-3,5-dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile Sulfuryl chloride (2.14 ml_, 26.6 mmol, 1.8 equiv) was added dropwise to a cold (5°C) suspension of 8-(3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile (Step 82.5) (4.51 g, 14.8 mmol) in CH3CN (80 ml_). The reaction mixture was stirred at 5°C for 10 min, quenched by addition of a saturated aqueous solution of NaHCO3 (250 ml.) and extracted with EtOAc (2 x 300 ml_). The organic phase was washed with a saturated aqueous solution of NaHCO3 (150 ml_), dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 9:1 → 2:3) to afford 4.93 g of a mixture of 8-(2,6- dichloro-3,5-dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile.
Step 82.5: 8-(3,5-Dimethoxy-phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline-5-carbonitrile
A mixture of 8-bromo-5-(3,5-dimethoxy-phenyl)-2-methyl-quinoxaline and 5-bromo-8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline (Step 82.6) (6.07 g, 16.9 mmol) and CuCN (1.98 g, 22 mmol, 1.3 equiv) in NMP (50 ml.) was stirred for 5 h at 1600C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, quenched by addition of a saturated aqueous solution of NaHCO3 (250 ml.) and extracted with EtOAc. The organic phase was washed with a saturated aqueous solution of NaHCO3 (2 x 100 ml_), dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 9:1 → 2:3) to afford 4.51 g of a mixture of 8-(3,5-dimethoxy- phenyl)-3-methyl-quinoxaline-5-carbonitrile and 8-(3,5-dimethoxy-phenyl)-2-methyl- quinoxaline-5-carbonitrile.
Step 82.6: 8-Bromo-5-(3,5-dimethoxy-phenyl)-2-methyl-quinoxaline and 5-bromo-8-(3,5- dimethoxy-phenyl)-2-methyl-quinoxaline
A mixture of 3,5-dimethoxyphenylboronic acid (Step 1.8) (4 g, 22 mmol) in EtOH (125 ml.) was added dropwise to a mixture of 5,8-dibromo-2-methyl-quinoxaline (Step 82.7) (13.2 g, 43.8 mmol, 2 equiv), PdCI2(dppf) (483 mg, 0.66 mmol, 0.03 equiv), Na2CO3 (2 M solution in H2O, 44 ml_, 88 mmol, 4 equiv) in toluene (250 ml.) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 105 0C for 4.5 h, allowed to cool to rt, quenched by addition of a saturated aqueous solution of NaHCOs and extracted with EtOAc. The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 1 :0 → 85:15) to afford 6.07 g of a mixture of 8-bromo-5-(3,5-dimethoxy- phenyl)-2-methyl-quinoxaline and 5-bromo-8-(3,5-dimethoxy-phenyl)-2-methyl-quinoxaline.
Step 82.7: 5,8-Dibromo-2-methyl-quinoxaline
A 40% aqueous solution of methylglyoxal (6.7 M, 6.3 ml_, 1 12 mmol, 1.48 equiv) was added to a suspension of 3,6-dibromo-benzene-1 ,2-diamine (Step 1.6) (20 g, 75.5 mmol) in EtOH (400 ml_). The reaction mixture was stirred for 2 h at rt and for 0.5 h at reflux, allowed to cool and filtered to afford 7.66 g of the title compound. The filtrate was concentrated and the residue triturated in EtOAc and filtered. The filtrate was concentrated and the residue was purified by silica gel column chromatography (Hex/EtOAc, 1 :0 → 9:1 ) to provide additional 2.15 g of the title compound. The title compound: ESI-MS: 300.9 / 302.9 / 304.9 [M+H]+; tR= 4.81 min (System 1 ); TLC: Rf = 0.90 (Hex/EtOAc, 1 :1 ).
Example 83: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-3-ylamide
Figure imgf000108_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 3-aminopyridine, 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carboxylic acid (Step 83.1 ) and stirring the reaction mixture for 2 days at rt. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.04 min (System 1 ); TLC: Rf = 0.33 (DCIWMeOH, 9:1 ).
Step 83.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1-ylmethyl)- quinoxaline-5-carboxylic acid
A solution of KOH (0.818 g, 14.6 mmol, 10 equiv) in H2O (20 ml.) was added to 710 mg (1.46 equiv) of the quinoxaline-5-carbonitriles mixture (Step 82.2) in ethylene glycol (20 ml_). The reaction mixture was stirred at 1500C for 3 h, allowed to cool to rt and washed with EtOAc (2 x 100 ml_). The aqueous layer was acidified to pH 3-4 by addition of 1 N HCI. The resulting suspension was filtered. The filtrate was extracted with DCM (2 x 100 ml_). The organic layer was dried (Na2SO4), filtered and concentrated. The residue was triturated in 1 N HCI (3 ml.) and filtered. The filtrate was basified to pH 5 and extracted with DCM (2 x 100 ml_). The organic layer was dried (Na2SO4), filtered and concentrated to afford 121 mg of the title compound as a white solid: ES-MS: 505.0 / 506.6 [M+H]+; tR= 3.45 min (System 1 ).
Example 84: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 -ylmethyl)- quinoxaline-5-carboxylic acid pyridin-2-ylamide
Figure imgf000109_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-aminopyridine, 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1 - ylmethyl)-quinoxaline-5-carboxylic acid (Step 83.1 ) and stirring the reaction mixture for 2 days at rt. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.62 min (System 1 ); TLC: Rf = 0.45 (DCM/MeOH, 9:1 ).
Example 85: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
Figure imgf000110_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid (Step 85.1 ) in Step 14.1. Title compound: ESI-MS: 544.0 / 545.9 [M+H]+; tR= 3.13 min (System 1 ); TLC: Rf = 0.21 (DCM/MeOH/NH3 aq, 91 :8:1 ).
Step 85.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino1- quinoxaline-5-carboxylic acid
A solution of KOH (268 mg, 4.79 mmol, 10 equiv) in H2O (2 ml.) was added to 8-(2,6- dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]-quinoxaline-5- carbonitrile (Step 85.2) (220 mg, 0.48 mmol) in ethylene glycol (2 ml_). The reaction mixture was stirred at 1500C for 48 h, allowed to cool to rt, diluted with Et2O/ H2O, and extracted with Et2O. The aqueous phase was acidified to pH 5 by addition of 6 N HCI. Vacuum filtration of the resulting suspension afforded 450 mg of the title compound as an impure yellow solid, which was used without further purification: ESI-MS: 479.0 / 480.9 [M+H]+; tR= 3.75 min (System 1 ).
Step 85.2: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino1- quinoxaline-5-carbonitrile A mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- amino]-quinoxaline-5-carbonitrile (Step 85.3) (210 mg, 0.53 mmol) and N, N, N'- triethylethylene diamine (0.14 ml_, 1.07 mmol, 2 equiv) in NMP (2 ml.) was stirred at 1200C for 5 min, allowed to cool, diluted with EtOAc/H2O and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in Et2O to provide 225 mg of the title compound as a yellow solid: ESI-MS: 460.1 / 461.9 [M+H]+; tR= 3.97 min (System 1 ).
Step 85.3: 2-Chloro-8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile Sulfuryl chloride (0.08 ml_, 0.98 mmol, 2 equiv) was added dropwise to a cold (5°C) suspension of 2-chloro-8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 85.4) (160 mg, 0.49 mmol) in CH3CN (3 ml_). The reaction mixture was stirred at 5°C for 10 min, quenched by addition of H2O, and concentrated. The residue was taken up in DCM, washed with a saturated aqueous solution of NaHCO3, H2O and brine, dried (Na2SO4), filtered and concentrated. Trituration of the residue in Et2O provided 163 mg of the title compound as a white solid: ESI-MS: 394.0 / 395.6 / 396.3 [M+H]+; tR= 5.13 min (System 1 ).
Step 85.4: 2-Chloro-8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile A mixture of 8-(3,5-dimethoxy-phenyl)-2-hydroxy-quinoxaline-5-carbonitrile (Step 85.5) (100 mg, 0.33 mmol) and POCI3 (1 ml.) was stirred at 120 0C for 3 h, allowed to cool to rt and concentrated. The residue was diluted with DCM/NaHCO3 saturated aqueous solution and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 7:3) to afford 90 mg of the title compound as a yellow solid: ES-MS: 326.1 [M+H]+; tR= 5.02 min (System 1 ); Rf = 0.34 (Hex/EtOAc, 7:3).
Step 85.5: 8-(3,5-Dimethoxy-phenyl)-2-hvdroxy-quinoxaline-5-carbonitrile
A mixture of 5-bromo-8-(3,5-dimethoxy-phenyl)-quinoxalin-2-ol and 8-bromo-5-(3,5- dimethoxy-phenyl)-quinoxalin-2-ol (Step 85.6) (609 mg, 1.7 mmol) (Step 1.4) and CuCN (183 mg, 2.0 mmol, 1.2 equiv) in NMP (5 ml.) was stirred at 180 0C for 2 h. The reaction mixture was allowed to cool to rt, diluted with EtOAc/10% aqueous solution of ethylenediamine (25 ml.) and extracted with EtOAc. The aqueous phase was acidified to pH 5 and extracted with EtOAc. The combined organic extracts were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 7:3) to afford 103 mg of the title compound as a yellow solid: ES-MS: 308.1 [M+H]+; tR= 4.05 min (System 1 ); Rf = 0.35 (Hex/EtOAc, 7:3).
Step 85.6: 5-Bromo-8-(3,5-dimethoxy-phenyl)-quinoxalin-2-ol and 8-bromo-5-(3,5- dimethoxy-phenyl)-quinoxalin-2-ol
A mixture of 4-bromo-3',5'-dimethoxy-biphenyl-2,3-diamine (Step 85.7) (1 g, 3.1 mmol) and glyoxylite acid monohydrate (313 mg, 3.4 mmol, 1.1 equiv) in EtOH (20 ml.) was stirred at reflux for 15 min, allowed to cool to rt. The resulting yellow solid was collected by vacuum filtration to provide 397 mg of the title mixture. The filtrate was concentrated and the residue was purified silica gel column chromatography (Hex/EtOAc, 1 :1 ) to afford additional 225 mg of the title mixture. Step 85.7: 4-Bromo-3',5'-dimethoxy-biphenyl-2,3-diamine
A mixture of 3, 5-dimethoxyphenylboronic acid (15.1 g, 82.7 mmol, 1.1 equiv ) (Step 1.8) in EtOH (50 mL) was added dropwise to a mixture of 3,6-dibromo-benzene-1 ,2-diamine (20 g, 75.2 mmol) (Step 1.6), PdCI2(dppf) (6.1 g, 7.5 mmol, 0.1 equiv), Na2CO3 (2 M solution in H2O, 150 mL, 300.8 mmol, 4 equiv) in toluene (300 mL) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 105 0C for 3 h, allowed to cool to rt, diluted with EtOAc and H2O and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM) followed by trituration in EtOH to afford 9.2 g of the title compound as a white solid: ES-MS: 323.0 / 325.0 [M+H]+; tR= 4.43 min (System 1 ); Rf = 0.15 (DCM).
Example 86: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid pyridin-2-ylamide
Figure imgf000112_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid (Step 85.1 ) and 2-aminopyridine. Title compound: ESI-MS: 555.0 / 557.2 [M+H]+; tR= 3.61 min (System 1 ); TLC: Rf = 0.42 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 87: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl- aminoi-quinoxaline-5-carboxylic acid pyridin-3-ylamide
Figure imgf000112_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid (Step 85.1 ) and 3-aminopyridine. Title compound: ESI-MS: 555.0 / 557.2 [M+H]+; tR= 3.16 min (System 1 ); TLC: Rf = 0.20 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 88: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl- piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000114_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 6-(4- ethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (prepared as described in Example 39 but using N-ethyl-piperazine in Step 39.2), and stirring the reaction mixture for 3 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NHs301, 94:5:1 ). Title compound: ESI-MS: 549.1 [M+H]+; tR= 3.22 min (System 1 ); TLC: Rf = 0.13 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 88.1 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid A solution of KOH (2.4 g, 42.8 mmol, 10 equiv) in H2O (10 ml.) was added to 8-(2,6-difluoro- 3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 88.2) (1.4 g mg, 4.3 mmol) in ethylene glycol (20 ml_). The reaction mixture was stirred at 1500C for 4 h, allowed to cool to rt, diluted with Et2O/ H2O, and extracted with Et2O. The aqueous phase was acidified to pH 5 by addition of 6 N HCI. Vacuum filtration of the resulting suspension afforded 1.47 g of the title compound as a brown solid, which was used without further purification: ESI-MS: 347.1 [M+H]+; tR= 4.22 min (System 1 ).
Step 88.2: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile
A mixture of 5-bromo-8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline (Step 88.3) (1.1 g, 2.9 mmol) (Step 88.3) and CuCN (312 mg, 3.4 mmol, 1.2 equiv) in NMP (10 ml.) was stirred for 4 h at 1500C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with DCM/(10% aqueous solution of ethylenediamine) (100 ml.) and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in EtOAc to provide 702 mg of the title compound as a beige solid: ESI-MS: 328.1 [M+H]+; tR= 4.48 min (System 1 ).
Step 88.3: 5-Bromo-8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline
SelectFluor (20.5 g, 58 mmol, 2 equiv) was added portionwise to a solution of 5-bromo-8- (3,5-dimethoxy-phenyl)-quinoxaline (Step 1.4) (10 g, 29 mmol) in CH3CN (300 ml.) at rt. The reaction mixture was stirred at rt for 0.5 h, quenched by addition of H2O and concentrated to remove CH3CN. The resulting mixture was diluted with EtOAc/H2O and filtered to provide a white solid (batch 1 ). The filtrate was extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford batch 2. The two batches were combined and purified by silica gel MPLC (Hex/EtOAc, 7:3) to afford a sample of 5-bromo-8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline (Step 94.3) and a sample of the title compound which was further purified by trituration in EtOAc to provide 2.28 g of a white solid. Title compound: ESI-MS: 381.0 / 382.9 [M+H]+; tR= 4.92 min (System 1 ); TLC: Rf = 0.26 (Hex/EtOAc, 7:3).
Example 89: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000115_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (Step 39.1 ), and stirring the reaction mixture for 16 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) followed by trituration in Et2O. Title compound: ESI-MS: 535.1 [M+H]+; tR= 3.15 min (System 1 ); TLC: Rf = 0.13 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 90: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3- ylamide
Figure imgf000115_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 3- aminopyridine, and stirring the reaction mixture for 72 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 96:3:1 ) followed by trituration in Et2O. Title compound: ESI-MS: 423.1 [M+H]+; tR= 3.53 min (System 1 ); TLC: Rf = 0.56 (DCM/MeOH/NH3 aq, 96:3:1 ).
Example 91 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-2- ylamide
Figure imgf000116_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 2- aminopyridine, and stirring the reaction mixture for 72 h at rt. The crude product was purified by silica gel column chromatography (DCIWMeOHZNH3 301, 96:3:1 ), followed by trituration in Et2O, a second silica gel column chromatography (Hex/EtOAc, 1 :4) and an additional trituration in Et2O. Title compound: ESI-MS: 423.1 [M+H]+; tR= 4.21 min (System 1 ); TLC: Rf = 0.19 (Hex/EtOAc, 1 :4).
Example 92: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000116_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 88.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 26.1 ), and stirring the reaction mixture for 48 h at rt and for 5 h at 500C after addition of further 1.2 equiv of TBTU. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ). Title compound: ESI-MS: 549.1 [M+H]+; tR= 3.39 min (System 1 ); TLC: Rf = 0.24 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 93: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- pyrrolidin-1 -ylmethyl-1 H-imidazol-2-yl)-amide
Figure imgf000117_0001
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for 6 h at 65°C and using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)- quinoxaline-5-carboxylic acid (Step 88.1 ). 2-Nitro-4-pyrrolidin-1-ylmethyl-1 H-imidazole (Step 19.1 ) instead of 2-nitroimidazole was used in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 495.0 [M+H]+; tR= 3.28 min (System 1 ); TLC: Rf = 0.08 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 94: 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
Figure imgf000117_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 94.1 ), N-(6- amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2) and stirring the reaction mixture for 18 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ). Title compound: ESI-MS: 519.2 [M+H]+; tR= 3.26 min (System 1 ); TLC: Rf = 0.13 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 94.1 : 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid
A solution of KOH (2.95 g, 52.7 mmol, 10 equiv) in H2O (20 mL) was added to 8-(2-fluoro- 3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile (Step 94.2) (1.63 g mg, 5.3 mmol) in ethylene glycol (20 mL). The reaction mixture was stirred at 1500C for 5 h, allowed to cool to rt, diluted with Et2O/ H2O, and extracted with Et2O. The aqueous phase was acidified to pH 3 by addition of HCI. The resulting yellow solid was collected by vacuum filtration to provide 1.71 g of the title compound: ESI-MS: 329.1 [M+H]+; tR= 4.18 min (System 1 ). Step 94.2: 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carbonitrile A mixture of 5-bromo-8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline (Step 94.3) (3.09 g, 8.5 mmol) and CuCN (918 mg, 10.2 mmol, 1.2 equiv) in NMP (30 ml.) was stirred for 6.5 h at 1600C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with DCM/(10% aqueous solution of ethylenediamine) (200 ml_, v/v 1 :1 ), filtered through celite and the filtrate extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in DCM to provide 1.63 g of the title compound as a white solid: ESI-MS: 310.1 [M+H]+; tR= 4.41 min (System 1 ).
Step 94.3: 5-Bromo-8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline SelectFluor (20.5 g, 58 mmol, 2 equiv) was added portionwise to a solution of 5-bromo-8- (3,5-dimethoxy-phenyl)-quinoxaline (Step 1.4) (10 g, 29 mmol) in CH3CN (300 ml.) at rt. The reaction mixture was stirred at rt for 0.5 h, quenched by addition of H2O and concentrated to remove CH3CN. The resulting mixture was diluted with EtOAc/H2O and filtered to provide a white solid (batch 1 ). The filtrate was extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford batch 2. The two batches were combined and purified by silica gel MPLC (Hex/EtOAc, 7:3) to afford a sample of 5-bromo-8-(2,6-difluoro-3,5-imethoxy-phenyl)-quinoxaline (Step 88.3) and a sample of the title compound which was further purified by trituration in EtOAc to provide 2.42 g of a white solid. Title compound: ESI-MS: 364.9 [M+H]+; tR= 4.95 min (System 1 ); TLC: Rf = 0.34 (Hex/EtOAc, 7:3).
Example 95: 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000118_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 94.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 6 days at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ). Title compound: ESI-MS: 531.2 [M+H]+; tR= 3.40 min (System 1 ); TLC: Rf = 0.19 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 96: 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin- 1 -ylmethyl-1 H-imidazol-2-yl)-amide
Figure imgf000119_0001
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for 6 h at 65°C and using 8-(2-fluoro-3,5-dimethoxy-phenyl)- quinoxaline-5-carboxylic acid (Step 94.1 ). 2-Nitro-4-pyrrolidin-1 -ylmethyl-1 H-imidazole (Step 19.1 ) instead of 2-nitroimidazole was used in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 477.2 [M+H]+; tR= 3.28 min (System 1 ); TLC: Rf = 0.11 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 97: 8-(3-Methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000119_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(3-methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Step 97.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 24 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ). Title compound: ESI-MS: 51 1.1 [M+H]+; tR= 3.75 min (System 1 ); TLC: Rf = 0.29 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 97.1 : 8-(3-Methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid The title compound was prepared in analogy to the procedures described in Steps 1.2 - 1.4 but with the following modifications. In Step 1.2, the reaction mixture was stirred at 1500C for 4 h. In Step 1.3, the reaction mixture was stirred at 1600C for 5 h; DCM was used instead of EtOAc; the crude product was purified by silica gel column chromatography (Hex/EtOAC, 1 :1 ). 3-Methoxy-2,5-dimethyl-phenyl boronic acid (Step 97.2) was used in Step 1.4. Title compound: ESI-MS: 309.2 [M+H]+; tR= 4.71 min (System 1 ).
Step 97.2: 3-Methoxy-2,5-dimethyl-phenyl boronic acid
The title compound was prepared in analogy to the procedure described in Step 1.8 but using 1-bromo-3-methoxy-2,5-dimethyl-benzene (Journal of Organic Chemistry 1992, 57(10), 2774-83). The title compound was obtained as an impure sample and used without further purification.
Example 98: 8-(2-Chloro-5-methoxy-3,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5- (4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000120_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2-chloro-5-methoxy-3,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Step 98.1 ), 5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 20 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ). Title compound: ESI-MS: 545.0 [M+H]+; tR= 3.91 min (System 1 ); TLC: Rf = 0.23 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 98.1 : 8-(2-Chloro-5-methoxy-3,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid
Sulfuryl chloride (29 μl_, 0.37 mmol) in CH3CN (1 ml.) was added dropwise to a cold (-50C) suspension of 8-(3-methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid (Step 97.1 ) (1 13 mg, 0.37 mmol) in CH3CN (4 ml_). The reaction mixture was stirred for 10 min at -5°C, quenched by addition of H2O (1 ml.) and filtered to afford 42 mg of the title compound as a yellow solid. Title compound: ESI-MS: 343.0 [M+H]+; tR= 4.90 min (System 1 ).
Example 99: 8-(2,5-Dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000121_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,5-dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid (Step 99.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine hydrochloride (Step 26.1 ) and stirring the reaction mixture for 24 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 91.5:7.5:1 ), followed by trituration in Et2O. Title compound: ESI-MS: 498.2 [M+H]+; tR= 2.41 min (System 1 ); TLC: Rf = 0.09 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Step 99.1 : 8-(2,5-Dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid
The title compound was prepared in analogy to the procedures described in Steps 1.2 - 1.3 but with the following modifications. In Step 1.2, 8-(2,5-dimethyl-1-oxy-pyridin-3-yl)- quinoxaline-5-carbonitrile (Step 99.2) was used; the reaction mixture was stirred at 1500C for 1 h; the aqueous phase was acidified to pH 1 by addition of 6 N HCI and extracted with DCM; the organic phase was concentrated to afford the title compound. Title compound: ESI-MS: 296.1 [M+H]+; tR= 2.51 min (System 1 ).
Step 99.2: 8-(2,5-Dimethyl-1-oxy-pyridin-3-yl)-quinoxaline-5-carbonitrile ( mCPBA (55% in H2O, 215 mg, 0.68 mmol, 1.2 equiv) was added to a cold (5°C) solution of 8-(2,5-dimethyl-pyridin-3-yl)-quinoxaline-5-carbonitrile (Step 99.3) (148 mg, 0.57 mmol) in DCM (3 ml_). The reaction mixture was stirred at 5°C for 20 min, diluted with DCM/saturated solution of NaHCO3 and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 106 mg of the title compound as a white solid. Title compound: ESI-MS: 277.2 [M+H]+; tR= 2.84 min (System 1 ).
Step 99.3: 8-(2,5-Dimethyl-pyridin-3-yl)-quinoxaline-5-carbonitrile
A mixture of 5-bromo-8-(2,5-dimethyl-pyridin-3-yl)-quinoxaline (Step 99.4) (189 mg, 0.60 mmol) and CuCN (70 mg, 0.78 mmol, 1.3 equiv) in NMP (2 m L) was stirred for 6 h at 1600C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with DCM/10% aqueous solution of ethylenediamine (25 mL), extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) to afford 150 mg of the title compound as a yellow solid. Title compound: ESI-MS: 261.2 [M+H]+; tR= 1.92 min (System 1 ); TLC: Rf = 0.68 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 99.4: 5-Bromo-8-(2,5-dimethyl-pyridin-3-yl)-quinoxaline n-BuLi (1.6 M in hexanes, 6.7 ml_, 10.8 mmol, 2.0 equiv) was added dropwise to a cold (- 78°C) solution of 3-bromo-2,5-dimethyl-pyridine (Bulletin de Ia Societe Chimique de France, 1972, (6), 2466-81 ) (1 g, 5.38 mmol) in Et2O (20 ml_), under an argon atmosphere. The reaction mixture was stirred for 1 h at -78°C. Triisopropyl borate (3.7 ml_, 16.1 mmol, 3.0 equiv) was then added. The reaction mixture was allowed to warm to rt, quenched by addition of a saturated solution of NH4CI (1 ml_), and concentrated. The residue was diluted with EtOAc/H2O and the pH adjusted to 7. The aqueous layer was separated and extracted with EtOAc. The organic phase was dried (Na2SO4), filtered and concentrated to afford 170 mg of the title compound as a beige solid (batch 1 ). The aqueous layer was concentrated, the residue combined with batch 1 and dissolved in EtOH (5 ml_). This solution was added to a mixture of 5,8-dibromo-quinoxaline (800 mg, 2.8 mmol) (Step 1.5), PdCI2(dppf) (1 13 mg, 0.1 mmol, 0.05 equiv), Na2COs (2 M solution in H2O, 5.6 ml_, 1 1.1 mmol, 4 equiv) in toluene (30 ml.) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 105 0C for 4 h, allowed to cool to rt, diluted with EtOAc and H2O, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (Hex/EtOAc, 1 :4) to afford 250 mg of the title compound as a purple solid: ES-MS: 314.0 / 316.0 [M+H]+; tR= 2.63 min (System 1 ); Rf = 0.09 (Hex/EtOAc, 1 :4).
Example 100: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((R)-3- hvdroxy-pyrrolidin-1-ylrnethyl)-pyridin-2-vH-amide
Figure imgf000122_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using (R)-1-(6-amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol (Step 100.1 ) and stirring the reaction mixture for 72 h at rt. The crude product was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 96:3:1 ). Title compound: ESI-MS: 554.0 / 556.2 [M+H]+; tR= 3.77 min (System 1 ); TLC: Rf = 0.29 (DCM/MeOH, 9:1 ).
Step 100.1 : (R)-1-(6-Amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol A mixture of [5-((R)-3-hydroxy-pyrrolidin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 100.2) (210 mg, 0.72 mmol), a 4 N solution of HCI in dioxane (2 ml_), and MeOH (2 ml.) was stirred for 16 h at rt and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 89:10:1 ) to afford 125 mg of the title compound as a yellow oil. Title compound: ESI-MS: 194.1 [M+H]+; TLC: Rf = 0.05 (DCM/MeOH, 9:1 ).
Step 100.2: ^-((RVS-Hydroxy-pyrrolidin-i-ylmethyD-pyridin^-yli-carbamic acid tert-butyl ester
A mixture of (5-methyl-pyridin-2-yl)-carbamic acid tert-butyl ester (Step 100.3) (10.7 g, 51.4 mmol), NBS (10.1 g, 56.7 mmol, 1.1 equiv), AIBN (843 mg, 5.14 mmol, 0.1 equiv) in CCI4 (500 mL) was stirred for 1 h at relfux. NBS (1.8 g, 10.1 mmol, 0.2 equiv) was added and the mixture was stirred at reflux for additional 30 min. The reaction mixture was filtered hot and the filtrate was concentrated. Trituration of the residue in CH3CN afforded of 12.88 g of impure (5-bromomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester (intermediate 100.2). (R)-3-Hydroxypyrrolidine (181 mg, 2.1 mmol, 1.2 equiv) was added to a mixture of intermediate 100.2 (500 mg, 1.75 mmol) and Cs2CO3 (684 mg, 2.1 mmol, 1.2 equiv) in DMF (5 ml). The reaction mixture was stirred for 24 h at rt, quenched by addition of a saturated aqueous solution of NaHCO3 (150 mL) and extracted with EtOAc. The organic layer was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 96:3:1 ) to afford 212 mg of the title compound as a white solid. Title compound: ESI-MS: 294.3 [M+H]+; tR= 1.95 min (System 1 ); TLC: Rf = 0.14 (DCM/MeOH, 9:1 ).
Step 100.3: (5-Methyl-pyridin-2-yl)-carbamic acid tert-butyl ester
A solution of di-te/f-butyl dicarbonate (33.3 g, 153 mmol, 1.1 equiv) in DCM (50 mL) was added dropwise to a solution of 2-amino-5-methylpyridine (15 g, 139 mmol) and DMAP (1.7 g, 13.9 mmol, 0.1 equiv) in DCM (50 mL) at rt, under an argon atmosphere. The reaction mixture was stirred for 16 h at rt, quenched by addition of a saturated aqueous solution of NaHCC>3 (100 ml.) and extracted with DCM. The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 9:1 ) to afford 1 1.73 g of the title compound as a white solid. Title compound: ESI-MS: 209.2 [M+H]+; tR= 2.40 min (System 1 ); TLC: Rf = 0.86 (Hex/EtOAc, 1 :1 ).
Example 101 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((S)-3- hvdroxy-pyrrolidin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000124_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using (S)-1-(6-amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol (Step 101.1 ) and stirring the reaction mixture for 20 h at rt. The crude product was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 96:3:1 ). Title compound: ESI-MS: 553.9 / 556.2 [M+H]+; tR= 3.79 min (System 1 ); TLC: Rf = 0.25 (DCM/MeOH, 9:1 ).
Step 101.1 : (S)-1-(6-Amino-pyridin-3-ylmethyl)-pyrrolidin-3-ol
The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using (S)-3-hydroxypyrrolidine in Step 100.2: 194.2 [M+H]+; TLC: Rf = 0.05 (DCM/MeOH, 9:1 ).
Example 102: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- acetyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000124_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 1-[4-(6-amino-pyridin-3-ylmethyl)-piperazin-1-yl]-ethanone (Step 102.1 ) and stirring the reaction mixture for 20 h at rt. The crude product was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 98:1 :1 ). Title compound: ESI-MS: 595.0 / 597.2 [M+H]+; tR= 3.82 min (System 1 ); TLC: Rf = 0.42 (DCM/MeOH, 9:1 ).
Step 102.1 : 1-[4-(6-Amino-pyridin-3-ylmethyl)-piperazin-1-yl1-ethanone The title compound was prepared in analogy to the procedures described in Steps 100.1- 100.2 but using 1-acetylpiperazine in Step 100.2: 235.3 [M+H]+; TLC: Rf = 0.36 (DCM/MeOH, 9:1 ).
Example 103: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3- oxo-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000125_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 4-(6-amino-pyridin-3-ylmethyl)-piperazin-2-one (Step 103.1 ) and stirring the reaction mixture for 72 h at rt. The crude product was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 ) followed by trituration in Et2O. Title compound: ESI-MS: 567.0 / 568.7 [M+H]+; tR= 3.68 min (System 1 ); TLC: Rf = 0.27 (DCM/MeOH, 9:1 ).
Step 103.1 : 4-(6-Amino-pyridin-3-ylmethyl)-piperazin-2-one
The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using piperazin-2-one in Step 100.2: 207.2 [M+H]+; TLC: Rf = 0.14 (DCM/MeOH, 9:1 ).
Example 104: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1- dioxothiomorpholin-4-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000125_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(1 ,1-dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine (Step 104.1 ) and stirring the reaction mixture for 72 h at rt. The crude product was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 95:4:1 ) followed by trituration in Et2O. Title compound: ESI-MS: 602.0 [M+H]+; tR= 4.01 min (System 1 ); TLC: Rf = 0.38 (DCM/MeOH, 9:1 ).
Step 104.1 : 5-(1 ,1-Dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using thiomorpholine-1 ,1-dioxide in Step 100.2: 242.2 [M+H]+; TLC: Rf = 0.33 (DCIWMeOH, 9:1 ).
Example 105: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000126_0001
Intermediate 105 was prepared in analogy to the procedure described in Step 14.1 but using 5-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ) and stirring the reaction mixture for 72 h at rt: ESI-MS: 673.0 [M+H]+; TLC: Rf = 0.51 (DCM/MeOH, 9:1 ).
A mixture of intermediate 105 (200 mg, 0.3 mmol) and TFA (5 mL) was stirred for 2 h at 1200C in a microwave apparatus. The reaction mixture was neutralized by addition of NaHCO3, extracted with EtOAc. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 95:4:1 ) followed by trituration in Et2O to afford 100 mg of the title compound as a yellow solid. Title compound: ESI-MS: 552.9 / 555.2 [M+H]+; tR= 3.42 min (System 1 ); TLC: Rf = 0.09 (DCM/MeOH, 9:1 ). Step 105.1 : 5-[4-(4-Methoxy-benzyl)-piperazin-1-ylmethyl1-pyridin-2-ylamine
The title compound was prepared in analogy to the procedures described in Steps 100.1 -
100.2 but using 1-(4-methoxybenzyl)piperazine in Step 100.2: 313.3 [M+H]+.
Example 106: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(2- hydroxy-ethyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
Figure imgf000127_0001
2-lodoethanol (26 μl_, 0.33 mmol, 10 equiv) was added to a mixture of 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl-pyridin-2-yl)-amide (Example 105) (18 mg, 0.033 mmol) in CH3CN (1 ml_), under an argon atmosphere. The reaction mixture was stirred for 14 h at rt, quenched by addition of a saturated aqueous solution of NaHCC>3 (50 ml.) and extracted with EtOAc. The organic layer was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 96:3:1 ) to afford 15 mg of the title compound as a yellow solid. Title compound: ESI-MS: 596.6 / 598.4 [M+H]+; tR= 3.45 min (System 1 ); TLC: Rf = 0.30 (DCIWMeOH, 9:1 ).
Example 107: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000127_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(3,3,4-trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 107.1 ) and stirring the reaction mixture for 20 h at rt. The crude product was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 97:2:1 ) followed by trituration in Et2O. Title compound: ESI-MS: 595.0 / 597.3 [M+H]+; tR= 4.40 min (System 1 ); TLC: Rf = 0.36 (DCM/MeOH, 9:1 ). Step 107.1 : 5-(3,3,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using 1 ,2,2-trimethyl-piperazine (Step 107.2) in Step 100.2: 253.3 [M+H]+; TLC: Rf = 0.09 (DCM/MeOH, 9:1 ).
Step 107.2: 1 ,2,2-Trimethyl-piperazine
LiAIH4 (1 M in THF, 47 mL, 47 mmol, 1.5 equiv) was added to a solution of 3,3,4-trimethyl- piperazin-2-one (Step 107.3) (4.5 g, 32 mmol) in THF (50 mL) at 500C, under an argon atmosphere. The resulting mixture was stirred for 2 h at 500C, quenched by addition of acetone, filtered through a pad of celite and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) to afford 1.9 g of the title compound as a yellow oil. Title compound: ESI-MS: 129.1 [M+H]+.
Step 107.3: 3,3,4-Trimethyl-piperazin-2-one
A mixture of ethyl-2-bromoisobutyrate (14.6 g, 74.9 mmol), ethylene diamine (33 mL, 487 mmol, 6.5 equiv) and potassium carbonate (11.4 g, 82.4 mmol, 1.1 equiv) in toluene (150 mL) was stirred for 22 h at reflux, cooled and filtered. The filtrate was concentrated and the residue triturated in Et2O to afford 6.3 g of 3,3-dimethyl-piperazin-2-one as a white solid. Methyl iodide (4 mL, 64.0 mmol, 1.3 equiv) was added dropwise to a suspension of 3,3- dimethyl-piperazin-2-one (6.3 g, 49.2 mmol) and potassium carbonate (8.8 g, 64.0 mmol, 1.3 equiv) in DME (20 mL). The reaction mixture was heated to 45°C, stirred for 3 h, cooled and filtered, washing the filter cake with DME. The filtrate was concentrated and the residue triturated in DME to afford 2.8 g (batch 1 ) of the title compound as a white solid. The filtrate from the trituration was concentrated and the residue purified by silica gel column chromatography (DCM/MeOH, 9:1 ) to afford 1.75 g (batch 2) of the title compound as a white solid. Title compound: ESI-MS: 143.1 [M+H]+; TLC: Rf = 0.25 (DCM/MeOH, 9:1 ).
Example 108: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000129_0001
Intermediate 108 was prepared in analogy to the procedures described in Step 14.1 but using 5-[4-(4-methoxy-benzyl)-3,3-dimethyl-piperazin-1 -ylmethyl]-pyridin-2-ylamine (Step 108.1 ) and stirring the reaction mixture for 20 h at rt: ESI-MS: 701.0 [M+H]+; tR= 4.88 min (System 1 ); The title compound was prepared in analogy to the procedure described in Example 105. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 4.20 min (System 1 ); TLC: Rf = 0.09 (DCM/MeOH, 9:1 ).
Step 108.1 : 5-[4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-1-ylmethyl1-pyridin-2-ylamine The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using 1-(4-methoxy-benzyl)-2,2-dimethyl-piperazine (Step 108.2) in Step 100.2: ESI-MS: 341.3 [M+H]+; TLC: Rf = 0.30 (DCM/MeOH, 9:1 ).
Step 108.2: 1-(4-Methoxy-benzyl)-2,2-dimethyl-piperazine LiAIH4 (1 M in THF, 27.8 mL, 27.8 mmol, 1.5 equiv) was added to a solution of 4-(4-methoxy- benzyl)-3,3-dimethyl-piperazin-2-one (Step 108.3) (4.6 g, 18.5 mmol) in THF (100 mL) at 500C, under an argon atmosphere. The resulting mixture was stirred for 2 h at 500C, quenched by sequential addition of H2O (1 mL), 1 N NaOH (1 mL) and H2O (3 mL), filtered through a pad of celite and concentrated to afford 4.0 g of the title compound as a white solid: ESI-MS: 235.2 [M+H]+.
Step 108.3: 4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-2-one
A mixture of 3,3-dimethyl-piperazin-2-one (Step 108.4) (3.7 g, 28.9 mmol), 4-methoxybenzyl bromide (5.4 mL, 37.6 mmol, 1.3 equiv) and triethylamine (5.2 mL, 37.6 mmol, 1.3 equiv) in DCM (60 mL) was stirred for 48 h at rt. Additional 5.0 mL of 4-methoxybenzyl bromide were added and the mixture was stirred for 72 h at rt, then concentrated. The residue was diluted with DCM/saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in DCM to provide 3.95 g of the title compound as a white solid: ESI-MS: 249.2 [M+H]+; TLC: Rf = 0.16 (Hex/EtOAc, 2:3).
Step 108.4: 3,3-Dimethyl-piperazin-2-one
A solution of ethyl-2-bromoisobutyrate (24 mL, 161 mmol) in toluene (150 mL) was added to a mixture of ethylene diamine (70 mL, 1046 mmol, 6.5 equiv) and potassium carbonate (24.4 g, 177 mmol, 1.1 equiv) in toluene (150 mL). The reaction mixture was heated for 20 h at 1 15°C, cooled and filtered. The filtrate was concentrated and the residue triturated in Et2O to afford 14.2 g of the title compound as a yellow solid: ESI-MS: 129.1 [M+H]+.
Example 109: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2- dimethyl-piperazin-1-ylmethyl)-Pvridin-2-yll-amide
Figure imgf000131_0001
Intermediate 109 was prepared in analogy to the procedure described in Step 14.1 but using 5-[4-(4-methoxy-benzyl)-2,2-dimethyl-piperazin-1 -ylmethyl]-pyridin-2-ylamine (Step 109.1 ) and stirring the reaction mixture for 20 h at rt: ESI-MS: 701.0 / 583.2 [M+H]+; TLC: Rf = 0.40 (DCM/MeOH, 9:1 ).
The title compound was prepared in analogy to the procedure described in Example 105. Title compound: ESI-MS: 581.0 / 582.8 [M+H]+; tR= 3.53 min (System 1 ); TLC: Rf = 0.14 (DCM/MeOH, 9:1 ).
Step 109.1 : 5-[4-(4-Methoxy-benzyl)-2,2-dimethyl-piperazin-1-ylmethyl1-pyridin-2-ylamine A mixture of {5-[4-(4-methoxy-benzyl)-2,2-dimethyl-piperazin-1-ylmethyl]-pyridin-2-yl}- carbamic acid tert-butyl ester (Step 109.2) (1.88 g, 4.3 mmol), a 4 N solution of HCI in dioxane (25 ml.) and MeOH (25 ml.) was stirred for 22 h at rt. The reaction mixture was allowed to cool, quenched by addition of a saturated aqueous solution of NaHCO3 and extracted with DCM. The organic layer was washed with a saturated aqueous solution of
NaHCO3, dried (Na2SO4), filtered and concentrated to provide 1.5 g of the title compound as a brown solid: ESI-MS: 341.3 [M+H]+; ]+; tR= 1.72 min (System 1 ).
Step 109.2: {5-[4-(4-Methoxy-benzyl)-2,2-dimethyl-piperazin-1 -ylmethyli-pyridin-2-yl)- carbamic acid tert-butyl ester A mixture of [5-(2,2-dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.3) (3.85 g, 12 mmol), 4-methoxybenzyl bromide (2.6 ml_, 18 mmol, 1.5 equiv) and triethylamine (1.83 ml_, 13.2 mmol, 1.1 equiv) in DCM (25 ml.) was stirred for 16 h at rt and concentrated. The residue was purified by silica gel column chromatography (DCM → DCM/MeOH, 97:3) to afford 1.88 g of the title compound as a white solid. Title compound: ESI-MS: 441.3 [M+H]+; tR= 3.12 min (System 1 ).
Step 109.3: [5-(2,2-Dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester LiAIH4 (1 M in THF, 78 ml_, 78 mmol, 2 equiv) was added to a solution of [5-(2,2-dimethyl-3- oxo-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.4) (13 g, 39 mmol) in THF (150 ml.) at 500C, under an argon atmosphere. The resulting mixture was stirred for 3 h at 500C, cooled to 00C, quenched by addition of acetone, filtered through a pad of celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 97.5:1.5:1 ) to afford 7.25 g of the title compound as a white solid. Title compound: ESI-MS: 321.3 [M+H]+; tR= 1.91 min (System 1 ); TLC: Rf = 0.1 1 (DCM/MeOH, 9:1 ).
Step 109.4: [5-(2,2-Dimethyl-3-oxo-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert- butyl ester A mixture of intermediate 100.2 (Step 100.2) (18.4 g, 64 mmol), 3,3-dimethyl-piperazin-2- one (Step 108.4) (9 g, 70 mmol, 1.1 equiv) and Cs2CO3 (27.1 g, 83.2 mmol, 1.3 equiv) in DMF (75 ml) was stirred for 12 h at rt, quenched by addition of H2O (500 ml.) and filtered to afford 14.5 g of the title compound as an off-white solid. Title compound: ESI-MS: 335.2 [M+H]+; tR= 2.22 min (System 1 ).
Example 1 10: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000132_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-[4-(4-methoxy-benzyl)-2,2-dimethyl-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 1 10.1 ) and stirring the reaction mixture for 20 h at rt. The crude product was purified by silica gel column chromatography (DCIWMeOHZNH3 301, 98:1 :1 ) followed by trituration in Et2O. Title compound: ESI-MS: 595.0 / 597.2 [M+H]+; tR= 3.74 min (System 1 ); TLC: Rf = 0.47 (DCM/MeOH, 9:1 ).
Step 1 10.1 : 5-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine
A mixture of [5-(2,2,4-trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 110.2) (1.94 g, 5.8 mmol), a 4 N solution of HCI in dioxane (20 ml.) and MeOH (5 ml.) was stirred for 12 h at rt and concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 95:4:1 ) to afford 1.02 g of the title compound as a white solid. Title compound: ESI-MS: 235.2 [M+H]+; TLC: Rf = 0.1 1 (DCM/MeOH, 9:1 ).
Step 1 10.2: [5-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-carbamic acid tert-butyl ester Methyl iodide (954 μL, 15.3 mmol, 1.3 equiv) was added dropwise to a suspension of [5- (2,2-dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (Step 109.3) (3.8 g, 11.8 mmol) and potassium carbonate (2.13 g, 15.4 mmol, 1.3 equiv) in DME (25 mL). The reaction mixture was heated to 500C, stirred for 2 h, allowed to cool, quenched by addition of a H2O and extracted with DCM. The organic layer was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 ) to afford 1.94 g of the title compound as an off-white solid. Title compound: ESI-MS: 335.3 [M+H]+; TLC: Rf = 0.31 (DCM/MeOH, 9:1 ).
Example 1 1 1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6
-piperazin-1-ylmethyl-pyridin-3-yl)-amide
1
Figure imgf000134_0001
Intermediate 11 1 was prepared in analogy to the procedure described in Step 14.1 but using 6-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-3-ylamine (Step 1 11.1 ) and stirring the reaction mixture for 14 h at rt: ESI-MS: 673.0 [M+H]+; tR= 3.88 min (System 1 ). The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 1 h at 1200C: ESI-MS: 553.0 / 554.8 [M+H]+; tR= 3.34 min (System 1 ); TLC: Rf = 0.05 (DCM/MeOH, 9:1 ).
Step 1 1 1.1 : 6-[4-(4-Methoxy-benzyl)-piperazin-1-ylmethyl1-pyridin-3-ylamine
A suspension of 1-(4-methoxy-benzyl)-4-(5-nitro-pyridin-2-ylmethyl)-piperazine (Step 1 1 1.2) (0.635 g, 1.85 mmol) and Raney Nickel (0.150 g) in MeOH/THF (1 :1 , v/v; 50 ml.) was stirred for 24 h at rt, under a hydrogen atmosphere. The mixture was filtered through a pad of celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 ) to afford 439 mg of the title compound as a white solid. Title compound: ESI-MS: 313.3 [M+H]+; tR=1.40min (System 1 ); TLC: Rf =0.18 (DCM/MeOH, 9:1 ).
Step 1 1 1.2: 1-(4-Methoxy-benzyl)-4-(5-nitro-pyridin-2-ylmethyl)-piperazine The title compound was prepared in analogy to the procedures described in Steps 39.1-
39.2 but using 1-(4-methoxybenzyl)piperazine, 3 equiv of sodium triacetoxyborohydride and stirring the reaction mixture for 20 h at rt, in Step 39.2. Title compound: ESI-MS: 343.2 [M+H]+; tR= 2.50 min (System 1 ); TLC: Rf = 0.40 (DCM/MeOH, 9:1 ). Example 1 12: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3- dimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000135_0001
lntermediate 112 was prepared in analogy to the procedure described in Step 14.1 but using 6-[4-(4-methoxy-benzyl)-3,3-dimethyl-piperazin-1 -ylmethyl]-pyridin-3-ylamine (Step 1 12.1 ) and stirring the reaction mixture for 3 h at rt: ESI-MS: 700.9 [M+H]+; tR= 4.00 min (System 1 ); TLC: Rf = 0.45 (DCIWMeOH, 9:1 ). The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 1 h at 1200C: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.47 min (System 1 ); TLC: Rf = 0.11 (DCM/MeOH, 9:1 ).
Step 1 12.1 : 6-[4-(4-Methoxy-benzyl)-3,3-dimethyl-piperazin-1-ylmethyl1-pyridin-3-ylamine A suspension of 1-(4-methoxy-benzyl)-2,2-dimethyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine (Step 1 12.2) (0.64O g, 1.72 mmol) and Raney Nickel (0.150 g) in MeOH/THF (1 :1 , v/v; 50 mL) was stirred for 20 h at rt, under a hydrogen atmosphere. The mixture was filtered through a pad of celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 97:2:1 ) to afford 455 mg of the title compound as a yellow foam. Title compound: ESI-MS: 341.3 [M+H]+; tR= 1.71 min (System 1 ); TLC: Rf = 0.30 (DCM/MeOH, 9:1 ).
Step 1 12.2: 1-(4-Methoxy-benzyl)-2,2-dimethyl-4-(5-nitro-pyridin-2-ylmethyl)-piperazine A mixture of methanesulfonic acid 5-nitro-pyridin-2-ylmethyl ester (Step 112.3) (0.5 g, 2.16 mmol), 1-(4-methoxy-benzyl)-2,2-dimethyl-piperazine (Step 108.2) (0.655 g, 2.8 mmol, 1.3 equiv), cesium carbonate (0.845 g, 2.6 mmol, 1.2 equiv), and DMF (4 ml) was stirred for 5 h at rt, quenched by addition of a saturated aqueous solution of NaHCO3 and extracted with EtOAc. The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by by silica gel column chromatography (DCM → DCM/MeOH, 99:1 ) to provide 0.642 g of the title compound as a red solid: ESI-MS: 371.2 [M+H]+; tR= 3.18 min (System 1 ); TLC: Rf = 0.44 (DCM/MeOH, 9:1 ).
Step 112.3: Methanesulfonic acid 5-nitro-pyridin-2-ylmethyl ester
Methanesulfonic anhydride (1.79 g, 10.3 mmol, 1.1 equiv) was added portionwise to a cold (5°C) mixture of (5-nitro-pyridin-2-yl)-methanol (Step 1 12.4) (1.44 g, 9.4 mmol) and triethylamine (1.57 mL, 1 1.3 mmol, 1.2 equiv) in DCM (20 mL), under an argon atmosphere. The reaction mixture was allowed to stir for 0.5 h at 5°C, quenched with H2O and extracted with DCM. The organic phase was washed with H2O, dried (Na2SO4), filtered and concentrated to provide 2.16 g of the title compound as a brown solid: : ESI-MS: 231.1 [M- H]"; tR= 2.85 min (System 1 ).
Step 1 12.4: (5-Nitro-pyridin-2-yl)-methanol Diisobutylaluminium hydride (1 M in DCM, 41.6 ml_, 41.6 mmol, 1.3 equiv) was added dropwise to a cold (-780C) solution of δ-nitro-pyridine^-carboxylic acid ethyl ester (Step 39.4) (6.4 g, 32 mmol) in DCM (120 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to rt, quenched by addition of an aqueous solution of potassium sodium tartrate, diluted with DCM and H2O, and filtered through a pad of celite. The filtrate was extracted several times with DCM. The organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 9:1 → 1 : 1 ) to provide 1.44 g of the title compound: ESI-MS: 153.1 [M-H]".
Example 1 13: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000137_0001
Methyl iodide (15 μl_, 0.24 mmol, 1.2 equiv) was added to a mixture of 8-(2,6-dichloro-3,5- dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3-dimethyl-piperazin-1 -ylmethyl)- pyridin-3-yl]-amide (Example 112) (115 mg, 0.2 mmol) and potassium carbonate (33 mg, 0.24 mmol, 1.2 equiv) in CH3CN (4 ml_). The reaction mixture was stirred for 72 h at rt, quenched by addition of a saturated aqueous solution of NaHCO3 and extracted with EtOAc. The organic layer was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/NH3 aq, 99:1 → DCM/MeOH/NH3 aq, 96:3:1 ) followed by trituration id Et2O to afford 27 mg of the title compound as a yellow solid. Title compound: ESI-MS: 595.1 / 596.6 [M+H]+; tR= 3.54 min (System 1 ); TLC: Rf = 0.17 (DCM/MeOH, 9:1 ).
Example 1 14: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000138_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 6-(2,2,4-trimethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (Step 1 14.1 ) and stirring the reaction mixture for 14 h at rt. ESI-MS: 595.1 / 597.2 [M+H]+; tR= 3.52 min (System 1 ); TLC: Rf = 0.37 (DCIWMeOH, 9:1 ).
Step 1 14.1 : 6-(2,2,4-Trimethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine The title compound was prepared in analogy to the procedures described in Steps 1 12.1 - 1 12.2 but using 1 ,3,3-trimethyl-piperazine (Step 114.2) in Step 1 12.2: ESI-MS: 235.3 [M+H]+; TLC: Rf = 0.13 (DCM/MeOH, 9:1 ).
Step 1 14.2: 1 ,3,3-Trimethyl-piperazine
LiAIH4 (1 M in THF, 32.5 mL, 32.5 mmol, 1.5 equiv) was added to a solution of 3,3-dimethyl- 2-oxo-piperazine-1-carboxylic acid tert-butyl ester (Step 114.3) (4.95 g, 21.7 mmol) in THF (1 oO mL) at 500C, under an argon atmosphere. The resulting mixture was stirred for 3 h at 500C, cooled to 0°C, quenched by addition of acetone and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) to afford 2 g of the title compound as a yellow oil. Title compound: ESI-MS: 129.1.
Step 1 14.3: 3,3-Dimethyl-2-oxo-piperazine-1-carboxylic acid tert-butyl ester
A solution of di-te/f-butyl dicarbonate (9.3 g, 42.5 mmol, 1.1 equiv) in DCM (20 mL) was added dropwise to a solution of 3,3-dimethyl-piperazin-2-one (Step 108.4) (4.95 g, 38.7 mmol) and DMAP (457 mg, 3.9 mmol, 0.1 equiv) in DCM (20 mL) at rt, under an argon atmosphere. The reaction mixture was stirred for 20 h at rt, quenched by addition of a saturated aqueous solution of NaHCC>3 (100 mL) and extracted with DCM. The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 ) to afford 4.97 g of the title compound as a colorless oil. Title compound: ESI-MS: 227.2 [M-H]"; tR= 1.62 min (System 1 ). Example 1 15: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin- 1 -ylmethyl)-pyridin-2-yl1-amide
Figure imgf000139_0001
Trimethyl aluminum (2 M in toluene, 0.37 ml_, 0.74 mmol, 2.5 equiv) was added to a mixture of
8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 115.1 ) (100 mg, 0.30 mmol) and 5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 26.1 ; purified by column chromatography) (78 mg, 0.36 mmol, 1.2 equiv) in toluene (2 ml_). The reaction mixture was stirred for 1 h at rt, heated to reflux, stirred for 3 h, allowed to cool, poured onto EtOAc and H2O, and filtered through a pad of celite. The filtrate was extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) followed by reverse-phase preparative HPLC to afford 54 mg of the title compound as a pale yellow solid. Title compound: ESI-MS: 513.2 [M+H]+; tR= 3.54 min (System 1 ); TLC: Rf = 0.29 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 1 15.1 : 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester A mixture of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 1.2) (10 g), H2SO4 cone. (3 mL) and EtOH (500 mL) was stirred at reflux for 7 h, allowed to cool and concentrated. The residue was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 10.1 g of the title compound as a beige solid. Title compound: ESI-MS: 339.2 [M- H]"; tR= 4.72 min (System 1 ).
Example 1 16: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(4-methoxy- benzyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
Figure imgf000140_0001
The title compound was in analogy to the procedure described in Example 1 15 but using 5- [4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ). The residue was purified by silica gel column chromatography (DCIWMeOHZNH3 301, 94:5:1 ) to afford 54 mg of the title compound as a yellow foam. Title compound: ESI-MS: 605.1 [M+H]+; tR= 3.98 min (System 1 ).
Example 1 17: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(4-methoxy- benzyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
Figure imgf000140_0002
α-Chloroethyl chloroformate (19 μl_, 0.17 mmol) was added to a cold (-780C) solution of 8- (3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(4-methoxy-benzyl)-piperazin-1 - ylmethyl]-pyridin-2-yl}-amide (Example 116) (103 mg, 0.17 mmol) in THF (2 ml_). The reaction mixture was stirred for 1 h at -78°C, quenched by addition of MeOH and concentrated. The residue was dissolved in MeOH (5 ml_), heated to reflux for 3 h, allowed to cool. The resulting solid was collected by filtration, diluted in in DCM and a saturated aqueous solution of NaHCO3, and extracted with DCM. The organic phase was dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 91.5:7.5:1 ) followed by trituration in Et2O to afford 28 mg of the title compound as a white solid. Title compound: ESI-MS: 485.2 [M+H]+; tR= 3.80 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 1 18: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- r(carbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000141_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-acetamide (Step 1 18.1 ) and stirring the reaction mixture for 14 h at rt. Title compound: ESI-MS: 555.0 / 556.8 [M+H]+; tR= 3.72 min (System 1 ); TLC: Rf = 0.40 (DCIWMeOH, 9:1 ).
Step 1 18.1 : 2-[(6-Amino-pyridin-3-ylmethyl)-methyl-amino1-acetamide The title compound was prepared in analogy to the procedures described in Steps 100.1- 100.2 but using 2-(methylamino)-acetamide hydrochloride in Step 100.2: 195.1 [M+H]+; TLC: Rf = 0.12 (DCM/MeOH/NH3 aq, 89:10:1 ).
Example 1 19: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000141_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-N,N-dimethyl-acetamide (Step 1 19.1 ) and stirring the reaction mixture for 72 h at rt. Title compound: ESI-MS: 583.0 / 585.2 [M+H]+; tR= 4.02 min (System 1 ); TLC: Rf = 0.36 (DCM/MeOH, 9:1 ).
Step 1 19.1 : 2-[(6-Amino-pyridin-3-ylmethyl)-methyl-amino1-N,N-dimethyl-acetamide
The title compound was prepared in analogy to the procedures described in Steps 100.1 - 100.2 but using N,N-dimethyl-2-(methylamino)-acetamide in Step 100.2: 223.2 [M+H]+; TLC: Rf = 0.31 (DCM/MeOH/NH3 aq, 89:10:1 ).
Example 120: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- imidazol-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000142_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-imidazol-1-ylmethyl-pyridin-2-ylamine (Step 120.1 ) and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 535.0 / 536.8 [M+H]+; tR= 4.00 min (System 1 ); TLC: Rf = 0.35 (DCIWMeOH, 9:1 ).
Step 120.1 : 5-lmidazol-1-ylmethyl-pyridin-2-ylamine
The title compound was prepared in analogy to the procedures described in Steps 100.1-
100.2 but using imidazole in Step 100.2: 175.1 [M+H]+; TLC: Rf = 0.24 (DCM/MeOH, 9:1 ).
Example 121 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- dimethylamino-ethyl)-1 H-pyrrol-3-yl1-amide
Figure imgf000143_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 1-(2-dimethylamino-ethyl)-1 H-pyrrol-3-ylamine (Step 121.1 ) and stirring the reaction mixture for 14 h at rt. Title compound: ESI-MS: 514.0 / 515.9 [M+H]+; tR= 3.86 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH, 9:1 ).
Step 121.1 : 1-(2-Dimethylamino-ethyl)-1 H-pyrrol-3-ylamine
A suspension of dimethyl-[2-(3-nitro-pyrrol-1-yl)-ethyl]-amine (Step 121.2) (650 mg, 3.55 mmol) and Raney Nickel (300 mg) in MeOH/THF (1 :1 , v/v; 150 m L) was stirred for 7 h at rt, under a hydrogen atmosphere. The mixture was filtered through a pad of celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 → 93:6:1 ) to afford 440 mg of the title compound as a red oil. Title compound: ESI-MS: 154.1 [M+H]+; TLC: Rf = 0.02 (DCM/MeOH, 9:1 ).
Step 121.2: Dimethyl-[2-(3-nitro-pyrrol-1-yl)-ethyll-amine
A mixture of 3-nitropyrrole (500 mg, 4.46 mmol), cesium carbonate (3.63 g, 11.2 mmol, 2.5 equiv), 1-chloro-2-dimethylaminoethane (835 mg, 5.8 mmol, 1.3 equiv) and DMF (5 mL) was stirred for 16 h at rt. The reaction mixture was quenched by addition of a saturated aqueous solution of NaHCOs and extracted with DCM/MeOH (9:1 , v/v). The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM → DCM/MeOH, 97:3) to afford 656 mg of the title compound as a yellow oil. Title compound: ESI-MS: 184.1 [M+H]+; TLC: Rf = 0.38 (DCM/MeOH, 9:1 ).
Example 122: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1 -ylmethyl)-pyridin-2-yl1-amide
Figure imgf000144_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid (Step 122.1 ), 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), and stirring the reaction mixture 18 h at rt. Title compound: ESI-MS: 595.0 [M+H]+; tR= 3.86 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 122.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid
The title compound was prepared in analogy to the procedures described in Steps 1.1 - 1.3 but using 5-bromo-8-(3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline (Step 122.2) in Step 1.3. Title compound: ESI-MS: 407.1 / 408.9 [M+H]+.
Step 122.2: 5-Bromo-8-(3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline
A mixture of 4-bromo-3',5'-dimethoxy-biphenyl-2,3-diamine (Step 85.7) (3 g, 9.3 mmol) and 2,3-butanedione (1 ml_, 1 1.1 mmol, 1.2 equiv) in EtOH (60 ml.) was stirred at reflux for 2 h, allowed to cool to rt and stirred for 16 h. Additional 2,3-butanedione (0.4 ml) was added. The reaction mixture was stirred at reflux for 2 h, allowed to cool and concentrated to half of the initial volume. The resulting yellow precipitate was collected vacuum filtration providing 2.9 g of the title compound: ES-MS: 373.1 / 375.0 [M+H]+; tR= 5.60 min (System 1 ).
Example 123: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl-pyridin-2-yl)-amide
Figure imgf000145_0001
Intermediate 123 was prepared in analogy to the procedure described in Step 14.1 but using 5-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ) and stirring the reaction mixture for 18 h at rt: ESI-MS: 701.0 [M+H]+; TLC: Rf = 0.54 (DCM/MeOH/NH3 aq, 94:5:1 ).
The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 1200C in a microwave apparatus. Title compound: ESI-MS: 581.0 / 583.2 [M+H]+; tR= 3.69 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 124: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000145_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ) and 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography). Title compound: ESI-MS: 535.1 [M+H]+; tR= 3.45 min (System 1 ); TLC: Rf = 0.19 (DCM/MeOH/NH3 aq, 94:5:1 ). Step 124.1 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester 2,6-dichloro-1-fluoropyridinium tetrafluoroborate (13.9 g, 54.6 mmol, 1.8 equiv) was added to a cold (-50C) solution of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 1 15.1 ) (10.1 g, 29.9 mmol) in CH3CN (100 ml_). The reaction mixture was allowed to warm to rt overnight, cooled to 5°C and quenched by addition of a saturated aqueous solution of NaHCO3 (20 ml_). The organic solvent was removed in vacuo and the residual layer was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. Several purifications by silica gel column chromatography (DCM/Hex/Et2O, 1 :3:6) provide 2.93 g of the title compound as a white solid. Title compound: ESI-MS: 375.1 [M+H]+; tR= 4.60 min (System 1 ); TLC: Rf = 0.19 (DCM/Hex/Et2O, 1 :3:6).
Example 125: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000146_0001
Intermediate 125 was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 9 h at 800C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM: ESI-MS: 641.0 [M+H]+; TLC: Rf = 0.61 (DCM/MeOH/NH3 aq, 94:5:1 ).
The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 1200C: ESI-MS: 521.1 [M+H]+; tR= 3.30 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ). Example 126: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-vH-amide
Figure imgf000147_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-(3,3,4-trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 107.1 ), stirring the reaction mixture for 15 min at reflux, pouring it onto a saturated aqueous solution of NaHCO3 and DCM. Title compound: ESI-MS: 563.1 [M+H]+; tR= 3.72 min (System 1 ); TLC: Rf = 0.33 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 127: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000147_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine (Step 22.1 ) instead of 2- nitroimidazole in Step 14.3. The title compound: ESI-MS: 469.1 [M+H]+; tR= 3.15 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 128: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000147_0003
The title compound was prepared in analogy to the procedures described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-(2,2,4-trimethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 110.1 ), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 800C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM. Title compound: ESI-MS: 563.1 [M+H]+; tR= 3.55 min (System 1 ); TLC: Rf = 0.08 (DCM/MeOH, 95:5).
Example 129: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2- dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000148_0001
Intermediate 129 was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-[4-(4-methoxy-benzyl)-2,2-dimethyl-piperazin-1 -ylmethyl]-pyridin-2-ylamine (Step 109.1 ), 1.5 equiv of trimethyl aluminum, and stirring the reaction mixture for 5 h at 800C: ESI-MS: 669.0 [M+H]+; TLC: Rf = 0.24 (DCM/MeOH/NH3 aq, 94:5:1 ). The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 120°C: ESI-MS: 549.1 [M+H]+; tR= 3.37 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ). Example 130: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3- dimethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000149_0001
Intermediate 130 was prepared in analogy to the procedure described in in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-[4-(4-methoxy-benzyl)-3,3-dimethyl-piperazin-1 -ylmethyl]-pyridin-2-ylamine (Step 108.1 ), 1.5 equiv of trimethyl aluminum, and stirring the reaction mixture for 5 h at 800C: ESI-MS: 669.0 [M+H]+; tR= 4.26 min (System 1 ); TLC: Rf = 0.13 (DCIWMeOH, 95:5). The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 1200C: ESI-MS: 549.1 [M+H]+; tR= 3.55 min (System 1 ); TLC: Rf = 0.11 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 131 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4- trimethyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000149_0002
The title compound was prepared in analogy to the procedures described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 6-(2,2,4-trimethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (Step 1 14.1 ), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 2 h at 80°C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM. Title compound: ESI-MS: 563.2 [M+H]+; t = 3.36 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 132: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6- piperazin-1-ylmethyl-pyridin-3-yl)-amide
Figure imgf000150_0001
Intermediate 132 was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 6-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-3-ylamine (Step 11 1.1 ), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 0.5 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM: ESI-MS: 641.1 [M+H]+; tR= 3.72 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ).
The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 1200C: ESI-MS: 521.1 [M+H]+; tR= 3.21 min (System 1 ); TLC: Rf = 0.06 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 133: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3-oxo- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000150_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 4-(6-amino-pyridin-3-ylmethyl)-piperazin-2-one (Step 103.1 ), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 7 h at 800C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM. The title compound: ESI-MS: 535.1 [M+H]+; tR= 3.50 min (System 1 ); TLC: Rf = 0.16 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 134: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
Figure imgf000151_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester
(Step 124.1 ), N-(6-amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2 and purified by column chromatography), 1.5 equiv of trimethyl aluminum, stirring the reaction mixture for 5 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM. The title compound: ESI-MS: 537.1 [M+H]+; tR= 3.31 min (System 1 ); TLC: Rf = 0.13 (DCM/MeOH, 95:5).
Example 135: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- morpholin-4-ylmethyl-1 H-imidazol-2-yl)-amide
Figure imgf000151_0002
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture for 2 h at 70°C and using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)- quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ). 4-(2-Nitro-1 H-imidazol-4-ylmethyl)- morpholine (Step 23.1 ) was used instead of 2-nitroimidazole in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 511.1 [M+H]+; tR= 3.21 min (System 1 ); TLC: Rf = 0.34 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 136: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(carbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000152_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-acetamide (Step 1 18.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 22 h at 800C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM. The title compound: ESI-MS: 523.1 [M+H]+; tR= 3.53 min (System 1 ); TLC: Rf = 0.16 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 137: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000152_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-N,N-dimethyl-acetamide (Step 1 19.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM. The title compound: ESI-MS: 551.1 [M+H]+; tR= 3.81 min (System 1 ); TLC: Rf = 0.36 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 138: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- imidazol-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000152_0003
The title compound was prepared in analogy to the procedure described in Example 115 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-imidazol-1-ylmethyl-pyridin-2-ylamine (Step 120.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 3 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM. The title compound: ESI-MS: 503.1 [M+H]+; tR= 3.76 min (System 1 ); TLC: Rf = 0.47 (DCM/MeOH, 9:1 ).
Example 139: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1-(2- dimethylamino-ethyl)-1 H-pyrrol-3-yl1-amide
Figure imgf000153_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 1-(2-dimethylamino-ethyl)-1 H-pyrrol-3-ylamine (Step 121.1 ) and stirring the reaction mixture for 14 h at rt. Title compound: ESI-MS: 482.1 [M+H]+; tR= 3.66 min (System 1 ); TLC: Rf = 0.21 (DCM/MeOH, 9:1 ).
Example 140: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1- dioxo-thiomorpholin-4-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000153_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), 5-(1 ,1-dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine (Step 104.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM. Title compound: ESI-MS: 570.0 [M+H]+; t = 3.86 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 141 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4- methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000154_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 1-methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3. Title compound: ESI-MS: 524.1 [M+H]+; tR= 3.03 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 142: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo- piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000154_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step
124.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in
Step 14.2, and 4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazin-2-one (Step 142.1 ) instead of 2- nitroimidazole in Step 14.3. Title compound: ESI-MS: 524.1 [M+H]+; tR= 3.10 min (System
1 ); TLC: Rf = 0.23 (DCM/MeOH, 9:1 ).
Step 142.1 : 4-(2-Nitro-1 H-imidazol-4-ylmethyl)-piperazin-2-one
The title compound was prepared in analogy to the procedures described in Step18.1 but using piperazin-2-one instead of diethyl amine, and it was obtained as an impure sample which was used without further purification.
Example 143: 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000155_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 143.1 ), 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), and stirring the reaction mixture for 1 h at reflux. Title compound: ESI-MS: 517.1 [M+H]+; tR= 3.37 min (System 1 ); TLC: Rf = 0.1 1 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 143.1 : 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester SelectFluor (105 mg, 0.30 mmol) was added to a cold (-50C) solution of 8-(3,5-dimethoxy- phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 1 15.1 ) (100 mg, 0.30 mmol) in CH3CN (2 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to rt over 6 h and stirred at that temperature for additional 12 h and diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) to provide 50 mg of the title compound as an off-white solid. Title compound: ESI-MS: 357.2 [M+H]+; tR= 4.58 min (System 1 ); TLC: Rf = 0.24 (Hex/EtOAc, 3:2).
Example 144: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5- (4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000155_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 4 h at 800C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM. Title compound: ESI-MS: 551.1 [M+H]+; tR= 3.50 min (System 1 ); TLC: Rf = 0.20 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 144.1 : 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester
Sulfuryl chloride (0.35 ml_, 4.33 mmol, 1.1 equiv) in CH3CN (10 ml.) was added dropwise to a cold (-300C) solution of 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 143.1 ) (1.4 g, 3.93 mmol) in CH3CN (40 ml_). The reaction mixture was quenched by addition of a saturated solution of NaHCO3, allowed to warm to rt and concentrated. The residue was diluted in EtOAc and a saturated solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) to provide 1.27 g of the title compound as a white solid. Title compound: ESI-MS: 391.1 [M+H]+; tR= 4.71 min (System 1 ); TLC: Rf = 0.12 (Hex/EtOAc, 3:2).
Example 145: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5- (4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000156_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 26.1 ; purified by silica gel column chromatography), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 7 h at 80°C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM. Title compound: ESI-MS: 564.8 [M+H]+; tR= 3.57 min (System 1 ); TLC: Rf = 0.25 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 146: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000157_0001
Intermediate 146 was prepared in analogy to the procedure described in in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 5-[4-(4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 4 h at 800C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM: ESI-MS: 657.0 [M+H]+; TLC: Rf = 0.58 (DCM/MeOH/NH3 aq, 94:5:1 ).
The title compound was prepared in analogy to the procedure described in Example 105 but stirring the reaction mixture for 0.5 h at 1200C: ESI-MS: 537.0 [M+H]+; tR= 3.38 min (System 1 ); TLC: Rf = 0.05 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 147: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5- (3-oxo-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000157_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 4-(6-amino-pyridin-3-ylmethyl)-piperazin-2-one (Step 103.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 80°C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM. The title compound: ESI-MS: 551.0 [M+H]+; tR= 3.59 min (System 1 ); TLC: Rf = 0.13 (DCM/MeOH/NH3 aq, 94:5:1 ). Example 148: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- {[(2-dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
Figure imgf000158_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), N-(6-amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl-ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl-ethane-1 ,2-diamine in Step 26.2 and purified by column chromatography), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 5 h at 800C, pouring it onto a saturated aqueous solution of
NaHCO3 and DCM. The title compound: ESI-MS: 553.1 [M+H]+; tR= 3.43 min (System 1 ); TLC: Rf = 0.06 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 149: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000158_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-N,N-dimethyl-acetamide (Step 1 19.1 ), stirring the reaction mixture for 72 h at rt. The title compound: ESI-MS: 583.0 [M+H]+; tR= 4.02 min (System 1 ); TLC: Rf = 0.36 (DCM/MeOH, 9:1 ).
Example 150: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(carbamoylmethyl-methyl-amino)-methyl1-pyridin-2-yl)-amide
Figure imgf000159_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 2-[(6-amino-pyridin-3-ylmethyl)-methyl-amino]-acetamide (Step 1 18.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 800C and pouring it onto a saturated aqueous solution of NaHCC>3 and DCM. The title compound: ESI-MS: 539.0 [M+H]+; tR= 3.61 min (System 1 ); TLC: Rf = 0.49 (DCM/MeOH/NH3 aq, 9:1 ).
Example 151 : 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- imidazol-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000159_0002
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 5-imidazol-1-ylmethyl-pyridin-2-ylamine (Step 120.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 3 h at 800C and pouring it onto a saturated aqueous solution of NaHCO3 and DCM. The title compound: ESI-MS: 519.0 [M+H]+; tR= 3.86 min (System 1 ); TLC: Rf = 0.40 (DCM/MeOH, 9:1 ).
Example 152: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5- (1 ,1-dioxo-thiomorpholin-4-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000159_0003
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), 5-(1 ,1-dioxothiomorpholin-4-ylmethyl)-pyridin-2-ylamine (Step 104.1 ), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 6 h at 800C, pouring it onto a saturated aqueous solution of NaHCO3 and DCM. Title compound: ESI-MS: 585.9 [M+H]+; tR= 3.96 min (System 1 ); TLC: Rf = 0.39 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 153: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000160_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine (Step 22.1 ) instead of 2- nitroimidazole in Step 14.3. The title compound: ESI-MS: 485.1 [M+H]+; tR= 3.24 min (System 1 ); TLC: Rf = 0.20 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 154: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4- (4-methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000160_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 1-methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3. Title compound: ESI-MS: 540.0 [M+H]+; tR= 3.07 min (System 1 ); TLC: Rf = 0.23 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 155: 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4- (3-oxo-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000161_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 144.1 ), Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2, and 4-(2-nitro-1 H-imidazol-4-ylmethyl)-piperazin-2-one (Step 142.1 ) instead of 2-nitroimidazole in Step 14.3. Title compound: ESI-MS: 540.0 [M+H]+; tR= 3.18 min (System 1 ); TLC: Rf = 0.18 (DCM/MeOH, 9:1 ).
Example 156: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4- benzyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000161_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(4-benzyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 156.1 ) and stirring the reaction mixture for 72 h at rt. Title compound: ESI-MS: 643.0 [M+H]+; tR= 4.02 min (System 1 ); TLC: Rf = 0.55 (DCM/MeOH, 9:1 ).
Step 156.1 : 5-(4-Benzyl-piperazin-1-ylmethyl)-pyridin-2-ylamine
The title compound was prepared in analogy to the procedures described in Steps 100.1 -
100.2 but using 1-benzyl-piperazine in Step 100.2: ESI-MS: 283.2 [M+H]+.
Example 157: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4-[(ethyl- methyl-amino)-methyl1-1 H-imidazol-2-yl)-amide
Figure imgf000161_0003
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ) and stirring the reaction mixture for 3 h at 700C. Ethyl-methyl-(2-nitro-1 H-imidazol-4- ylmethyl)-amine (Step 157.1 ) instead of 2-nitroimidazole was used in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. Title compound: ESI-MS: 483.9 [M+H]+; TLC: Rf = 0.10 (DCM/MeOH, 9:1 ).
Step 157.1 : Ethyl-methyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine
The title compound was prepared in analogy to the procedure described in Step 18.1 but using 2 equivalents of 2-nitroimidazole, ethyl-methyl-amine instead of diethyl amine, and stirring the reaction mixture for 72 h at 82°C. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 89:10:1 , then 84:15:1 ) to afford an impure sample of the title compound which was used without further purification.
Example 158: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- diethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000162_0001
The title compound was prepared in analogy to the procedures described in Example 14 but stirring the reaction mixture at 700C for 7 h and using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)- quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ). Diethyl-(2-nitro-1 H-imidazol-4- ylmethyl)-amine (Step 18.1 ) instead of 2-nitroimidazole was used in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. Title compound: ESI-MS: 497.0 [M+H]+; tR= 3.36 min (System 1 ); TLC: Rf = 0.18 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 159: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4-ethyl- piperazin-1 -vD-phenyli-amide
Figure imgf000163_0001
Step 157.2 Step 157.1 Example 157
Figure imgf000163_0002
A mixture of propylphosphonic anhydride (50% in DMF, 0.41 ml_, 0.70 mmol, 2 equiv), 5- (2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ) (132 mg, 0.35 mmol), 4-(4-ethylpiperazin-1-yl)-aniline (Step 1.9) (79 mg, 0.39 mmol, 1.1 equiv), DMAP (3 mg), and Et3N (0.49 ml_, 3.5 mmol, 10 equiv) in DMF (3 ml_), was stirred for 16 h at rt, under an argon atmosphere. The reaction mixture was diluted with EtOAc and H2O. The aqueous layer was separated and extracted with EtOAc. The combined organic phase was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified by trituration in EtOAc to afford the title compound as a yellow solid: ES-MS: 564.9 / 566.9 [M+H]+; tR= 4.45 min (System 1 ).
Step 159.1 : 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid Sulfuryl chloride (0.1 ml_, 1.19 mmol, 1.5 equiv) was added dropwise to a cold (5°C) suspension of 5-(3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.2) (245 mg, 0.79 mmol) in CH3CN (5 ml_). The reaction mixture was stirred at 5°C for 15 min, quenched by addition of H2O (0.2 ml_), and concentrated. Trituration of the residue in H2O provided 270mg of the title compound as a white solid: ESI-MS: 378.0 / 380.0 [M+H]+; tR=4.48min (System 1 ).
Step 159.2: 5-(3,5-Dimethoxy-phenyl)-quinoline-8-carboxylic acid
A mixture of 3,5-dimethoxyphenylboronic acid (217 mg, 1.19 mmol, 1.2 equiv) (Step 1.8) in
EtOH (0.5 ml.) was added dropwise to a mixture of δ-bromo-quinoline-δ-carboxylic acid (Step 159.3) (250 mg, 0.99 mmol), PdCI2(dppf) (22mg, 0.03 mmol, 0.03 equiv), Na2CO3 (2M solution in H2O, 1 ml_, 3.97mmol, 4equiv) in toluene (5ml_) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 1050C for 1 h, allowed to cool to rt, diluted with EtOAc and H2O, basified by addition of a 2N aqueous solution of NaOH (2ml_), filtered through a pad of celite and the filtrate was extracted with EtOAc. The aqueous layer was separated and acidified to pH 5. The resulting precipitate was collected by vacuum filtration to provide 248mg of the title compound as a white solid: ESI-MS:310.1 [M+H]+; tR=4.06min (System 1 ).
Step 159.3: 5-Bromo-quinoline-8-carboxylic acid
A solution of potassium permanganate (18.2 g, 1 15.5 mmol, 2 equiv) in H2O (200 ml.) was added to a hot (1 10°C) solution of 5-bromo-8-methyl-quinoline (Step 159.4) (12.8 g, 57.7 mmol) in pyridine (120 ml_). The reaction mixture was stirred for 10 min at 1 10°C and filtered while hot. The residue in the filter was washed with H2O and pyridine. The filtrate was concentrated to remove pyridine, diluted with Et2O and basified by addition of a 2 N aqueous solution of NaOH (20 ml_). The aqueous layer was separated and made acidic (pH 3) by addition of a 2 N aqueous solution of HCI. The resulting precipitate was collected by vacuum filtration to provide 1.45 g of the title compound as a green solid: ESI-MS: 251.9 / 253.9 [M+H]+; tR= 3.56 min (System 1 ).
Step 159.4: 5-Bromo-8-methyl-quinoline
NBS (13.7 g, 76.9 mmol, 1.1 equiv) was added portionwise to a cold (5°C) solution of 8- methyl-quinoline (10 g, 69.9 mmol) in concentrated H2SO4 (150 ml_). The reaction mixture was stirred for 18 h at 5°C, diluted in ice (300 ml.) and basified by addition of an aqueous solution of NaOH (10% wt). The resulting white solid was collected by vacuum filtration, rinsed with water, and dissolved in DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 15.2 g of the title compound as a beige solid: ESI-MS: 221.9 / 223.9 [M+H]+; tR= 3.59 min (System 1 ).
Example 160: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (1-benzyl- 1 H-imidazol-2-vD-amide
Figure imgf000165_0001
The title compound was prepared in analogy to the procedure described in Example 159 but using 1-benzyl-1 H-imidazol-2-ylamine (Step 160.1 ). The title compound: ESI-MS: 532.9 [M+H]+; tR= 4.75 min (System 1 ).
Step 160.1 : 1-Benzyl-1 H-imidazol-2-ylamine
A suspension of 1-benzyl-2-nitro-1 H-imidazole (Step 160.2) (410 mg, 1.16 mmol) and Raney nickel (40 mg) in MeOH (10 ml.) was stirred for 3 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated to afford 345 mg of the title compound as a brown solid: ESI-MS: 173.9 [M+H]+; tR= 2.02 min (System 1 ).
Step 160.2: 1-Benzyl-2-nitro-1 H-imidazole
Benzyl chloride (1.8 ml_, 15.4 mmol, 1.2 equiv) was added to a solution of 2-nitroimidazole (1.45 g, 12.8 mmol) and triethylamine (3.6 mL, 25.7 mmol, 2 equiv) in DCM (40 ml_). The reaction mixture was stirred at reflux for 72 h, allowed to cool to rt, diluted with DCM, washed with H2O and brine, dried (sodium sulfate), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 7:3) to afford 1.31 g of the title compound as a white solid: ES-MS: 204.0 [M+H]+; tR= 3.72 min (System 1 ); TLC: Rf = 0.22 (Hex/EtOAc, 7:3).
Example 161 : 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (1 H- imidazol-2-vD-amide
Cl \ OMe
O
H _f >= < J
IL> -N H > < Cl OMe
A suspension of 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (1- benzyl-1 H-imidazol-2-yl)-amide (Example 160) (100 mg, 1.16 mmmol) and palladium hydroxyde (75 mg) in MeOH (5 mL) was stirred for 72 h at rt, under a hydrogen atmosphere. The reaction mixture was filtered through a pad of celite and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 1 :4) followed by trituration in Et2O to provide 15 mg of the title compound as a yellow solid: ES-MS: 442.9 [M+H]+; tR= 4.05 min (System 1 ); TLC: Rf = 0.08 (Hex/EtOAc, 1 :4).
Example 162: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (3H- imidazol-4-vD-amide
Figure imgf000166_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), stirring the reaction mixture for 3 h at 700C, and using 4-nitro-imidazole instead of 2-nitroimidazole in Step 14.3. The title compound: ESI-MS: 442.9 [M+H]+; tR= 3.93 min (System 1 ); TLC: Rf = 0.17 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 163: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4H- ri ,2,41triazol-3-yl)-amide
Figure imgf000166_0002
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), stirring the reaction mixture for 4 h at 700C, and using 3-nitro-1 ,2,4-triazole instead of 2- nitroimidazole in Step 14.3. The title compound: ESI-MS: 443.9 [M+H]+; tR= 4.60 min (System 1 ); TLC: Rf = 0.33 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 164: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000167_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 566.1 [M+H]+; TLC: Rf = 0.22 (DCIWMeOH, 9:1 ).
Example 165: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000167_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Step 26.1 ; purified by silica gel column chromatography), and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 580.1 [M+H]+; tR= 3.80 min (System 1 ); TLC: Rf = 0.27 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 166: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid {5-[4-(4- methoxy-benzyl)-piperazin-1-ylmethyl1-pyridin-2-yl)-amide
Figure imgf000167_0003
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 5-[4- (4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-ylamine (Step 105.1 ) and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 672.0 [M+H]+; TLC: Rf = 0.25 (DCIWMeOH, 9:1 ).
Example 167: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
Figure imgf000168_0001
The title compound was prepared in analogy to the procedure described in Example 105 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid {5-[4-(4- methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-2-yl}-amide (Example 166) and stirring the reaction mixture for 1 h at 1200C. Title compound: ESI-MS: 552.1 [M+H]+; TLC: Rf = 0.12 (DCM/MeOH, 9:1 ).
Example 168: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000168_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (Step 39.1 ), and stirring the reaction mixture for 3 h at rt. Title compound: ESI-MS: 566.0 [M+H]+; tR= 3.64 min (System 1 ); TLC: Rf = 0.24 (DCM/MeOH, 9:1 ).
Example 169: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [6-(4-ethyl- piperazin-1-ylmethyl)-pyridin-3-yl1-amide
Figure imgf000169_0001
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 6-(4- ethyl-piperazin-1-ylmethyl)-pyridin-3-ylamine (prepared as described in Example 39 but using N-ethyl-piperazine in Step 39.2), and stirring the reaction mixture for 3 h at rt. Title compound: ESI-MS: 580.1 [M+H]+; tR= 3.70 min (System 1 ); TLC: Rf = 0.33 (DCIWMeOH, 9:1 ).
Example 170: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid {6-[4-(4- methoxy-benzyl)-piperazin-1-ylmethyl1-pyridin-3-yl)-amide
Figure imgf000169_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.1 ), 6-[4- (4-methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-3-ylamine (Step 1 1 1.1 ) and stirring the reaction mixture for 20 h at rt. Title compound: ESI-MS: 672.1 [M+H]+; TLC: Rf = 0.45 (DCM/MeOH, 9:1 ).
Example 171 : 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (6- piperazin-1-ylmethyl-pyridin-3-yl)-amide
The title compound was prepared in analogy to the procedure described in Example 105 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (6-piperazin-1- ylmethyl-pyridin-3-yl)-amide (Example 170) and stirring the reaction mixture for 1 h at 120°C. Title compound: ESI-MS: 552.0 [M+H]+; tR= 3.57 min (System 1 ); TLC: Rf = 0.12 (DCM/MeOH, 9:1 ).
Example 172: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (A- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000170_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (6-piperazin-1- ylmethyl-pyridin-3-yl)-amide (Example 170), dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)-amine (Step 22.1 ) instead of 2-nitroimidazole in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 500.0 [M+H]+; tR= 3.50 min (System 1 ); TLC: Rf = 0.20 (DCM/MeOH, 9:1 ).
Example 173: 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino1-methyl)-pyridin-2-yl)-amide
Figure imgf000170_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (6-piperazin-1- ylmethyl-pyridin-3-yl)-amide (Example 170), N-(6-amino-pyridin-3-ylmethyl)-N,N',N'-trimethyl- ethane-1 ,2-diamine (prepared as described in Example 26 but using N,N,N'-trimethyl- ethane-1 ,2-diamine in Step 26.2), and stirring the reaction mixture for 14 h at rt. Title compound: ESI-MS: 568.0 [M+H]+; TLC: Rf = 0.15 (DCM/MeOH, 9:1 ).
Example 174: 5-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000171_0001
The title compound was prepared in analogy to the procedure described in Example 1 15 but using 5-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester (Step 174.1 ), 5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), 2 equiv of trimethyl aluminum, stirring the reaction mixture for 2 h at 800C. Title compound: ESI-MS: 534.1 [M+H]+; tR= 3.56 min (System 1 ); TLC: Rf = 0.14 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 174.1 : 5-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester SelectFluor (2.04 g, 5.8 mmol, 2 equiv) was added to a cold (-50C) solution of 5-(3,5- dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester (Step 174.2) (970 mg, 2.9 mmol) in CH3CN (40 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to rt, stirred at that temperature for 6 h, quenched by addition of a saturated aqueous solution of NaHCO3, and concentrated. The residue was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) followed by trituration in Et2O to provide 257 mg of the title compound: ESI-MS: 374.0 [M+H]+; tR= 3.81 min (System 1 ); TLC: Rf = 0.13 (Hex/EtOAc, 3:2).
Step 174.2: 5-(3,5-Dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester
A mixture of 5-(3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (Step 159.2) (2 g), H2SO4 cone. (0.6 mL) and EtOH (100 mL) was stirred at reflux for 30 h, allowed to cool and concentrated. The residue was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) to provide 1.77 g of the title compound as a white solid. Title compound: ESI-MS: 338.2 [M+H]+; tR= 3.81 min (System 1 ); TLC: Rf = 0.29 (Hex/EtOAc, 3:2).
Example 175: 5-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (4-d imethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000172_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 124.1 ), stirring the reaction mixture for 7 h at 700C, and using dimethyl-(2-nitro-1 H-imidazol- 4-ylmethyl)-amine (Step 22.1 ) instead of 2-nitroimidazole in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 468.1 [M+H]+; tR= 3.29 min (System 1 ); TLC: Rf = 0.18 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 176: 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-yl1-amide
Figure imgf000172_0002
The title compound was prepared in analogy to the procedure described in Step 14.1 but using 5-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic (Step 176.1 ), 5-(4- methyl-piperazin-1-ylmethyl)-pyridin-2-ylamine (Example 31 ; purified by silica gel column chromatography), and stirring the reaction mixture for 16 h at rt. Title compound: ESI-MS: 550.1 [M+H]+; TLC: Rf = 0.20 (DCM/MeOH/NH3 aq, 94:5:1 ).
Step 176.1 : 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid
A mixture of 5-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester (Step 176.2) (235 mg, 0.60 mmol), a 2 N aqueous solution of LiOH (3 mL) and THF (3 mL) was stirred for 20 h at rt, diluted with H2O and extracted with Et2O. The aqueous layer was acidified to pH 4 by addition of a 2 N aqueous solution of HCI. The resulting white precipitate was collected by vacuum filtration providing 210 mg of the title compound: ESI- MS: 362.1 [M+H]+; tR= 4.24 min (System 1 ). Step 176.2: 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylicacid ethyl ester
Sulfuryl chloride (75 μl_, 0.93 mmol) was added dropwise to a cold (-200C) solution of 5-(2- fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester (Step 176.3) (330 mg, 0.93 mmol) in CH3CN (6 ml_). The reaction mixture was stirred for 10 min at -200C, quenched by addition of a saturated solution of NaHCC>3, and concentrated. The residue was diluted in EtOAc and a saturated solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) to provide 240 mg of the title compound as a white solid. Title compound: ESI-MS: 390.1 [M+H]+; tR= 3.98 min (System 1 ); TLC: Rf = 0.15 (Hex/EtOAc, 3:2).
Step 176.3: 5-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester SelectFluor (2.04 g, 5.8 mmol, 2 equiv) was added to a cold (-5°C) solution of 5-(3,5- dimethoxy-phenyl)-quinoline-8-carboxylic acid ethyl ester (Step 174.2) (970 mg, 2.9 mmol) in CH3CN (40 ml_), under an argon atmosphere. The reaction mixture was allowed to warm to rt, stirred at that temperature for 6 h, quenched by addition of a saturated aqueous solution of NaHCO3, and concentrated. The residue was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (Hex/EtOAc, 3:2) followed by trituration in Et2O to provide 355 mg of the title compound: ESI-MS: 356.2 [M+H]+; tR= 3.80 min (System 1 ); TLC: Rf = 0.18 (Hex/EtOAc, 3:2).
Example 177: 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (A- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000173_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic (Step 176.1 ), stirring the reaction mixture for 8 h at 700C, and using dimethyl-(2-nitro-1 H-imidazol-4-ylmethyl)- amine (Step 22.1 ) instead of 2-nitroimidazole in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2. The title compound: ESI-MS: 484.1 [M+H]+; tR= 3.39 min (System 1 ); TLC: Rf = 0.15 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 178: 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4- methyl-piperazin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000174_0001
The title compound was prepared in analogy to the procedures described in Example 14 but using 5-(2-chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic (Step 176.1 ), stirring the reaction mixture for 8 h at 700C, and using 1-methyl-4-(2-nitro-1 H-imidazol-4-ylmethyl)- piperazine (Step 20.1 ) instead of 2-nitroimidazole in Step 14.3, and Raney nickel and MeOH/THF (1 :1 ) instead of palladium on carbon and MeOH in Step 14.2,. Title compound: ESI-MS: 539.1 [M+H]+; tR= 3.33 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 179: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- formyl-1 H-imidazol-2-yl)-amide
Figure imgf000174_0002
A mixture of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (300 mg, 0.791 mmol) (Step 179.1 ), 2-amino-4-diethoxymethyl-imidazole-1-carboxylic acid tert-butyl ester (226 mg, 0.791 mmol) (Step 179.8), TBTU (305 mg, 0.949 mmol, 1.2 equiv) and DIEA (409 mg, 3.17 mmol, 4 equiv) in DMF (6 mL) was stirred for 48 h at rt. After further addition of 2-amino-4-diethoxymethyl-imidazole-1-carboxylic acid tert-butyl ester (80 mg, 0.280 mmol) (Step 179.8), the reaction mixture was stirred for additional 72 h at rt, diluted with EtOAc/H2O and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (EtOAc/Hex, 1 : 1 ) to afford 470 mg of a mixure of products. Part of this mixture (280 mg) was dissolved in acetone (3 mL) and H2O (2 mL) and treated with PPTS (10.9 mg). The reaction mixture was stirred for 7 h at rt, heated to 5O0C, stirred for 20 h, allowed to cool to rt and diluted with EtOAc/H2O. The resulting yellow precipitate was collected by vacuum filtration and dried to provide 128 mg of the title compound: ES-MS: 472 [M+H]+; tR= 4.16 min (System 1 ).
Step 179.1 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid Sulfuryl chloride (1.7 ml_, 21.3 mmol, 2 equiv) was added dropwise to a cold (5°C) suspension of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 179.2) (3.3 g, 10.6 mmol) in CH3CN (30 ml_). The reaction mixture was stirred at 5°C for 2 h, quenched by addition of H2O, and concentrated. Trituration of the residue in H2O provided 4.0 g of the title compound as a white solid: ESI-MS: 379 [M+H]+; tR= 4.54 min (System 1 ).
Step 179.2: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid KOH (6.0 g, 107 mmol, 10 equiv) was added to 8-(3,5-dimethoxy-phenyl)-quinoxaline-5- carbonitrile (Step 179.3) (3.12 g, 10.7 mmol) in ethylene glycol (30 ml_). The reaction mixture was stirred at 1500C for 3 h (a solution was obtained), allowed to cool to rt, diluted with Et2O/ H2O, and extracted with Et2O. The aqueous phase was acidified to pH 5 by addition of HCI. Vacuum filtration of the resulting suspension afforded 3.3 g of the title compound as a yellow solid: ESI-MS: 31 1 [M+H]+; tR= 4.34 min (System 1 ).
Step 179.3: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carbonitrile
A mixture of 5-bromo-8-(3,5-dimethoxy-phenyl)-quinoxaline (Step 179.4) (4.54 g, 13.2 mmol) and CuCN (1.54 g, 17.1 mmol, 1.3 equiv) in NMP (50 ml.) was stirred for 2 h at 1800C, under an argon atmosphere. The reaction mixture was allowed to cool to rt, diluted with EtOAc/(10% aqueous solution of ethylenediamine) (150 ml_), and filtered to afford 1.19 g (batch 1 ) of the title compound as a yellow solid. The filtrate was extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in EtOAc to provide 2.31 g (batch 2) of the title compound: ESI- MS: 292 [M+H]+; tR= 4.53 min (System 1 ).
Step 179.4: 5-Bromo-8-(3,5-dimethoxy-phenyl)-quinoxaline
A mixture of 3,5-dimethoxyphenylboronic acid (3.38 g, 18.6 mmol) in EtOH (15 ml.) was added dropwise to a mixture of 5,8-dibromo-quinoxaline (Step 179.5) (10.7 g, 37.1 mmol, 2 equiv), PdCI2(dppf) (530 mg, 0.7 mmol, 0.03 equiv), Na2CO3 (2 M solution in H2O, 37 ml_, 74.3 mmol, 4 equiv) in toluene (100 ml.) at 1050C, under an argon atmosphere. The reaction mixture was stirred at 105 0C for 2 h, allowed to cool to rt, diluted with EtOAc and H2O, filtered through a pad of celite and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated in vacuo. The crude product was purified by trituration in DCM, followed by silica gel column chromatography (Hex/EtOAc, 4:1 ) to afford 4.54 g of the title compound as a yellow solid: ES-MS: 345 [M+H]+; tR= 5.13 min (System 1 ); Rf = 0.17 (Hex/EtOAc, 4:1 ).
Step 179.5: 5,8-Dibromo-quinoxaline A 40% aqueous solution of glyoxal (8.8 M, 6.3 ml_, 55.1 mmol, 1.3 equiv) was added to a suspension of 3,6-dibromo-benzene-1 ,2-diamine (Step 179.6) (11.3 g, 42.4 mmol) in EtOH (280 ml_). The reaction mixture was heated to reflux for 3 h and allowed to cool to rt overnight. Vacuum filtration of the reaction mixture afforded 9.7 g of the title compound as a yellow solid: APCI-MS: 286 / 288 / 291 [M-1]"; tR= 4.40 min (System 1 ).
Step 179.6: 3,6-Dibromo-benzene-1 ,2-diamine
NaBH4 (26 g, 680 mmol, 10 equiv) was added portionwise (2h) to a vigorously stirred suspension of 4,7-dibromo-benzo[1 ,2,5]thiadiazole (Step 179.7) (20 g, 68.0 mmol) in EtOH (400 ml_), under a nitrogen atmosphere and keeping the internal temperature below 15°C. The reaction mixture was allowed to warm to 300C, stirred for 1 h, cooled to 5°C, quenched by addition of H2O (50 ml_), and concentrated. The residue was diluted with Et2O/H2O. The resulting suspension was filtered and the filtrate extracted with Et2O. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was triturated in hexane to provide 12 g of the title compound as a white solid: ESI-MS: 263 / 265 / 267 [M-H]"; tR= 4.20 min (System 1 ).
Step 179.7: 4,7-Dibromo-benzoπ ,2,51thiadiazole
Bromine (18.6 ml_, 265 mmol, 1.2 equiv) was added to a refluxing solution of 1 ,2,5- benzothiazole (30 g, 220 mmol) in HBr (48% in H2O, 150 ml_). The reaction mixture was stirred for 4 h at reflux and allowed to cool to rt. The resulting solid was collected by vacuum filtration, washed with H2O, dried under vacuum, and triturated in MeOH to afford 63 g of the title compound as an off-white solid: 1H NMR (400 MHz, DMSO-c/6) δ(ppm): 8.00 (s, 2H); tR= 5.05 min (System 1 ). Step 179.8: 2-Amino-4-diethoxymethyl-imidazole-1-carboxylic acid tert-butyl ester A mixture of 3-bromo-1 ,1-diethoxy-propan-2-one (21.3 g, 95 mmol) (Step 179.9) and N-tert- butoxycarbonylguanidine (45.3 g, 284 mmol, 3 equiv) (Step 179.10) was stirred at 5O0C for 8 h. The reaction mixture was concentrated, diluted in EtOAc/H2O and extracted with EtOAc. The organic phase was washed with water and brine, dried (Na2SO4) and concentrated. The residue was purified by silica gel column chromatography (DCIWEtOAc, 3:7) followed by trituration in Et2O to afford 1 1.3 g of the title compound as a white solid: ES-MS: 286 [M+H]+; Rf = 0.34 (DCIWEtOAc, 3:7).
Step 179.9: 3-Bromo-1 ,1-diethoxy-propan-2-one
Copper (II) bromide (159 g, 71 1 mmol, 2.1 equiv) was added to a mechanically stirred solution of pyruvic aldehyde dimethyl acetal (40 g, 339 mmol) in EtOAc (1.5 L) at rt. The reaction mixture was heated to reflux, stirred for 3 h, cooled to rt, quenched by addition of a saturated aqueous solution of NaHCO3 (500 ml_), stirred for 30 min and filtered through a pad of celite. The filtrate was extracted with EtOAc and the combined organic extracts were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by distillation to afford 22.4 g of the title compound as a yellow oil: ES-MS: 223 / 225 [M+H]+; bp: 80°C/40 mmbar.
Step 179.10: N-tert-Butoxycarbonylguanidine
Guanidine hydrochloride (175 g, 1833 mmol, 4 equiv) was added to a solution of NaOH (147 g, 3666 mmol, 8 equiv) in H2O (360 ml_), portionwise and keeping the internal temperature around O0C. tert-Butoxycarbonyl anhydride (100 g, 458 mmol) in acetone (1.5 L) was then added over 2 h and the reaction mixture was allowed to warm to rt over 14 h. The acetone was removed under vacuum and the resulting aqueous mixture was extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 61.6 g of the title compound as a white solid: ES-MS: 160 [M+H]+.
Example 180: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-{[(2- dimethylamino-ethyl)-methyl-amino1-methyl)-1 H-imidazol-2-yl)-amide
Figure imgf000178_0001
Sodium triacetoxyborohydride (168 mg, 0.794 mmol, 3 equiv) was added to a suspension of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H-imidazol-2- yl)-amide (125 mg, 0.265 mmol) (Example 179) and N,N,N'-trimethylethylenediamine (81 mg, 0.792 mmol, 3 equiv) in DCM (4 ml.) at rt, under an argon atmosphere. The reaction mixture was stirred for 18 h at rt, diluted in DCIWH2O and extracted with DCM. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 94:5:1 ) followed by trituration in Et2O to afford 88 mg of the title compound as a yellow solid: ES- MS: 558 [M+H]+; tR= 3.14 min (System 1 ); TLC: Rf = 0.05 (DCM/MeOH/NH3 aq, 94:5:1 ).
Example 181 : 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4- r(2,2,2-trifluoro-ethylamino)-methyl1-1 H-imidazol-2-yl)-amide
Figure imgf000178_0002
Sodium triacetoxyborohydride (101 mg, 0.476 mmol, 3 equiv) was added to a suspension of 8-(2,6-dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H-imidazol-2- yl)-amide (75 mg, 0.159 mmol) and trifluoroethylamine (15 μl, 0.188 mmol), 1.18 equiv) in DCM (3 ml.) at rt, under an argon atmosphere. The reaction mixture was stirred for 18 h at rt, quenched by addition of H2O and extracted with DCM. The organic phase was washed with a saturated aqueous solution of NaHCO3, dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 98:1 :1 ) followed by trituration in Et2O to afford 55 mg of the title compound as a yellow solid: ES- MS: 555 [M+H]+; tR= 3.78 min (System 1 ); TLC: Rf = 0.55 (DCM/MeOH, 9:1 ).
Example 182: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4- [(cvanomethyl-methyl-amino)-methyl1-1 H-imidazol-2-yl)-amide
Figure imgf000179_0001
The title compound was prepared in analogy to the procedure described in Example 181 but using ethylaminoacetonitrile hydrochloride instead of trifluoroethylamine. Title compound: ES-MS: 526 / 528 [M+H]+; tR= 3.88 min (System 1 ); TLC: Rf = 0.24 (DCIWMeOH, 9:1 ).
Example 183: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3- cyano-azetidin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000179_0002
The title compound was prepared in analogy to the procedure described in Example 181 but using ethylaminoacetonitrile hydrochloride instead of trifluoroethylamine. Title compound: ES-MS: 538 / 540 [M+H]+; tR= 3.49 min (System 1 ); TLC: Rf = 0.48 (DCM/MeOH, 9:1 ).
Example 184: 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3,3- difluoro-azetidin-1 -ylmethyl)-1 H-imidazol-2-yli-amide
Figure imgf000179_0003
The title compound was prepared in analogy to the procedure described in Example 180 but using 3,3-difluoroazetidine hydrochloride (1.2 equiv) instead of N, N, N'- trimethylethylenediamine and stirring the reaction mixture for 72 h at rt. Title compound: ES- MS: 549 / 551 [M+H]+; tR= 3.65 min (System 1 ); TLC: Rf = 0.55 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
Example 185: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl- 1 H-imidazol-2-vD-amide
Figure imgf000180_0001
A mixture of 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (200 mg, 0.578 mmol) (Step 185.1 ), 2-amino-4-diethoxymethyl-imidazole-1-carboxylic acid tert-butyl ester (198 mg, 0.693 mmol, 1.2 equiv) (Step 179.8), TBTU (223 mg, 0.693 mmol, 1.2 equiv), DIEA (74.7 mg, 0.578 mmol) in DMF (4 ml.) was stirred for 18 h at rt. The reaction mixture was diluted in EtOAc/H2O and extracted with EtOAc. The organic phase was washed with H2O and brine, dried (Na2SO4), filtered and concentrated. The resulting yellow foam (405 mg) was dissolved in acetone (5 ml.) and H2O (3 ml.) and treated with PPTS (30 mg). The reaction mixture was heated to 5O0C, stirred for 2 h, allowed to cool to rt and diluted with EtOAc/H2O. The resulting yellow precipitate was collected by vacuum filtration and dried to provide 174 mg of the title compound: ES-MS: 440 [M+H]+; tR= 3.89 min (System 1 ).
Step 185.1 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid A mixture of 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (885 mg, 2.37 mmol) (Step 185.2), a 2N aqueous solution of LiOH (8 ml.) and THF (8 ml.) was stirred for 16 h at rt. THF was removed under vacuum. The resulting mixture was diluted with Et2O/H2O. The aqueous layer was separated and extracted with Et2O. The aqueous layer was acidified to pH 6 by addition of a 2N aqueous solution of HCI. The resulting yellow precipitate was collected by vacuum filtration and dried to provide 701 mg of the title compound: ESI-MS: 347 [M+H]+; tR= 3.16 min (System 1 )
Step 185.2: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester 2,6-dichloro-1-fluoropyridinium tetrafluoroborate (13.9 g, 54.6 mmol, 1.8 equiv) was added to a cold (-50C) solution of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester (Step 185.3) (10.1 g, 29.9 mmol) in CH3CN (100 ml_). The reaction mixture was allowed to warm to rt overnight, cooled to 5°C and quenched by addition of a saturated aqueous solution of NaHCO3 (20 ml_). The organic solvent was removed in vacuo and the residual layer was diluted in EtOAc and a saturated aqueous solution of NaHCO3. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated. Several purifications by silica gel column chromatography (DCM/Hex/Et2O, 1 :3:6) provide 2.93 g of the title compound as a white solid. Title compound: ESI-MS: 375 [M+H]+; tR= 4.60 min (System 1 ); TLC: Rf = 0.19 (DCM/Hex/Et2O, 1 :3:6).
Step 185.3: 8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid ethyl ester
A mixture of 8-(3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (Step 179.2) (10 g), H2SO4 cone. (3 ml.) and EtOH (500 ml.) was stirred at reflux for 7 h, allowed to cool and concentrated. The residue was diluted in EtOAc and a saturated aqueous solution of NaHCOs. The aqueous phase was separated and extracted with EtOAc. The combined organic layers were washed with H2O and brine, dried (Na2SO4), filtered and concentrated to afford 10.1 g of the title compound as a beige solid. Title compound: ESI-MS: 339 [M-H]"; tR= 4.72 min (System 1 ).
Example 186: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- methylaminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000181_0001
Sodium triacetoxyborohydride (72.4 mg, 0.341 mmol, 1.5 equiv) was added to a suspension of 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H- imidazol-2-yl)-amide (100 mg, 0.228 mmol) (Example 185) and methylamine (40% wt in H2O, 40 μl_, 0.455 mmol, 2 equiv) in DCM (4 ml.) at rt, under an argon atmosphere. The reaction mixture was stirred for 4 h at rt. After further addition of sodium triacetoxyborohydride (72.4 mg, 0.341 mmol, 1.5 equiv), the reaction mixture was stirred for additional 16 h at rt. Then, methylamine (50 μl_) and sodium triacetoxyborohydride (150 mg) were added. The reaction mixture was stirred for 4 h at rt, diluted with EtO Ac/saturated aqueous solution of NaHCOs and extracted with DCM. The organic phase was dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 91.5:7.5:1 ) to afford 41 mg of the title compound as a yellow solid: ES-MS: 455 [M+H]+; tR= 3.00 min (System 1 ); TLC: Rf = 0.10 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ). Example 187: 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-N,N- dimethyl-N-oxidyl-aminomethyl-1 H-imidazol-2-yl)-amide
Figure imgf000182_0001
A mixture of 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide (30 mg, 0.64 mmol) (Step 187.1 ) and mCPBA (20.1 g, 0.064 mmol) was stirred for 30 min at 5°C, diluted with DC M/satu rated aqueous solution of NaHCC>3 and extracted with DCIWMeOH (9:1 , v/v). The organic phase was dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel column chromatography (DCM/MeOH/NH3 aq, 89:10:1 ) to afford 20 mg of the title compound as a yellow solid: ES-MS: 485 [M+H]+; tR= 3.21 min (System 1 ); TLC: Rf = 0.05 (DCM/MeOH/NH3 aq, 89:10:1 ).
Step 187.1 : 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (A- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
The title compound was prepared in analogy to the procedure described in Example 180 but using dimethylamine hydrochloride (1.5 equiv) instead of N, N, N'- trimethylethylenediamine and 8-(2,6-difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H-imidazol-2-yl)-amide (Example 7). Title compound: ES-MS: 469 [M+H]+; tR= 3.14 min (System 1 ); TLC: Rf = 0.22 (DCM/MeOH/NH3 aq, 91.5:7.5:1 ).
1 H NMR data for selected examples are provided in the following table:
Figure imgf000182_0002
Figure imgf000183_0001
Figure imgf000184_0001
br: broad; s: singlet; d: doublet; t: triplet; q: quartet; Hz: Hertz; ppm: part per million
The 1H-NMR spectra were measured on either a Varian Mercury 400 spectrometer or a Bruker Avance 600 spectrometer. Example 188: Pharmaceutical formulations Example 188.1 : Soft Capsules
5000 soft gelatin capsules, each comprising as active ingredient 0.05 g of any one of the compounds of formula (I) mentioned in any one of the preceding Examples are prepared as follows: 250 g pulverized active ingredient is suspended in 2 liters Lauroglykol* (propylene glycol laurate, Gattefosse S.A., Saint Priest, France) and ground in a wet pulverizer to produce a particle size of about 1 to 3 μm. 0.419 g portions of the mixture are then introduced into soft gelatin capsules using a capsule-filling machine.
Example 188.2: Tablets
Tablets, comprising, as active ingredient 100 mg of any one of the compounds of formula (I) mentinoened in any one of the preceding Examples are prepared with the following composition according to standard procedures. compound (I) 100 mg crystalline lactose 240 mg
Avicel 80 mg
PVPPXL 20 mg
Aerosil 2 mg magnesium stearate 5 mg
The active ingredient is mixed with the carrier materials and compressed by means of a tabletting machine (Korsch EKO, stamp diameter 10 mm). Avicel® is microcrystalline cellulose (FMC, Philadelphia, USA). PVPPXL is polyvinylpolypyrrolidone, cross-linked (BASF, Germany). Aerosil® is silicon dioxide (Degussa, Germany).
Example 189: Protein kinase activities assays
Selected compounds of formula (I) are assayed to measure their capacity to inhibit protein kinases as described herein.
Example 189.1 : Protein kinase activities measured by a radiometric assay generic assay set-up: Enzyme activities were measured by mixing 10 μL of a 3-fold concentrated compound solution or control with 10 μL of the corresponding substrate mixture (peptidic substrate, ATP and [γ33p]ATP). The reactions were initiated by addition of 10 μL of a 3-fold concentrated solution of the respective enzyme in assay buffer. The final concentrations of the assay components were as following: (FGFR-3-K650E) 10 ng of GST- FGR-3-K650E, 20 mM Tris-HCI, pH 7.5, 3 mM MnCI2, 3 mM MgCI2, 1 mM DTT, 250 μg/mL PEG 20O00, 2 μg/mL poly(EY) 4:1 , 1 % DMSO and 0.5 μM ATP (γ-[33P]-ATP 0.1 μCi), (KDR) 15 ng of GST-KDR, 20 mM Tris-HCI, pH 7.5, 1.0 mM MnCI2, 10 mM MgCI2, 1 mM DTT, 10 μM Na3VO4, 250 μg/mL PEG 20O00, 8.0 μg/mL poly(Glu,Tyr) 4:1 , 1% DMSO and 8.0 μM ATP (γ-[33P]-ATP 0.1 μCi), (PDGFR-beta) 30 ng of GST-Xa-PDGF-beta, 20 mM Tris- HCI, pH 7.5, 10 mM MnCI2, 3.0 mM MgCI2, 1 mM DTT, 10 μM Na3VO4, 250 μg/mL PEG 20O00, 3.0 μg/mL poly(Glu,Tyr) 4:1 , 1 % DMSO and 1.0 μM ATP (γ-[33P]-ATP 0.1 μCi), (RET) 15 ng of GST-Ret, 20 mM Tris-HCI, pH 7.5, 1.0 mM MnCI2, 10 mM MgCI2, 1 mM DTT, 3.0 μg/mL poly(Glu,Tyr) 4:1 , 1% DMSO and 2.0 μM ATP (γ-[33P]-ATP 0.1 μCi. Filter binding (FB) method: FB assays were carried out in 96-well plates at room temperature for 10 min in a finial volume of 30 μL including the components as indicated in section above. The enzymatic reactions were stopped by the addition of 20 μL of 125 mM
EDTA and the incorporation of 33p jnto the poly-peptidic substrates were quantified as following: 30 μL of the stopped reaction mixture were transferred onto Immobilon-PVDF membranes previously soaked for 5 min with methanol, rinsed with water, soaked for 5 min with 0.5% H3PO4 and mounted on vacuum manifold with disconnected vacuum source. After spotting, vacuum was connected and each well rinsed with 200 μL 0.5% H3PO4. Free membranes were removed and washed 4 times on a shaker with 1% H3PO4 and once with ethanol. Membranes were dried and overlaid with addition of 10 μL/well of a scintillation fluid. The plates were eventually sealed and counted in a microplate scintillation counter. IC5O values were calculated by linear regression analysis of the percentage inhibition of the compound.
Example 189.2: Protein kinase activities measured by the LanthaScreen TR-FRET method generic assay set-up: The assay has been run at room temperature on a liquid handling robot. To the assay plates containing 50 nL compound or control solutions, 4.5 μL of solution A (5OmM Tris-HCI pH7.4, 2.0m MDTT, 0.05% Tween20, 0.02mM Na3VO4) including a generic concentration of 2.0μM ATP was added per well, followed by 4.5μL of solution B (0.5% BSA) including a generic concentration of 50 nM poly(EAY) to give 9.05μL of a reaction volume with final concentrations of 2.0μM ATP, 5OnM poly(EAY), 25mM Tris-HCI pH7.4, 1.OmM DTT, 0.025% Tween20, 0.01 mM Na3VO4, 0.025%BSA as well as specific concentration of the respective enzyme and individual concentrations of divalent cations: (FGFR-3-K650E) 0.2nM GST-FGR-3-K650E, 3.OmM MgCI2, (KIT) 36.6nM GST-KIT, 10 mM MnCI2, (RET) 0.11 nM GST-Xa-RET, 1.0 mM MnCI2, 10 mM MgCI2, (LCK) 3.3nM His-LCK, 10 mM MnCI2. (KDR) 0.38nM GST-KDR, 1 OmM MgCI2, 1.OmM MnCI2, (PDGFaV561 D) 4.4nM GST-PDGFRaV561 D, 1OmM MnCI2. After 1 hour of incubation the kinase reactions have been stopped by the addition of 4.5 μl_ of stop solution D (48mM EDTA, 0.08% CH3COONa, 0.04% NP-40) immediately followed by 4.5 μl_ of solution A including the Tb- labeled P-20 antibody to detect phosphorylated poly(EAY) by TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer). The total detection volume of 18.05μl_ included the following components: 1.OmM ATP, 25nM poly(EAY), half the concentrations of individual enzymes and divalent cations as indicated above and 12mM EDTA, 0.43μg/ml_ Tb-PY20 antibody (2.85nM), 25mM Tris-HCI pH7.4, 1.OmMDTT, 0.025% Tween20, 0.01 mM Na3VO4, O.OI mM Na3VO4, 0.025%, , 0.02% CH3COONa, 0.01% NP-40). After an incubation time of 45 min in the dark, the plates were transferred into a fluorescence reader for counting. The effect of compound on the enzymatic activity was obtained from the linear progress curves and determined from one reading (end point measurement).
Example 189.3: Protein kinase activities measured by the microfluidic Caliper method (I) generic assay set-up: The assay was prepared and incubated on a liquid handling robot system using 384 well plates. To the assay plates containing 5OnL compound or control solutions, 4.5μl_ of solution A consisting of the peptide substrate and ATP in assay buffer were added. The reactions were initiated by adding 4.5μl_ of solution B consisting of the respective kinase in assay buffer. The reactions were incubated for 1 hour at 300C in a final reaction volume of 9.05μl_. Based on a generic assay buffer (5OmM HEPES pH7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA), the following components were added: (cAbl) 16nM His-cAbl, 5μM peptide substrate (FITC-Ahx-EAIYAAPFAKKK-CONH2), 1OmM MgCI2, 10μM ATP. After incubation, the kinase reactions were stopped by the addition of 16 μL of stop solution (100 mM HEPES, 5% DMSO, 0.1 % Coating reagent, 10 mM EDTA, 0.015% Brij 35). Subsequently, the assay plates were transfered to a Caliper LabChip3000 reader and the unphosphorylated substrate and the phosphorylated product were separated and quantitated in a microfluidic chip. From these data the turnover of the kinase reactions and the effects of the compounds were calculated.
Example 189.4: Protein kinase activities measured by the microfluidic Caliper method (II) generic assay set-up: The assay was prepared and incubated on a liquid handling robot system using 384 well plates. To the assay plates containing 5OnL compound or control solutions, 4.5μl_ of solution A consisting of the peptide substrate and ATP in assay buffer were added. The reactions were initiated by adding 4.5μl_ of solution B consisting of the respective kinase in assay buffer. The reactions were incubated for 1 hour at 300C in a final reaction volume of 9.05μl_. Based on a generic assay buffer (5OmM HEPES pH7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA), the following components were added: (cAbl-T315l) 2.4nM His-cAbl-T315l, 5μM peptide substrate (FITC-Ahx-EAIYAAPFAKKK- CONH2), 1 OmM MgCI2 , 10μM ATP. After incubation, the kinase reactions were stopped by the addition of 16 μl_ of stop solution (100 mM HEPES, 5% DMSO, 0.1 % Coating reagent, 10 mM EDTA, 0.015% Brij 35). Subsequently, the assay plates were transfered to a Caliper LabChip3000 reader and the unphosphorylated substrate and the phosphorylated product were separated and quantitated in a microfluidic chip. From these data the turnover of the kinase reactions and the effects of the compounds were calculated. Compounds of formula (I) are assayed to measure their capacity to inhibit FGFR3 kinase as described above.
Results are provided in the following table:
Figure imgf000188_0001
Selected results for specific compounds are provided in the following table:
Figure imgf000188_0002
Figure imgf000189_0001
Figure imgf000190_0001
IC5O values are the average IC5O values of 2 independent measurements. * Single value.
Further, selected compounds of formula (I) are assayed to measure their capacity to inhibit other kinases, such as KDR, cKIT, PDGF-R, LCK, cABL, RET as described above. Results are provided in the following table:
Figure imgf000190_0002

Claims

1. A compound of the formula (I),
Figure imgf000191_0001
or a salt, solvate, ester, N-oxide thereof, wherein X represents N or CH;
R1 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy; R2 represents hydrogen, halogen, alkyl, alkyl substituted with saturated heterocyclyl which is unsubstituted or substituted by alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, di-substituted amino wherein the substituents are selected from the group consisting of alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, substituted alkoxy wherein the substituents are selected from the group consisting of halo and alkoxy;
A represents aryl or heteroaryl; B represents aryl or heteroaryl;
RA1 represents hydrogen or a substituent different from hydrogen; RA2 represents a direct bond or an alkanediyl; R represents hydrogen or a substituent different from hydrogen;
RB2 represents a direct bond or aminocarbonyl; m represents an integer from 0 to 3; n represents an integer selected from 0 to 5.
A compound of the formula (I) according to claim 1 , wherein R1 represents hydrogen, halogen, Ci-i2alkyl, substituted Ci-i2alkyl wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci-i2alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci.-i2alkyl, amino Ci.-i2alkyl, Ci.i2alkyl-amino-Ci.i2alkyl, di-Ci.
12alkyl-amino-Ci-i2alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci.-i2alkyl, amino Ci.-i2alkyl, Ci.i2alkyl-amino-Ci.i2alkyl, di-Ci. 12alkyl-amino-Ci-i2alkyl, Ci.i2alkoxy, halo-Ci-i2alkoxy; R2 represents hydrogen, halogen, Ci.i2alkyl, substituted d.i2alkyl wherein the subtitutents are selected from the group of saturated, mono-, bi-, tri- or spirocyclic heterocyclyl having 5 to 10 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci.-i2alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci.-i2alkyl, amino Ci.-i2alkyl, Ci.i2alkyl-amino-Ci.i2alkyl, di-Ci. 12alkyl-amino-Ci-i2alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci.-i2alkyl, amino Ci.-i2alkyl, Ci.i2alkyl-amino-Ci.i2alkyl, di-Ci.
12alkyl-amino-Ci-i2alkyl, Ci_i2alkoxy, halo-Ci_i2alkoxy;
A represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaro- matic moiety with 5 - 13 ring atoms; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RA1-RA2; B represents an aromatic moiety with 6 to 14 ring carbon atoms or a heteroaromatic moiety with 5 to 13 ring atoms; whereby such aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RB1-RB2 ; RA1 represents hydrogen; or formyl, Ci-7alkylcarbonyl, Ci-7alkoxycarbonyl, aminocarbonyl, N-Ci-7alkylaminocarbonyl, IS^N-di-C-i-T-alkylaminocarbonyl; ; benzyl; or hydroxy, Ci-7alkoxy, amino-Ci-7alkoxy, N-Ci-7alkylamino- Ci-7alkoxy, N,N-di- Ci-7alkylamino-Ci-7alkoxy; heterocyclyl-Ci-7alkoxy whereby said heterocyclyl has 3 to 10 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci-7alkyl and/or hydroxy; or a group -NRA3RA4 or a group -C(O)-NRA3RM
RA2 represents a direct bond or a straight-chain or branched-chain Ci_i2 alkanediyl; RA3 and RM represent independent from each other hydrogen, Ci-7alkyl, hydroxy-Ci-7 alkyl, halogen-Ci-7alkyl, cyano-Ci-7alkyl, amino-Ci-7alkyl, N-Ci-7alkylamino-Ci-7- alkyl, N,N-di-Ci-7alkylamin- Ci-7-alkyl, aminocarbonyl-Ci-7alkyl, N- Ci-7alkylaminocarbonyl-Ci-7-alkyl, N^-di-Ci-T-alkylaminocarbonyl-d-T-alkyl, a saturated, partly saturated or unsaturated hetereocycle which has 3 to 10 ring atoms, and which is optionally substituted by 1 to 3 substituents selected from the group consisting of Ci-7alkyl, hydroxyl, oxo, hydroxy-Ci-7alkyl, benzyl, methoxybenzyl, amino, Ci-7alkylamino, N,N-di-Ci-7alkylamino or RA3 and RM represent together with the nitrogen to which they are bound a saturated, partly saturated or unsaturated hetereocycle which has 3 to 10 ring atoms, and which is optionally substituted by 1 to 3 substituents selected from the group consisting of Ci-7alkyl, cyano, halogen, hydroxyl, oxo, hydroxy-Ci.
7alkyl, Ci-7alkylcarbonyl, benzyl, methoxybenzyl, amino, Ci-7alkylamino, N,N-di-
Ci-7alkylamino;
RB1 represents halo, a straight-chain or branched-chain unsubstituted Ci-7alkyl, a straight-chain or branched-chain unsubstituted Ci-7alkoxy, straight-chain or branched-chain halo-Ci-7alkyl; R represents a direct bond; m represents 0, 1 ,
2, 3 or 4; n represents 0, 1 or 2; or a salt, solvate, ester, N-oxide thereof.
3. A compound of the formula (I) according to claim 1 or 2, wherein, R1 represents hydrogen, fluoro, chloro, Ci-4alkyl, substituted Ci-4alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci-4alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl- amino Ci-4alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl- amino Ci-4alkyl, Ci-4alkoxy, fluoro-Ci_4alkoxy, chloro-Ci-4alkoxy; R2 represents hydrogen, fluoro, chloro,
C1-4alkyl, substituted Ci-4alkyl wherein the subtitutents are selected from the group of saturated, monocyclic heterocyclyl having 5 to 6 ring atoms and which heterocyclyl is unsubstituted or substituted by Ci-4alkyl, amino, mono-substituted amino wherein the substituent is selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl- amino Ci-4alkyl, di-substituted amino wherein the substituents are selected from the group consisting of Ci-4alkyl, amino-Ci-4alkyl, Ci-4alkyl-amino-Ci-4alkyl, di-Ci-4alkyl- amino Ci-4alkyl, Ci-4alkoxy, fluoro-Ci_4alkoxy, chloro-Ci-4alkoxy; A represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 6 ring and whereby at least one of the heteroatoms is nitrogen, each aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RA1-RA2; B represents an aromatic moiety selected from the group consisting of phenyl, naphtyl or a heteroaromatic moiety with 5 to 10 ring and whereby at least one of the heteroatoms is nitrogen or sulfur, each aromatic or heteroaromatic moiety is unsubstituted or substituted by one or more substituents -RB1-RB2; RA1 represents hydrogen; or Ci-4alkylcarbonyl, Ci-4alkoxycarbonyl, aminocarbonyl,
N,N-di-Ci-4alkylaminocarbonyl; or hydroxy, Ci-4alkoxy, N,N-di-Ci-4 alkylamino-Ci. 4alkoxy; heterocyclyl-Ci-4alkoxy whereby said heterocyclyl has 5 to 6 ring atoms, at least one ring atom is nitrogen, is bound via nitrogen, is optionally substituted by Ci-4alkyl; or a group -NRA3RM; RA2 represents a direct bond or a straight-chain or branched-chain d-β alkanediyl; RA3 and RM represent independent from each other methyl, ethyl, n- or iso-propyl, n- , iso-, sec- or tert-butyl, hydroxymethyl, 2-hydroxyethyl, amino-methyl or -ethyl, dimethylaminomethyl or -ethyl, aminocarbonyl-methyl or -ethyl, N,N-dimethyl- aminocarbonyl-methyl or -ethyl, N,N-diethylaminocarbonyl-methyl or -ethyl or RA3 and RM represent together with the nitrogen to which they are bound a saturated, partly saturated or unsaturated hetereocycle selected from the group consisting of azetidine, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and which is optionally substituted by 1 substituent selected from the group consisting of methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, cyano, halogen, hydroxy, oxo, hydroxyethyl, benzyl, methoxybenzyl, N, N- dimethylamino, N,N-diethylamino;
R represents methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert-butyl, n-pentyl, n- hexyl, n-heptyl, methyoxy, ethyoxy, n- or iso-propoxy, n-, iso-, sec- or tert- butoxy, n-pentoxy, n-hexoxy, n-heptoxy, fluormethyl, chlormethyl, trifluoromethyl, fluoro, chloro, bromo; m represents 0, 1 or 4; n represents 0 or 1 ; or a salt, solvate, ester, N-oxide thereof.
A compound of the formula (I) according to any of claims 1 to 3, wherein
R1 represents hydrogen, (2-dimethylamino-ethyl)-methyl-amino, 4-ethyl-piperazin-1- ylmethyl, methyl; with particular preference given to hydrogen; R2 represents hydrogen, (2-dimethylamino-ethyl)-methyl-amino, 4-ethyl-piperazin-1- yl-methyl, methyl; with particular preference given to hydrogen; A represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selcected from the group consisting of phenyl, pyridyl, pyrimidyl, pyrolyl, imidazolyl, pyrazolyl, triazolyl and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -RA1-RA2; B represents optionally substituted aryl or heteroaryl wherein said aryl or heteroaryl is selcected from the group consisting of phenyl, naphthyl, pyridyl, pyridiyl-N-oxide, chinolinyl, isochinolinyl, thiophenyl, thionaphthenyl and wherein said aryl or heteroaryl is unsubstituted or substituted by one or more substituents -RB1-RB2; RA1 represents hydrogen; or methoxycarbonyl, tert.butoxycarbonyl, aminocarbonyl; or a group -NRA3RM; RA2 represents a direct bond, methandiyl, 1 ,2-ethanediyl, 1 ,1-ethanediyl, 1 ,1-, 1 ,2-,
1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,
4-butanediyl, with particular preference given to direct bond, methandiyl, 1 ,2-ethanediyl;
R1
R represents methyl, methoxy, trifluormethyl, fluoro, chloro; or a salt, solvate, ester, N-oxide thereof.
5. A compound of the formula (IA) according to claim 1 ,
Figure imgf000197_0001
or a salt, solvate, ester, N-oxide thereof, wherein the substituents are as defined in any of claims 1 to 4.
6. A compound of the formula (I) selected from 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 - yl)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1 - yl)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-carbamoyl-phenyl)- amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-morpholin-4-yl- phenyl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino- ethoxy)-phenyl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-carbamoyl-pyridin-2- yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-hydroxy-phenyl)- amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-piperazin-1 -yl- phenyl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-
1-yl)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-isopropyl- piperazin-1 -yl)-phenyl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-isopropyl- piperazin-1-ylmethyl)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 - ylmethyl)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2-pyrrolidin-1 -yl- ethoxy)-phenyl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)- amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (2H-pyrazol-3-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (3H-imidazol-4-yl)- amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4H-[1 ,2,4]triazol-3-yl)- amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-diethylaminomethyl-
1 H-imidazol-2-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin-1 -ylmethyl-
1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-
1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 - ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-morpholin-4- ylmethyl-1 H-imidazol-2-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-oxo-1 ,6-dihydro- pyridin-3-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazine-
1 -carbonyl)-pyridin-2-yl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-diethylaminomethyl- pyridin-2-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5- dimethylaminomethyl-pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-morpholin-4- ylmethyl-pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-pyrrolidin-1 -ylmethyl- pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-
1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4,5-bis- dimethylaminomethyl-1 H-imidazol-2-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-isopropyl- piperazin-1-yl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl-piperazin-1 - yl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [2-(4-isopropyl- piperazin-1 -yl)-pyrimidin-5-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [2-(4-ethyl-piperazin-1 - yl)-pyrimidin-5-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {6-[methyl-(1 -methyl- piperidin-4-yl)-amino]-pyridin-3-yl}-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {6-[(2-dimethylamino- ethyl)-methyl-amino]-pyridin-3-yl}-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4- methyl-piperazin-1-ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-pyrrolidin-1 -ylmethyl- pyridin-3-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-diethylaminomethyl- pyridin-3-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-morpholin-4- ylmethyl-pyridin-3-yl)-amide
8-(2-Fluoro-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino-ethoxy)-phenyl]- amide 8-(2-Fluoro-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1 -yl)-phenyl]-amide
8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid (5-diethylaminomethyl-pyridin-2-yl)-amide
8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1 -ylmethyl)-pyridin-2- yl]-amide 8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1 -yl)-pyridin-3-yl]- amide
8-Naphthalen-1 -yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-ylmethyl)-1 H- imidazol-2-yl]-amide 8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1-yl)-phenyl]-amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 -yl)-phenyl]-amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [4-(2-dimethylamino-ethoxy)-phenyl]-amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2- yl]-amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1 -yl)-pyridin-3-yl]- amide
8-lsoquinolin-4-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-ylmethyl)-1 H- imidazol-2-yl]-amide 8-Benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)- pyridin-2-yl]-amide
8-Benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-Benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1 -yl)-pyridin-3- yl]-amide 8-Benzo[b]thiophen-3-yl-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-ylmethyl)-
1 H-imidazol-2-yl]-amide
8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1 -yl)- phenyl]-amide 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 -yl)- phenyl]-amide
8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino-ethoxy)- phenyl]-amide 8-(2-Chloro-5-methoxy-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1 -ylmethyl)- pyridin-2-yl]-amide
8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1-yl)-pyridin-
3-yl]-amide 8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1 -ylmethyl)-
1 H-imidazol-2-yl]-amide
8-(4-Methyl-thiophen-3-yl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [3-(4-ethyl-piperazin-1 -yl)-phenyl]- amide 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1-yl)-phenyl]- amide
8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(2-dimethylamino-ethoxy)-phenyl]- amide
8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide 8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)- pyridin-2-yl]-amide
8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-1 -yl)-pyridin-3- yl]-amide
8-(2,6-Dimethyl-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-1-ylmethyl)-1 H- imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3-ylamide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-2-ylamide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-methyl-pyridin-2-yl)- amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-3-(4-ethyl-piperazin-1-ylmethyl)-quinoxaline-5- carboxylic acid pyridin-3-ylamide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1-ylmethyl)-quinoxaline-5- carboxylic acid pyridin-3-ylamide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-(4-ethyl-piperazin-1-ylmethyl)-quinoxaline-5- carboxylic acid pyridin-2-ylamide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid (1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid pyridin-2-ylamide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2-[(2-dimethylamino-ethyl)-methyl-amino]- quinoxaline-5-carboxylic acid pyridin-3-ylamide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-methyl-piperazin-
1 -ylmethyl)-pyridin-3-yl]-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-3-ylamide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid pyridin-2-ylamide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin-1 -ylmethyl- 1 H-imidazol-2-yl)-amide
8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide
8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide 8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin-1 -ylmethyl-1 H- imidazol-2-yl)-amide
8-(3-Methoxy-2,5-dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4- ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-5-methoxy-3,6-dimethyl-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,5-Dimethyl-1 -oxy-pyridin-3-yl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((R)-3-hydroxy- pyrrolidin-1-ylmethyl)-pyridin-2-yl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-((S)-3-hydroxy- pyrrolidin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-acetyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3-oxo-piperazin-1- ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1- dioxothiomorpholin-4-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl- pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(2-hydroxy-ethyl)- piperazin-1-ylmethyl]-pyridin-2-yl}-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4-trimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4-trimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2-dimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4-trimethyl- piperazin-1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6
-piperazin-1 -ylmethyl-pyridin-3-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3-dimethyl- piperazin-1-ylmethyl)-pyridin-3-yl]-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(3,3,4-trimethyl- piperazin-1-ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4-trimethyl- piperazin-1-ylmethyl)-pyridin-3-yl]-amide
8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 -ylmethyl)- pyridin-2-yl]-amide
8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(4-methoxy-benzyl)-piperazin-
1 -ylmethyl]-pyridin-2-yl}-amide
8-(3,5-Dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[4-(4-methoxy-benzyl)-piperazin-
1 -ylmethyl]-pyridin-2-yl}-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[(carbamoylmethyl- methyl-amino)-methyl]-pyridin-2-yl}-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-
[(dimethylcarbamoylmethyl-methyl-amino)-methyl]-pyridin-2-yl}-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-imidazol-1-ylmethyl- pyridin-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1 -(2-dimethylamino- ethyl)-1 H-pyrrol-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid [5-(4- methyl-piperazin-1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-2,3-dimethyl-quinoxaline-5-carboxylic acid (5- piperazin-1-ylmethyl-pyridin-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-
1 -ylmethyl)-pyridin-2-yl]-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-piperazin-1 -ylmethyl- pyridin-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3,4-trimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2,4-trimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(2,2-dimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3,3-dimethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(2,2,4-trimethyl- piperazin-1-ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (6-piperazin-1 -ylmethyl- pyridin-3-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3-oxo-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-morpholin-4-ylmethyl-
1 H-imidazol-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-[(carbamoylmethyl- methyl-amino)-methyl]-pyridin-2-yl}-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-
[(dimethylcarbamoylmethyl-methyl-amino)-methyl]-pyridin-2-yl}-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-imidazol-1 -ylmethyl- pyridin-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [1 -(2-dimethylamino- ethyl)- 1 H-pyrrol-3-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1-dioxo- thiomorpholin-4-ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-
1 -ylmethyl)-1 H-imidazol-2-yl]-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo-piperazin-1- ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2-Fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl- piperazin-1 -ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-piperazin-1 - ylmethyl-pyridin-2-yl)-amide 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(3-oxo- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5- [(dimethylcarbamoylmethyl-methyl-amino)-methyl]-pyridin-2-yl}-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {5-
[(carbamoylmethyl-methyl-amino)-methyl]-pyridin-2-yl}-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-imidazol-1 - ylmethyl-pyridin-2-yl)-amide 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(1 ,1-dioxo- thiomorpholin-4-ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl- piperazin-1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo- piperazin-1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-benzyl-piperazin- 1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4-[(ethyl-methyl- amino)-methyl]-1 H-imidazol-2-yl}-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-diethylaminomethyl-
1 H-imidazol-2-yl)-amide 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4-ethyl-piperazin-1 -yl)- phenyl]-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (1-benzyl-1 H-imidazol-2- yl)-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (1 H-imidazol-2-yl)-amide 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (3H-imidazol-4-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4H-[1 ,2,4]triazol-3-yl)- amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4-methyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4-ethyl-piperazin-1- ylmethyl)-pyridin-2-yl]-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid {5-[4-(4-methoxy-benzyl)- piperazin-1-ylmethyl]-pyridin-2-yl}-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (5-piperazin-1 -ylmethyl- pyridin-2-yl)-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [6-(4-methyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [6-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide methoxy-benzyl)-piperazin-1-ylmethyl]-pyridin-3-yl}-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid {6-[4-(4-
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (6-piperazin-1 -ylmethyl- pyridin-3-yl)-amide 5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (4-dimethylaminomethyl-
1 H-imidazol-2-yl)-amide
5-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide
5-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4-methyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
5-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (4-d imethylaminomethyl-1 H-imidazol-2-yl)-amide
5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [5-(4-methyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide 5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
5-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoline-8-carboxylic acid [4-(4-methyl- piperazin-1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H-imidazol- 2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4-[(2,2,2-trifluoro- ethylamino)-methyl]-1 H-imidazol-2-yl}-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4-[(cyanomethyl- methyl-amino)-methyl]-1 H-imidazol-2-yl}-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-cyano-azetidin-1 - ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3,3-difluoro- azetidin-1-ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-formyl-1 H-imidazol-2- yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-methylaminomethyl-
1 H-imidazol-2-yl)-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-N,N-dimethyl-N- oxidyl-aminomethyl-1 H-imidazol-2-yl)-amide
7. A compound of the formula (I) selected from 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-diethylaminomethyl-
1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin-1 -ylmethyl-
1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin- 1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-ethyl-piperazin-1 - ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-morpholin-4- ylmethyl-1 H-imidazol-2-yl)-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin- 1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [6-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-3-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl-piperazin-1 - ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-pyrrolidin-1 -ylmethyl- 1 H-imidazol-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-
1 -ylmethyl)-pyridin-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2-dimethylamino- ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-morpholin-4-ylmethyl-
1 H-imidazol-2-yl)-amide 8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl-piperazin-
1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo-piperazin-1 - ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl- piperazin-1 -ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-ethyl- piperazin-1-ylmethyl)-pyridin-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (5-{[(2- dimethylamino-ethyl)-methyl-amino]-methyl}-pyridin-2-yl)-amide 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4- dimethylaminomethyl-1 H-imidazol-2-yl)-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(4-methyl- piperazin-1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [4-(3-oxo- piperazin-1 -ylmethyl)-1 H-imidazol-2-yl]-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid {4-[(ethyl-methyl- amino)-methyl]-1 H-imidazol-2-yl}-amide
8-(2,6-Difluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4-diethylaminomethyl-
1 H-imidazol-2-yl)-amide
8. A compound of the formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof, as pharmaceutical.
9. A compound of the formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof, for use as pharmaceutical, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
10. Use of a compound of formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof, for the treatment of one or more Protein tyrosine kinase mediated diseases, in particular a FGFR kinase mediated disease.
1 1. Use of a compound of formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof, for the manufacture of a medicament for the treatment of one or more Protein tyrosine kinase mediated diseases, in particular a FGFR kinase mediated disease.
12. A method for the treatment of a Protein tyrosine kinase mediated disease, in particular a FGFR kinase mediated disease, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof, as active in-gredient; one or more pharmaceutically acceptable carrier material(s) and / or diluents.
14. A combined pharmaceutical composition, adapted for simultaneous or sequential administration, comprising a therapeutically effective amount of a compound of formula (I) according to any one of claims 1 to 7 in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; therapeutically effective amount of one or more combination partners; one or more pharmaceutically acceptable carrier material(s) and / or diluents.
15. A pharmaceutical composition according to claim 13 or a combined pharmaceutical composition according to claim 14 for use in the treatment of a Protein tyrosine kinase mediated disease, in particular a FGFR kinase mediated disease.
16. A process for the manufacture of a compound of the formula (I) according to any one of cairns 1 to 7 comprising either
Method A: reacting a carboxylic acid of the formula (II),
Figure imgf000211_0001
wherein the substituents are as defined for a compound of the formula (I), with an amine of the formula (III)
Figure imgf000211_0002
optionally in the prensence of a diluent, optionally in the presence of a reaction aid, optionally in the presence of a base to obtain a compound of formula I; or Method B: reacting a compound of formula (X)
Figure imgf000211_0003
wherein the substituents are as defined for a compound of the formula (I) and Hal represents halo (in particular bromo) with a boron compound of the formula (V)
Figure imgf000211_0004
wherein the substituents are as defined for a compound of the formula (I) and L2B represents represents a boronic acid residue or an ester thereof, optionally in the presence of a diluent, optionally in the presence of a catalyst, optionally in the presence of an reaction aid to obtain a compound of formula I; and, if desired, converting a compound of the formula (I) obtained according to method A or method B into a different compound of the formula (I), and/or converting an obtainable salt of a compound of the formula (I) into a different salt thereof, and/or converting an obtainable free compound of the formula (I) into a salt thereof, and/or separating an obtainable isomer of a compound of the formula (I) from one or more different obtainable isomers of the formula (I).
PCT/EP2009/056154 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors WO2009141386A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP09749876.0A EP2282995B1 (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
EA201001769A EA021421B1 (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors, process for preparation thereof, pharmaceutical composition comprising same and method for treating diseases using such compounds
AU2009248774A AU2009248774B2 (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
JP2011509980A JP5351254B2 (en) 2008-05-23 2009-05-20 Quinoxaline- and quinoline-carboxamide derivatives
MX2010012699A MX2010012699A (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors.
NZ588511A NZ588511A (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
UAA201013893A UA103478C2 (en) 2008-05-23 2009-05-20 Quinoline and quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
BRPI0913031 BRPI0913031A2 (en) 2008-05-23 2009-05-20 quinoline and quinoxaline derivatives as protein tyrosine kinase inhibitors, their uses and manufacturing process, as well as pharmaceutical compositions and combinations comprising them
CN2009801187578A CN102036963B (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
KR1020107026049A KR101257158B1 (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CA2725185A CA2725185C (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
ES09749876.0T ES2554513T3 (en) 2008-05-23 2009-05-20 Quinoline and quinoxaline derivatives as protein tyrosine kinase inhibitors
ZA2010/07086A ZA201007086B (en) 2008-05-23 2010-10-05 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
TNP2010000480A TN2010000480A1 (en) 2009-05-20 2010-10-15 Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
IL209124A IL209124A (en) 2008-05-23 2010-11-04 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
CU2010000219A CU24001B1 (en) 2008-05-23 2010-11-12 DERIVATIVES OF QUINOLINES AND QUINOXALINES AS INHIBITORS OF KINASE OF PROTEIN TIROSINA
MA33351A MA32306B1 (en) 2008-05-23 2010-11-12 Quinolines and quinoxaline derivatives as protein tyrosine kinase inhibitors
SM201000124T SMP201000124B (en) 2008-05-23 2010-12-16 Quinoline and quinossaline derivatives as protein tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08156846.1 2008-05-23
EP08156846 2008-05-23

Publications (1)

Publication Number Publication Date
WO2009141386A1 true WO2009141386A1 (en) 2009-11-26

Family

ID=39643838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056154 WO2009141386A1 (en) 2008-05-23 2009-05-20 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors

Country Status (33)

Country Link
US (4) US8273882B2 (en)
EP (1) EP2282995B1 (en)
JP (1) JP5351254B2 (en)
KR (1) KR101257158B1 (en)
CN (1) CN102036963B (en)
AR (1) AR071867A1 (en)
AU (1) AU2009248774B2 (en)
BR (1) BRPI0913031A2 (en)
CA (1) CA2725185C (en)
CO (1) CO6321283A2 (en)
CR (1) CR11727A (en)
CU (1) CU24001B1 (en)
DO (1) DOP2010000343A (en)
EA (1) EA021421B1 (en)
EC (1) ECSP10010627A (en)
ES (1) ES2554513T3 (en)
GE (1) GEP20125502B (en)
HN (1) HN2010002491A (en)
IL (1) IL209124A (en)
MA (1) MA32306B1 (en)
MX (1) MX2010012699A (en)
MY (1) MY155535A (en)
NI (1) NI201000190A (en)
NZ (1) NZ588511A (en)
PA (1) PA8827901A1 (en)
PE (1) PE20091955A1 (en)
SM (1) SMP201000124B (en)
SV (1) SV2010003741A (en)
TW (1) TWI448460B (en)
UA (1) UA103478C2 (en)
UY (1) UY31838A (en)
WO (1) WO2009141386A1 (en)
ZA (1) ZA201007086B (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135376A1 (en) 2010-04-30 2011-11-03 Astex Therapeutics Limited Pyrazolyl quinazoline kinase inhibitors
US20120309766A1 (en) * 2008-05-23 2012-12-06 Pascal Furet Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
WO2013061081A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer benzopyrazines via the inhibition of fgfr kinases
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013061080A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer pyridopyrazines via the inhibition of fgfr kinases
WO2013061074A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Quinolines as fgfr kinase modulators
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013061077A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited New compounds
WO2014011284A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
JP2014515001A (en) * 2011-04-20 2014-06-26 塩野義製薬株式会社 Aromatic heterocyclic derivatives having TRPV4 inhibitory activity
US8933099B2 (en) 2013-02-20 2015-01-13 Eisai R&D Management Co., Ltd. Monocyclic pyridine derivative
WO2015097621A2 (en) 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015144803A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9290478B2 (en) 2010-11-29 2016-03-22 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US9340509B2 (en) 2013-12-02 2016-05-17 Chemocentryx, Inc. CCR6 compounds
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
EP3617213A1 (en) 2011-12-30 2020-03-04 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10730868B2 (en) 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2023034811A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11932658B2 (en) 2016-07-14 2024-03-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12060347B2 (en) 2016-07-14 2024-08-13 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US12122767B2 (en) 2020-09-30 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2350075T3 (en) 2008-09-22 2014-07-31 Array Biopharma Inc Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
EP2648754A4 (en) 2010-12-07 2016-02-24 Philadelphia Health & Educatio Methods of inhibiting metastasis from cancer
EA036160B1 (en) * 2013-03-15 2020-10-08 Селджен Кар Ллс Heteroaryl compounds and uses thereof
KR102350704B1 (en) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 Heteroaryl compounds and uses thereof
AR095464A1 (en) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc HETEROARILO COMPOUNDS AND USES OF THE SAME
WO2017003723A1 (en) * 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
GEP20227339B (en) 2016-04-04 2022-01-25 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)- pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydro-xypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3439663B1 (en) 2016-04-04 2024-07-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3024603A1 (en) 2016-05-18 2017-11-23 Charles Todd Eary Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
KR102466192B1 (en) * 2016-08-23 2022-11-14 에자이 알앤드디 매니지먼트 가부시키가이샤 Combination therapy for the treatment of hepatocellular carcinoma
JP7206188B2 (en) * 2016-10-10 2023-01-17 ディベロップメント センター フォー バイオテクノロジー Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
WO2019023278A1 (en) * 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
KR102653681B1 (en) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 SPRAY-DRIED DISPERSIONS AND FORMULATIONS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUORO PROPAN-2-YL)-lH-PYRAZOLE-4-CARBOXAMIDE
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN110840876A (en) * 2019-11-18 2020-02-28 青海民族大学 Application of gallic acid in Agaricus campestris in CDC25 phosphoric acid protease
CA3161339A1 (en) 2019-12-27 2021-07-01 Schrodinger, Inc. Cyclic compounds and methods of using same
CN115210226B (en) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 Quinoline compounds
AU2021228767A1 (en) * 2020-02-28 2022-09-29 Remix Therapeutics Inc. Heterocyclic amides and their use for modulating splicing
CN111646945A (en) * 2020-05-29 2020-09-11 凯美克(上海)医药科技有限公司 Synthetic method of 4-bromo-2-nitro-1H-imidazole
WO2022055963A1 (en) 2020-09-10 2022-03-17 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
US20240148732A1 (en) 2021-01-26 2024-05-09 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (en) 2021-03-18 2023-01-01 美商薛定諤公司 Cyclic compounds and methods of using same
CN114605391B (en) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 Quinoxaline derivative, preparation method and application thereof
CN117510471A (en) * 2022-07-29 2024-02-06 江苏天士力帝益药业有限公司 Abeli synthesis method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
HUP0201514A3 (en) * 1999-04-06 2003-11-28 Abbott Gmbh & Co Kg Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US6858600B2 (en) 2001-05-08 2005-02-22 Yale University Proteomimetic compounds and methods
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003024446A1 (en) 2001-09-11 2003-03-27 Mitsubishi Pharma Corporation Oxidation stress inhibitor and method of measuring oxidation stress
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
CA2458533C (en) 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
AR046845A1 (en) 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
US7501416B2 (en) 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
SE0401345D0 (en) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
AR058051A1 (en) 2005-09-21 2008-01-23 Astrazeneca Ab ALQUILNITRILO QUINOLINAS. OBTAINING PROCESS AND PHARMACEUTICAL COMPOSITIONS.
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
AR066879A1 (en) 2007-06-08 2009-09-16 Novartis Ag DERIVATIVES OF QUINOXALINE AS INHIBITORS OF THE TYPOSINE CINASA ACTIVITY OF THE JANUS CINASES
MX2010004604A (en) 2007-11-26 2010-08-04 Pfizer Pyrazole derivatives as 5-lo inhibitors.
WO2009143153A1 (en) 2008-05-23 2009-11-26 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine h3 receptor
JP5351254B2 (en) 2008-05-23 2013-11-27 ノバルティス アーゲー Quinoxaline- and quinoline-carboxamide derivatives
EA018817B1 (en) 2008-05-23 2013-10-30 Глэксо Груп Лимитед Tricyclic nitrogen containing compounds and their use as antibacterials
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
NZ588526A (en) 2008-05-23 2012-08-31 Wyeth Llc Triazine compounds as pi3 kinase and mtor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUPURAN A ET AL: "Protein tyrosine kinase inhibitors as anticancer agents", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 14, no. 1, 1 January 2004 (2004-01-01), pages 35 - 53, XP002336074, ISSN: 1354-3776 *

Cited By (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536175B2 (en) 2008-05-23 2013-09-17 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US20120309766A1 (en) * 2008-05-23 2012-12-06 Pascal Furet Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US8815901B2 (en) 2008-05-23 2014-08-26 Novartis Ag Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors
US8674099B2 (en) * 2008-05-23 2014-03-18 Novartis Ag Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US9850228B2 (en) 2010-04-30 2017-12-26 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
WO2011135376A1 (en) 2010-04-30 2011-11-03 Astex Therapeutics Limited Pyrazolyl quinazoline kinase inhibitors
US10519137B2 (en) 2010-04-30 2019-12-31 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
EP3590934A1 (en) 2010-04-30 2020-01-08 Astex Therapeutics Limited Pyrazolyl quinoxaline kinase inhibitors
US9464071B2 (en) 2010-04-30 2016-10-11 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US8895601B2 (en) 2010-04-30 2014-11-25 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9290478B2 (en) 2010-11-29 2016-03-22 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9856236B2 (en) 2010-11-29 2018-01-02 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
JP2014515001A (en) * 2011-04-20 2014-06-26 塩野義製薬株式会社 Aromatic heterocyclic derivatives having TRPV4 inhibitory activity
US9340500B2 (en) 2011-04-20 2016-05-17 Shionogi & Co., Ltd. Aromatic heterocyclic derivative having TRPV4-inhibiting activity
CN104011025A (en) * 2011-10-28 2014-08-27 阿斯特克斯治疗有限公司 Quinolines as fgfr kinase modulators
US9439896B2 (en) 2011-10-28 2016-09-13 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US10045982B2 (en) 2011-10-28 2018-08-14 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
RU2625303C2 (en) * 2011-10-28 2017-07-13 Астекс Терапьютикс Лимитед Quinolines as fgfr kinase modulators
US10039759B2 (en) 2011-10-28 2018-08-07 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
WO2013063000A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
US9303029B2 (en) 2011-10-28 2016-04-05 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
WO2013061077A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited New compounds
US9309242B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US9309241B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
US9757364B2 (en) 2011-10-28 2017-09-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
WO2013061081A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer benzopyrazines via the inhibition of fgfr kinases
KR102072869B1 (en) 2011-10-28 2020-03-02 아스텍스 테라퓨틱스 리미티드 Quinolines as fgfr kinase modulators
WO2013061074A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Quinolines as fgfr kinase modulators
WO2013061080A1 (en) 2011-10-28 2013-05-02 Astex Therapeutics Limited Anticancer pyridopyrazines via the inhibition of fgfr kinases
US9527844B2 (en) 2011-10-28 2016-12-27 Astex Therapeutics Limited Naphthyridine derivative compounds
US10052320B2 (en) 2011-10-28 2018-08-21 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140093665A (en) * 2011-10-28 2014-07-28 아스텍스 테라퓨틱스 리미티드 Quinolines as fgfr kinase modulators
EP3617213A1 (en) 2011-12-30 2020-03-04 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
US9737544B2 (en) 2012-05-30 2017-08-22 Astex Therapeutics Limited Compounds
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US10272087B2 (en) 2012-05-30 2019-04-30 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014011284A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US8933099B2 (en) 2013-02-20 2015-01-13 Eisai R&D Management Co., Ltd. Monocyclic pyridine derivative
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US11708412B2 (en) 2013-09-26 2023-07-25 Novartis Ag Methods for treating hematologic cancers
US9340509B2 (en) 2013-12-02 2016-05-17 Chemocentryx, Inc. CCR6 compounds
US10117865B2 (en) 2013-12-02 2018-11-06 Chemocentryx, Inc. CCR6 compounds
US10786494B2 (en) 2013-12-02 2020-09-29 Chemocentryx, Inc. CCR6 compounds
US9795599B2 (en) 2013-12-02 2017-10-24 Chemocentryx, Inc. CCR6 compounds
WO2015097621A2 (en) 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11827704B2 (en) 2014-01-24 2023-11-28 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10981990B2 (en) 2014-01-31 2021-04-20 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US11155620B2 (en) 2014-01-31 2021-10-26 Novartis Ag Method of detecting TIM-3 using antibody molecules to TIM-3
EP4324518A2 (en) 2014-01-31 2024-02-21 Novartis AG Antibody molecules to tim-3 and uses thereof
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10421747B2 (en) 2014-03-26 2019-09-24 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US11918576B2 (en) 2014-03-26 2024-03-05 Astex Therapeutics Ltd Combination of an FGFR inhibitor and a CMET inhibitor
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US9902714B2 (en) 2014-03-26 2018-02-27 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10716787B2 (en) 2014-03-26 2020-07-21 Astex Therapeutics Ltd Combinations
WO2015144803A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
WO2016054555A2 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
EP3662903A2 (en) 2014-10-03 2020-06-10 Novartis AG Combination therapies
WO2016057841A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
EP4245376A2 (en) 2014-10-14 2023-09-20 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11684620B2 (en) 2015-02-10 2023-06-27 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US11040053B2 (en) 2015-03-10 2021-06-22 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP4378957A2 (en) 2015-07-29 2024-06-05 Novartis AG Combination therapies comprising antibody molecules to pd-1
US10517870B2 (en) 2015-07-30 2019-12-31 Bristol-Myers Squibb Company Aryl substituted bicycle heteroaryl compounds
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
EP4424322A2 (en) 2015-12-17 2024-09-04 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US10730868B2 (en) 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
US11932658B2 (en) 2016-07-14 2024-03-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors
US12060347B2 (en) 2016-07-14 2024-08-13 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
WO2018198076A1 (en) 2017-04-28 2018-11-01 Aduro Biotech, Inc. Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof
US10975114B2 (en) 2017-04-28 2021-04-13 Chinook Therapeutics, Inc. Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
US12024517B2 (en) 2018-05-04 2024-07-02 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12083124B2 (en) 2019-10-14 2024-09-10 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2020-09-30 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2023034811A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Also Published As

Publication number Publication date
NI201000190A (en) 2011-08-01
CU20100219A7 (en) 2011-11-15
CO6321283A2 (en) 2011-09-20
AR071867A1 (en) 2010-07-21
ECSP10010627A (en) 2010-12-30
CN102036963B (en) 2013-08-21
IL209124A (en) 2014-06-30
JP2011520941A (en) 2011-07-21
SMP201000124B (en) 2011-09-09
CR11727A (en) 2010-12-29
EA201001769A1 (en) 2011-06-30
US8273882B2 (en) 2012-09-25
JP5351254B2 (en) 2013-11-27
IL209124A0 (en) 2011-01-31
TW201000468A (en) 2010-01-01
US20100105667A1 (en) 2010-04-29
EA021421B1 (en) 2015-06-30
MX2010012699A (en) 2010-12-07
PE20091955A1 (en) 2010-01-09
KR20100135929A (en) 2010-12-27
AU2009248774B2 (en) 2012-05-31
US20120309766A1 (en) 2012-12-06
US20130324519A1 (en) 2013-12-05
EP2282995B1 (en) 2015-08-26
ZA201007086B (en) 2011-12-28
US8536175B2 (en) 2013-09-17
EP2282995A1 (en) 2011-02-16
DOP2010000343A (en) 2010-11-30
UA103478C2 (en) 2013-10-25
CA2725185C (en) 2016-10-25
CU24001B1 (en) 2014-06-27
US8815901B2 (en) 2014-08-26
MA32306B1 (en) 2011-05-02
PA8827901A1 (en) 2009-12-16
MY155535A (en) 2015-10-30
HN2010002491A (en) 2013-01-28
TWI448460B (en) 2014-08-11
US8674099B2 (en) 2014-03-18
UY31838A (en) 2010-01-05
CA2725185A1 (en) 2009-11-26
SV2010003741A (en) 2011-07-05
NZ588511A (en) 2012-04-27
BRPI0913031A2 (en) 2019-11-26
SMAP201000124A (en) 2011-01-19
KR101257158B1 (en) 2013-04-23
AU2009248774A1 (en) 2009-11-26
CN102036963A (en) 2011-04-27
ES2554513T3 (en) 2015-12-21
GEP20125502B (en) 2012-04-25
US20120309741A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
US8674099B2 (en) Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors
US8420657B2 (en) Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors
JP2010504933A (en) Pyrazolopyrimidines as PI3K lipid kinase inhibitors
US20080300245A1 (en) Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors
JP2010526120A (en) Substituted imidazopyridazines as PI3K lipid kinase inhibitors
CN102796099A (en) Imidazoquinolines as lipid kinase inhibitors
EP2025678A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
US8389526B2 (en) 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980118757.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09749876

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009749876

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 588511

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 201011727

Country of ref document: CR

Ref document number: CR2010-011727

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2009248774

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: D2010219

Country of ref document: CU

WWE Wipo information: entry into national phase

Ref document number: 10145575

Country of ref document: CO

Ref document number: MX/A/2010/012699

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20107026049

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011509980

Country of ref document: JP

Ref document number: 2725185

Country of ref document: CA

Ref document number: 12010

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 12010502634

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009248774

Country of ref document: AU

Date of ref document: 20090520

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201001769

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 8972/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2010000776

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: A201013893

Country of ref document: UA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0913031

Country of ref document: BR

Free format text: NA PETICAO INICIAL, FALTA NUMERAR AS PRIMEIRAS FOLHAS DO RELATORIO DESCRITIVO, DAS REIVINDICACOES E DO RESUMO.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: PI0913031

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2540 DE 10/09/2019 POR TER SIDO INDEVIDA.

ENP Entry into the national phase

Ref document number: PI0913031

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101122